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1 
Summary 
 
The induction of angiogenesis by stimulation of physiological vessel growth using pro-
angiogenic growth factors is currently under intense investigation in medical research. It is well 
accepted, that angiogenesis is a rate-limiting step in skin regeneration, as it ensures supply of 
novel tissue with nutrients and oxygen. Chronic wounds are characterized by a lack of 
angiogenesis and thus represent a major target for the induction of angiogenesis by therapeutic 
means. For the delivery of VEGF-A165 to chronic wounds and the induction of effective 
angiogenesis, in general it is proposed that first, the stabilization of the growth factor against 
protease activities, and second, the tight control of its release are beneficial. 
The aim of this study was to optimize wound angiogenesis in non-healing wounds in response to 
recombinant VEGF-A165 by improving bioavailability and potency of the growth factor. 
To stabilize the growth factor in the chronic wound environment, recently a mutated form of 
VEGF-A165 (VEGFmut) resistant to plasmin cleavage was generated in our group. This mutant 
was used in this study for the analysis of protein delivery. For this purpose, a hybrid protein 
composed of VEGFmut and a factor XIIIa transglutaminase substrate sequence (TG) was 
generated. This sequence allows covalent incorporation of the recombinant protein a into fibrin 
matrix. Furthermore, a second strategy to increase the angiogenic response was investigated 
which aimed at the stimulation of synergistic signaling downstream of VEGFR-2 and integrin 
αvβ3. To this end, bi-functional proteins consisting of the fibronectin type III domain 10 
(FNIII10) and VEGFmut denoted as FLV were generated for the concomitant activation of both 
receptors.  
The recombinant proteins were expressed in E. coli. FNIII10 and TG-FNIII10 were purified as 
GST-fusion proteins, whereas VEGF-containing constructs were produced in bacterial inclusion 
bodies, refolded, dimerized, and purified by heparin affinity chromatography. However, 
purification of the bi-functional proteins was challenging, as they tended to precipitate and 
dimerization was ineffective. To overcome these problems, in a subsequent approach, FNIII10, 
TG-FNIII10, VEGFmut, TG-VEGFmut, FLV and TG-FLV were expressed in eucaryotic cells 
(HEK293-EBNA) and purified by a C-terminal poly-histidine tag.  
The biological activity of these proteins was confirmed in various in vitro assays. First, HUVECs 
were shown to attach to TG-FNIII10 in a concentration dependent manner, and this attachment 
was reduced by integrin αvβ3 function-blocking antibodies. Second, recombinant proteins fused 
to a TG sequence were covalently incorporated into fibrin gels by the activity of factor XIIIa, 
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and were retained by up to 90 % after two days of washing, whereas their soluble counterparts 
were released in a burst release during the first 8 hours. Third, the biological activity of the 
VEGF-variants was shown in vitro by their ability to induce VEGFR-2 phosphorylation in 
HUVECs by western blot analysis and ELISA. Intriguingly, the bi-functional protein FLV failed 
to induce detectable synergistic signaling on the receptor level when it was added to HUVECs. 
In contrast, when HUVECs were seeded on microscopy slides coated with the recombinant 
proteins, FLV promoted attachment and spreading to a higher degree than FNIII10 or VEGFmut 
alone. Together, these findings indicate that the immobilized proteins show different potential in 
the induction of cellular responses. 
The potency of these proteins to induce angiogenesis was also assessed in vivo using wound 
healing as a model. Fibrin gels containing 0.468 µM (corresponding to 20 µg/mL effective 
VEGF-concentration) of either VEGFmut, TG-VEGFmut, TG-FLV or no recombinant protein 
were applied to full-thickness punch biopsy wounds created on the back of db/db mice, which 
are used as a model of impaired wound healing. When compared to fibrin treatment only, wound 
closure was accelerated upon treatment with various VEGF-proteins. More important, both 
TG-VEGF and TG-FLV proved to be significantly more potent in inducing blood vessel growth 
into the wound area, when compared to soluble VEGFmut. Differences between the two TG-
isoforms were observed in the maturity of neovessels as indicated by the recruitment of 
pericytes: pericyte recruitment was more efficient in fibrin/TG-VEGF treated wounds than in 
fibrin/TG-FLV treated wounds at day 10. 
Collectively, the findings of this study support a critical role for the interplay between VEGF-A 
and extracellular matrix during wound angiogenesis, and suggest that protein engineering 
provides a novel molecular approach to use these interactions for therapeutic angiogenesis. 
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Zusammenfassung 
 
Im klinischen Alltag sind chronische Wundheilungsstörungen ein häufiges Krankheitsbild, dem 
eine Fehlregulation der Angiogenese in Folge eines proteasereichen Mikromilieus zugrunde 
liegt. Die Stimulation der Angiogenese durch therapeutische Maßnahmen stellt daher eine 
vielversprechende Behandlungsoption dar.  
Ziel dieser Arbeit war es, die durch VEGF-A165 stimulierte Angiogenese in chronischen Wunden 
zu optimieren. In dieser Arbeit wurde die Fragestellung bearbeitet, ob die Stabilisierung von 
VEGF-A gegen in der Wunde angereicherte Proteasen, sowie die räumlich und zeitlich 
kontrollierte Verfügbarkeit des Wachstumsfaktors der Wundheilung förderlich sind. 
Eine Mutation im VEGF-A165 Protein (VEGFmut) verhindert den Abbau durch Plasmin in 
chronischen Wunden, wie unsere Arbeitsgruppe bereits in früheren Untersuchungen zeigen 
konnte. Die Verfügbarkeit von VEGFmut kann über die  kovalente Bindung an Fibrin 
kontrolliert werden. Zu diesem Zweck wurde ein Fusionsprotein generiert, welches VEGFmut an 
die Substratsequenz für Faktor XIIIa koppelt (TG-VEGFmut). Um die Angiogenese darüber 
hinaus zu verstärken, wurde ein weiteres bifunktionales Fusionsprotein hergestellt, welches 
VEGFmut über einen Linker mit der Fibronektin Typ III Domäne 10 (FNIII10) verbindet und 
somit simultan an den VEGF-Rezeptor 2 und das Integrin αvβ3 binden soll. Dieses 
Fusionsprotein FNIII10-Linker-VEGFmut (FLV) soll einen synergistischen Effekt in Folge der 
Kostimulation von VEGF-Rezeptor 2 und Integrin αvβ3 erzielen. 
Die rekombinanten Proteine wurden zunächst in E. coli exprimiert. FNIII10 und TG-FNIII10 
wurden als GST-Fusionsproteine aufgereinigt, während die VEGFmut-basierten Proteine aus 
bakteriellen Inklusionskörperchen gewonnen und über ihre Heparinaffinität aufgereinigt wurden. 
Insbesondere für die bifunktonalen Proteine erwies sich die Aufreinigung als schwierig, da 
Präzipitatbildung und unvollständige Dimierisierung beobachtet wurden. Aus diesem Grund 
wurden FNIII10, TG-FNIII10, VEGFmut, TG-VEGFmut, FLV und TG-FLV in einem zweiten 
Ansatz in eukaryotischen Zellen (HEK293-EBNA) exprimiert.  
Die biologische Aktivität der aufgereinigten Proteine wurde in unterschiedlichen in vitro und in 
vivo Experimenten untersucht. In vitro Versuche an primären Endothelzellen aus der 
Nabelschnurvene (HUVECs) zeigten, dass TG-FNIII10 die Zelladhäsion konzentrationsabhängig 
fördert. Die Zelladhäsion konnte teilweise durch funktionsblockierende Antikörper gegen 
Integrin αvβ3 gehemmt werden. Desweiteren wurden VEGFmut und FLV über die Faktor XIIIa 
Substratsequenz kovalent im Fibringel gebunden und wurden auch nach zweitägigem Waschen 
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im Gel zurückgehalten. Demgegenüber wurden die löslichen Proteine VEGFmut und FLV 
innerhalb von 8 Stunden vollständig aus dem Fibringel herausgewaschen. Ferner führte die 
Stimulation mit den rekombinanten VEGF-Proteinen in HUVECs zur Phosphorylierung von 
VEGFR-2, wie mittels Western Blot Untersuchungen und ELISA nachgewiesen wurde. 
Interessanterweise war die Phosphorylierung des Rezeptors nach Stimulation mit löslichem FLV 
im Vergleich zu VEGFmut reduziert, obwohl beide Proteine VEGFR-2 mit hoher Affinität 
binden, wie Oberflächenplasmon-Resonanzmessungen zeigten. Im Gegensatz dazu förderte auf 
Objektträgern immobilisiertes FLV die Zelladhäsion und -ausbreitung stärker als FNIII10 oder 
VEGFmut alleine. Diese Ergebnisse deuten darauf hin, dass insbesondere die bifunktionalen 
Proteine in gebundener Form ein anderes Signalisierungspotential haben als in löslicher Form. 
In vivo Untersuchungen der rekombinanten Proteine in einem Model für gestörte Wundheilung 
an diabetischen Mäusen zeigten eine beschleuningte Wundheilung, wenn die Wunden mit 
Fibringelen, die 0.468 µM (entsprechend 20 µg/ml effektiver VEGF-Konzentration) VEGFmut, 
TG-VEGFmut oder TG-FLV enthielten, behandelt wurden. Wunden, die mit den kovalent an 
Fibrin gebundenen Proteinen TG-VEGFmut und TG-FLV behandelt wurden, zeigten an Tag 10 
nach Wundsetzung eine deutlich erhöhte Angiogenese gegenüber Wunden, die mit löslichem 
VEGFmut in Fibrin oder nur mit Fibringel behandelt wurden. Darüberhinaus unterschieden sich 
zu diesem Zeitpunkt die Blutgefäße der mit TG-VEGFmut oder TG-FLV behandelten Wunden 
hinsichtlich ihrer Reife; die Rekrutierung von Perizyten in den mit TG-VEGFmut behandelten 
Wunden war deutlich weiter fortgeschritten. 
Zusammenfassend deuten die Ergebnisse dieser Arbeit auf eine entscheidende Rolle für das 
Zusammenspiel von VEGF-A und der extrazellulären Matrix während der Wundangiogenese 
hin. Diese Ergebnisse könnten ferner als Grundlage neuer Ansätze für die Steuerung der 
Angiogenese auf molekularer Ebene und deren therapeutische Nutzung dienen. 
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1 Introduction 
 
1.1 Structure and function of the skin 
The skin is the outer barrier of the body, separating the “inside” from the “foreign outside” and 
hence has important protective functions. In humans, the skin is the body’s largest organ, 
measuring between 1.5 and 2 m2 in area and 2-3 mm in thickness, with a weight of about 9 kg. 
Being a physical barrier, the skin protects the body passively from pathogens, but also hosts 
compounds of the humoral, cellular and complement immune response. Further, the skin plays a 
major role in homeostasis: it is semi-permeable, and protects the body from loss of water and 
nutrients. This organ is also an important storage compartment for water and lipids, and the place 
of vitamin D synthesis. Due to its high degree of vascularization, the skin regulates the body’s 
temperature by controlled vascular dilation or constriction. Importantly, the skin is also highly 
innervated and thus enables sensory perceptions of temperature, pressure, touch, vibration and 
pain (McGrath et al. 2008).  
This important organ is divided into two layers (Figure 1), namely the highly cellular epidermis 
and the underlying dermis consisting of connective tissue, that are separated from each other by 
the basal lamina. In the epidermis, up to 95 % of all cells found are keratinocytes. Besides 
sensatory Merkel cells, melanocytes, and Langerhans cells, a subset of dentritic cells, are present 
whereas vasculature is absent (McGrath et al. 2008). The epidermis regenerates continuously, 
which is accomplished by a permanent turnover of keratinocytes (Koster 2009). During its 
developmental program, the keratinocyte moves from the basement membrane towards the 
body’s surface, thereby forming defined layers according to its differentiation state that 
characterize the epidermis as a stratified epithelium (Figure 1 A). These layers are named 
stratum basale, spinosum, granulosum and corneum (McGrath et al. 2008). In the stratum 
basale, as well as in the bulge region of hair follicles, clusters of epidermal stem cells are 
located, which constantly replenish the pool of developing keratinocytes via a pool of transiently 
amplifying daughter cells. Subsequent keratinocyte differentiatiation comprises a state of 
increased synthetic activity and ultimately results in the loss of cytoplasmic organells and the 
formation of a cornified envelope consisting of various crosslinked proteins (Proksch et al. 2008; 
Smack et al. 1994). At the body’s surface, the cornified, dead cells are continuously shed off and 
replaced by underlying cells. This process, named keratinization, contributes to the protection 
against UV-damage, water loss and environmental damage (McGrath et al. 2008). 
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The dermis predominantly consists of connective tissue and is a cushion that protects the body 
from mechanical injury. The connective tissue of the dermis is mainly formed of proteoglycan 
macromolecules, which attract and retain water due to their negative charge. Collagen is another 
major component that accounts for approximately 75 % of the dermis’ dry weight and gives 
tensile strength to the skin. Networks formed by elastic fibers interconnect with the collagen 
fibers and confer elasticity to the tissue (McGrath et al. 2008). Fibroblasts are the major cell type 
found in the dermis, and synthesize the extracellular matrix components described. Furthermore, 
the dermis contains melanocytes as well as cells of the immune system such as lymphocytes, 
macrophages and mast cells. It is also the location of sensual preception, as it is highly 
innervated by sensory as well as by peripheral and motor nerve endings. The dermis hosts the 
appendages of the skin, namely hair follicles, sebaceous glands, apocrine and eccrine sweat 
glands and also carries many blood and lymphatic vessels (McGrath et al. 2008). 
 
 
Figure 1: Anatomy of the skin. (A) Schematic representation of organization and composition of the skin (Rush University Medical 
Center). (B) Histological sections of the skin. 
 
1.2 Wound healing 
As skin functions described above are essential for health and survival of organisms, skin repair 
after injury is a critical process that aims at the quick re-establishment of tissue integrity. It is a 
highly organized process involving many different cell types, cytokines and proteins of the 
extracellular matrix. Commonly, the healing process is divided into three overlapping phases, 
namely inflammation, tissue formation and tissue remodeling.  
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1.2.1 Inflammation 
The formation of a blood clot consisting of platelets and extravasated plasma proteins is the first 
step during tissue regeneration, and is part of the inflammatory response. Damage of the vessel 
wall or exposure of subendothelial structures to the blood flow result in the activation of pro-
enzymes of the coagulation cascade in the plasma, ultimately leading to the proteolytic activation 
of thrombin and fibrin polymerization. Thrombin in addition activates the transglutaminase 
factor XIIIa, which crosslinks fibrin fibers covalently, and platelets, that bind to fibrin via 
platelet integrin αIIbβ3 (Du and Ginsberg 1997; Laurens et al. 2006).  
Besides stopping bleeding and thereby reestablishing homeostasis, the clot fills the disrupted 
tissue and provides a provisional matrix meeting all prerequisites for cell invasion, proliferation 
and differentiation required for tissue regeneration (Shaw and Martin 2009). This provisional 
matrix is an excellent substrate for cell migration. Fibrin itself has been shown to promote 
migration of several cell types such as keratinocytes, fibroblasts and endothelial cells (Geer et al. 
2002; Gorodetsky et al. 1998), and this ability to promote cell migration is additionally 
potentiated by binding of other plasma derived proteins to the provisional matrix such as 
fibronectin and vitronectin (Clark 2003; Makogonenko et al. 2002; Preissner and Jenne 1991). 
The fibrin clot also serves as a reservoir of growth factors. An important source of 
chemoattractants are the platelets entrapped in the clot, as they release vascular endothelial 
growth factor-A (VEGF-A), platelet-derived growth factor-B (PDGF-B), transforming growth 
factor-β (TGF-β), hepatocyte growth factor (HGF), among others (Anitua et al. 2004). Cytokines 
sequestered in the clot either bind directly to fibrin, as it is known for the basic fibroblast growth 
factor (bFGF), VEGF-A, PDGF, and TGF-β (Clark 2003; Sahni and Francis 2000; Sahni et al. 
1998), or interact with fibrin indirectly via heparin or fibronectin (Makogonenko et al. 2002; 
Odrljin et al. 1996; Raut and Gaffney 1996). Storage of a variety of different growth factors such 
as bFGF, heparin-binding epidermal growth factor (HB-EGF), PDGF, or VEGF in the clot can 
be accomplished by this means (Clark 2003; Martino and Hubbell 2010).  
 
Neutrophils from the blood immobilized in the clot are the first immune cells present at the 
wound site. They become activated and release chemokines and cytokines which in turn results 
in the activation of tissue-resident immune cells and, together with factors of the complement 
system and fibrinopeptides, promote the recruitment of additional neutrophils from the 
bloodstream to the wound site within several hours (Cumberbatch et al. 2000; Jameson et al. 
2004; Noli and Miolo 2001; Shaw and Martin 2009). Also mast cells in the tissue contribute to 
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the recruitment of neutrophils from the blood flow by the exocytosis of vascoactive mediators 
and cytokines within several hours after injury (Eming et al. 2007c; Trautmann et al. 2000; 
Weller et al. 2006). Neutrophils phagocytose pathogens, tissue, and cell debris in the wound, and 
are also an important source of pro-inflammatory cytokines that serve to activate local 
keratinocytes and fibroblasts (Hubner et al. 1996). 
Monocytes arrive at the wound side slightly later than neutrophils, at around day one post-injury. 
They become recruited from the circulation by factors released in the wound and differentiate 
into macrophages when invading the tissue (Eming et al. 2007c). Macrophages phagocytose 
damaged extracellular matrix components and cells as well as dead neutrophils. Furthermore, 
they play an essential role in antigen presentation and in the synthesis of growth factors, which 
in turn promote the recruitment of tissue resident cells to the clot and their proliferation and the 
synthesis of a novel extracellular matrix. VEGF-A, bFGF, PDGF, TGF-β and TGF-α are among 
the cytokines secreted (DiPietro and Polverini 1993; Eming et al. 2007c). 
 
1.2.2 Tissue formation 
The fibrin clot only serves as a temporary wound closure and becomes replaced by granulation 
tissue, which is characterized by a granular appearance due to the formation of a microvascular 
network and by high cell density. As a general principle, cells at the wound edges become 
activated by factors released in the wound, proliferate, and invade the wound to substitute the 
fibrin clot by novel tissue. This activation requires that cells change their integrin-expression 
profile and start to synthesize proteases to proteolytically invade the provisional matrix.  
Fibroblasts at the wound edges begin to proliferate as an early response to injury, and invade the 
provisional matrix around day 3 or 4 post-injury (Fernandez et al. 2008; Hinz et al. 2007; 
Rajkumar et al. 2006; Shaw and Martin 2009). In the fibrin clot, fibroblasts depose an early new 
matrix consisting of collagen, and re-arrange it by bundling collagen fibers and adjusting these 
collagen bundles (Hinz et al. 2007). Furthermore, a subset of fibroblasts differentiates into highly 
contractile myofibroblasts characterized by the expression of α-smooth-muscle actin (α-SMA). 
Both fibroblasts and myofibroblasts contract to draw the wound edges closer together (Hinz et 
al. 2007).  
Only several hours after injury, both basal and suprabasal keratinocytes from the wound edges 
and hair follicles start to migrate collectively over and through the provisional matrix towards 
the middle of the wound (Martin 1997; Matoltsy and Viziam 1970; Nguyen et al. 2000). By the 
expression of matrix-metalloproteases (MMPs) and plasmin activators, migrating keratinocytes 
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carve a path between scab and viable tissue (Grondahl-Hansen et al. 1988; Pilcher et al. 1999; 
Shaw and Martin 2009). Keratinocytes next to the wound edges proliferate strongly to replace 
cells lost during injury, which is reflected by the formation of a thick, hyperproliferative 
epithelium (Garlick and Taichman 1994; Martin 1997). Once the wound area has been covered 
by a layer of keratinocytes, their migration stops due to contact inhibition. A new basal lamina is 
synthesized, to which both keratinocytes and fibroblasts contribute (Werner et al. 2007), 
followed by reestablishment of the stratified epithelium starting at the wound margins (Gipson et 
al. 1988). 
Simultaneously, capillaries from the surrounding tissue become activated by pro-angiogenic 
mediators released in the wound, and sprout into the provisional matrix (Tonnesen et al. 2000) in 
order to supply the granulation tissue with oxygen and nutrients, and to remove metabolic end 
products. Angiogenesis is an essential process during normal wound repair and requires tight 
temporal and spatial coordination of the interaction between various cell types, cytokines and the 
extracellular matrix (Eming et al. 2007a). During wound healing, the induction of an appropriate 
angiogenic response is crucial for successful skin regeneration, and this work aims at the optimal 
induction of wound angiogenesis. The molecular regulation of angiogenesis will be discussed 
more in detail in section 1.5. 
 
1.2.3 Tissue remodelling 
During the last and longest phase of wound healing, the cell-rich granulation tissue gets 
transformed into a matrix-rich scar tissue. To that end, myofibroblasts and many fibroblasts 
undergo apoptosis, and the vascular network matures by the recruitment of pericytes and 
reorganization by pruning. Further, collagen is reorganized, and collagen III, the predominant 
collagen-isoform in the provisional matrix, is substituted by collagen I. Collagen gets 
crosslinked, and elastic fibers are deposited, which increases strength and elasticity of the scar 
(Braiman-Wiksman et al. 2007). 
 
1.3 The medical need of pro-angiogenic therapies 
For many medical applications, the modulation of the angiogenic response is a major target in 
research. While angiogenesis can occur in various pathologic settings such as tumor growth or 
retinal angiopathy, the induction of a functional vasculature is desirable in various diseases 
resulting from malperfusion of tissues, such as myocardial or leg ischemia and wound healing 
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impairments. Therapeutic angiogenesis aims at the induction of a functional vasculature by 
stimulation of tissue resident cells by biochemical means (Zisch et al. 2003). 
 
1.3.1 Non-healing wounds as targets for pro-angiogenic therapy 
The normal progression through the stages of wound healing is orchestrated and tightly 
controlled by a multitude of mediators, coordinating the behavior of various cell types as 
described in earlier sections. However, some wounds fail to progress through these normal 
stages of wound healing and become chronic. Such non-healing wounds are rather frequent with 
3-4 % of people older than 60 years of age affected in western societies (Tredget and Ding 
2009). As many of the causes are age related, due to the demographic development of these 
societies, an increase of cases is to be expected in future years (Clark et al. 2007). Chronic 
wounds severely reduce the overall quality of life of the concerned patients, as they are care 
intensive, often cause chronic pain and longstanding unfitness for work, impair normal 
ambulating and lead to social isolation (Eming et al. 2007b; Menke et al. 2007). Furthermore, 
infections and malignant transformations are severe problems, often requiring amputation as 
ultimate mean of treatment (Chraibi et al. 2004). As of today, there is no efficient treatment for 
chronic wounds, thus therapy and care cause important costs to the health care system 
(Walmsley, 2002). 
Wound healing impairments may have several causes, but the primary one is tissue ischemia 
secondary to venous insufficiency, diabetes or pressure (Nwomeh et al. 1998b). The resulting 
hypoxia leads to cell death in tissues and the recruitment of macrophages, which in turn secrete 
neutrophil chemoattractants and pro-inflammatory substances (Eming et al. 2007c). Neutrophils 
release extensive amounts of MMPs and neutrophil-derived elastase (Nwomeh et al. 1998a) 
whereas, during normal wound healing, protease expression is tightly regulated in time and 
space and coordinated with the expression of their inhibitors. These proteases together with 
neutrophil-derived reactive oxygen species damage resident cells, components of the 
extracellular matrix, and tissue growth factors, which prevents tissue formation and contributes 
to an amplification of the inflammatory response (Menke et al. 2007). Thus, chronic wounds are 
characterized by an inflammatory response that is sustained, uncontrolled and self-amplifying, 
and represent a major target for pro-angiogenic therapies, as these aim at treating the underlying, 
primary cause of disease.  
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1.3.2 Pro-angiogenic therapies as pre-requisite for tissue 
engineering 
Not only during tissue regeneration, but also for tissue engineering approaches, the induction of 
capillary growth is of importance, as oxygen diffusion into tissues is spatially limited. For this 
reason, the controlled induction of functional angiogenesis is under investigation for the 
amelioration of organ or grafted tissue take after transplantation, and also crucial for the in vitro 
generation of organ substitutes (Zisch et al. 2003). 
 
1.3.3 Basic principles for the use of growth factors in tissue 
engineering 
Major tissue engineering approaches for the stimulation of angiogenesis consist in the delivery 
of growth factors either as protein or expression vector to the site of hypoxia. For the induction 
of a functional vasculature, a sustained presence of the growth factor within the tissue at a low 
dose is required, as the side effects of excessive local doses of pro-angiogenic growth factors 
counteract physiological vessel growth. VEGF-A is recognized to regulate all steps required to 
induce angiogenesis as described in the following section, and hence has been a major molecule 
of interest in the development of pro-angiogenic drugs (Zisch et al. 2003). However, exposure of 
tissues to extensive local doses of this growth factor resulted in the formation of instable, 
abnormal, highly tortuous and leaky vessels as well as haemangionoma (Horowitz et al. 1997; 
Ozawa et al. 2004; Yancopoulos et al. 2000; Zisch et al. 2003). 
 
1.4 The vascular endothelial growth factor 
1.4.1 Discovery and effect on endothelial cells 
The vascular endothelial growth factor-A (VEGF-A) is the master regulator of angiogenesis and 
was discovered twice independently for its most striking characteristic properties. First, in 1983, 
a tumor-secreted protein was described capable to increase vascular leakage in the skin very 
potently, and therefore named vascular permeability factor (VPF, Senger et al. 1983). Second, in 
1989, two groups described a heparin-binding protein secreted by pituitary follicular cells, acting 
as an endothelial cell specific mitogen, hence termed vascular endothelial growth factor (VEGF, 
Ferrara and Henzel 1989; Gospodarowicz et al. 1989). When the cDNA of both proteins was 
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cloned in the same year, it turned out that VEGF and VPF were identical (Ferrara 2004; Keck et 
al. 1989; Leung et al. 1989). 
Since its discovery, VEGF-A has been a major target in research and is well characterized as the 
main growth factor controlling all steps during angiogenesis. VEGF-A induces proliferation and 
migration in endothelial cells, and is an important survival factor counteracting apoptosis. 
VEGF-A signaling leads to the expression of proteases to allow for basal membrane degradation 
and alters the expression of integrins to mediate cell attachment to provisional matrices. 
Furthermore, VEGF-A induces tube formation by endothelial cells and favors vasodilatation 
(Bates and Curry 1996; Bates and Jones 2003; Connolly et al. 1989; Conolly 1989; Ferrara and 
Henzel 1989; Koolwijk et al. 1996; Ku et al. 1993; Senger et al. 1983).  
 
1.4.2 Molecular properties and regulation of expression 
VEGF-A belongs to the VEGF family of growth factors that in mamals currently comprises five 
members named VEGF-A through D and placental growth factor (PlGF). Related proteins are 
also found in parapoxvirus (VEGF-E) and snake venom (VEGF-F). Members of this family are 
secreted homodimeric glycoproteins and share a homology domain, composed of eight spatially 
highly conserved cysteine residues organized in a cysteine knot motif (reviewed in Ferrara 
2004). Out of these, six cysteines stabilize the monomers by the formation of intramolecular 
disulfide bounds, and the monomers are linked to each other by two additional disulfide bounds 
in an anti-parallel fashion (Wiesmann et al. 1997).  
VEGF-A is the most abundant and best investigated family member. The growth factor is 
encoded by a single gene comprising 8 exons, and differential splicing gives rise to isoforms of 
different molecular weight. To date, at least 13 isoforms have been described, and they are 
commonly denoted by their amino acid length following signal peptide removal. Out of these, 
VEGF-A 121, 145, 148, 162, 165, 183, 189, and 206 promote angiogenesis. Splicing at a distal 
site gives rise to the so-called VEGF-Axxxb isoforms, VEGF-A 121b, 145b, 165b, 183b and 
189b, which are thought to have anti-angiogenic properties (Woolard et al. 2004). VEGF-A 121, 
165, 189 and 206 are the isoforms predominantly expressed by VEGF-A-expressing cells 
(Houck et al. 1991). VEGF-A isoforms differ in their biological activity, and in their affinity to 
the extracellular matrix, which is due to the presence or absence of sequences required for the 
binding to co-receptors and heparan sulfate proteoglycans. In the VEGF-A-gene, exons 6 and 7 
encode for two independent heparin-binding domains. VEGF-A121, which is encoded by exons 
1-5 and 8, is a freely diffusible protein. In contrast, VEGF-A165 additionally comprises exon 7 
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and shows moderate heparin affinity, and therefore, about 50-70% of secreted VEGF-A165 
remains extracellular matrix-associated (Ferrara and Henzel 1989; Gospodarowicz et al. 1989). 
VEGF-A189 and VEGF-A206 are completely sequestered in the extracellular matrix as they bind 
to heparin very strongly due to amino acids encoded by exons 6 and 7 (Houck et al. 1992). 
 
As the overall effect of angiogenesis on a tissue under physiological as well as under 
pathological conditions is the increase of oxygen and nutrients supply (Bates and Jones 2003), it 
is not surprising that one of the major regulators of VEGF-A expression is the availability of 
oxygen. Under hypoxia, VEGF-A-transcription is initiated by the hypoxia-inducible factor-1 
(HIF-1), a hetero-dimeric protein formed from HIF-1α and HIF-1β (Mole et al. 2002). Under 
normoxia, HIF-α is ubiquitinated, targeted for the proteasome and quickly degraded (Ivan et al. 
2001). By contrast, under hypoxic conditions, HIF-1α is stabilized and translocates into the 
nucleus, where it forms an active transcription factor complex with HIF-1β and other co-factors 
(Ivan et al. 2001). This complex induces transcription of genes downstream of hypoxia-response 
elements, such as VEGF-A (Kietzmann et al. 1999). Under hypoxia, both the transcription and 
the translation rate of VEGF-A are increased, and VEGF-A-mRNA is protected from 
degradation (Akiri et al. 1998; Bates and Jones 2003; Levy et al. 1997). Additionally, several 
growth factors, including EGF, TGF-α and -β, keratinocyte growth factor (KGF), insulin-like 
growth factor-1, FGF and PDGF, as well as the pro-inflammatory cytokines interleukin-1α and 
-6, hormones, oncogenes, and tumor supressor genes upregulate the transcription of VEGF-A 
(Deroanne et al. 1997; Finkenzeller et al. 1997; Goad et al. 1996; Li et al. 1995; Neufeld et al. 
1999; Ryuto et al. 1996). 
 
1.4.3 VEGF-A receptors and signaling 
VEGF-A binds to VEGF receptor (VEGFR)-1 and -2, which are members of the receptor 
tyrosine kinase superfamily. The extracellular domain of VEGFRs folds into seven 
immunoglobulin-like domains. A single transmembrane domain is followed by a juxta-
membrane domain, a split tyrosin kinase domain and a C-terminal, intracellular tail (de Vries et 
al. 1992; Shibuya et al. 1990). Ligand binding leads to receptor homo- or hetero-dimerization 
and activation of the kinase domain (Figure 2).  
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The role of signaling mediated by VEGFR-1 has been under debate for a long time (Ferrara 
2004). VEGF-A binds to VEGFR-1 with a much higher affinity than to VEGFR-2 (Joukov et al. 
1997; Waltenberger et al. 1994), but VEGFR-1 autophosphorylation is barely detectable in 
response to VEGF-A (de Vries et al. 1992). Nevertheless, this receptor is crucial during 
embryonic development, as the knock-out of VEGFR-1 is embryonic lethal, due to endothelial 
overgrowth and to the formation of an unorganized vasculature (Fong et al. 1999). In these mice, 
VEGFR-2 phosphorylation is increased. However, mice expressing a VEGFR-1 in which the 
kinase domain was deleted are healthy (Hiratsuka et al. 1998). These observations led to the idea 
that VEGFR-1 might act as a negative regulator of VEGFR-2 by exerting a decoy function by 
trapping VEGF-A, thereby weakening VEGF-A-mediated signaling (Fong et al. 1999). In a 
recent publication, the understanding of VEGFR-1’s role in VEGF-A signaling was extended. 
Expressing a chimeric receptor consisting of the extracellular domain of the epidermal growth 
factor recetor fused to the intracellular domain of VEGFR-1, confirmed that VEGFR-1 is indeed 
a negative regulator of VEGFR-2 signaling, but that this effect is regulated by VEGFR-1 
downstream signaling and not only by ligand trapping (Zeng et al. 2001). Also, macrophage and 
monocyte migration towards VEGF-A is dependent of VEGFR-1 (Barleon et al. 1996). 
 
 
Figure 2: Schematic representation of VEGF-A receptors and VEGF-A165 co-receptors (Lohela et al. 2009; Olsson et al. 
2006). 
 
VEGF-A exerts its striking effects on endothelial cell biology via VEGFR-2 mediated signaling, 
and major donstream signaling pathways are summarized in Figure 3 (reviewed in Lamalice et 
al. 2007 and Zachary 2005). 
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The major downstream target of VEGFR-2 is phospholipase C γ (PLCγ). PLCγ is recruited to the 
plasma membrane upon VEGF-A stimulation and binds to phospho-tyrosine 1175 of VEGFR-2 
via its C-terminal src homology 2 (SH2) domain (Takahashi et al. 1999; Takahashi et al. 2001). 
PLCγ catalyzes the generation of diacylglycerol and inositol-1, 4, 5-trisphosphate from 
phosphatidylinositol-4, 5-bisphosphate, and signaling leads to activation of the Raf-MEK-
MAPK pathway (Takahashi et al. 1999) downstream of the calcium dependent protein kinase C 
(PKC) and the protein kinase D (Wong and Jin 2005). Thereby, VEGFR-2 signaling mediates 
the major signal towards proliferation in endothelial cells. 
Another major downstream pathway of VEGFR-2 is the PI3K – Akt/protein kinase B (PKB) 
pathway promoting endothelial cell survival. Upon VEGF-A stimulation, the adapter protein Shb 
is recruited to phosphorylated tyrosine 1175 of VEGFR-2 and becomes tyrosine phosphorylated 
in a Src-dependent manner (Holmqvist et al. 2004). Subsequent activation of PI3K and 
generation of phosphorylated inositolphospholipids at the plasma membrane allows the 
recruitment and activation of the serine-threonine kinase Akt/PKB. Akt in turn phosphorylates 
and thereby inhibits the death-promoting protein Bad (Datta et al. 1997). 
 
VEGF-A is a strong chemoattractant for endothelial cells, and chemotactic migration is induced 
by VEGFR-2. In general, cell migration is based on modifications of the cell’s cytoskeleton. 
Particularly, the formation of membrane protrusions such as filopodia and lamellipodia, and the 
formation of contractile stress fibers underlie this process. Regulation of the actin cytoskeleton 
downstream of VEGFR-2 can be accomplished by the recruitment of the SH2 domain containing 
adapter protein Nck to the autophosphorylation site on tyrosine 1214, and activation of the Src-
kinase Fyn. Fyn activity subsequently leads to activation of p21 activated kinase (PAK-2), cell 
divison control protein 42 (Cdc42), mitogen-activated protein kinase kinase 3 (MKK3/6), stress-
activated protein kinase 2/p38 (SAPK2/p38) and mitogen-activated protein kinase activated 
protein kinase 2 ( MAPKAP K2, Lamalice et al. 2004). Actin polymerization and the formation 
of stress fibers downstream of MAPKAP K2 can be induced either by phosphorylation of the 
actin filament capping protein heat shock protein 27 (HSP27), resulting in uncapping of the 
filaments (Landry and Huot 1995), or by activation of LIM kinases that phosphorylate cofilin, 
which in turn inhibits its actin filament destabilizing activity (Kobayashi et al. 2006). An 
additional pathway inducing actin nucleation downstream of Nck involves the activation of the 
Arp2/3 complex downstream of the neuronal Wiskott-Aldrich symptome protein (N-WASP, Li 
et al. 2001). 
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Besides on the re-arrangement of the cytoskeleton, cell migration also depends on the formation 
and the turnover of focal adhesions. The focal adhesion kinase (FAK) is a key regulator for focal 
adhesion turnover, and its activation downstream of VEGFR-2 and integrin αvβ3, a receptor for 
the provisional matrix constituent vitronectin with a crucial role in angiogenesis, was 
investigated in much detail. Upon VEGF-A stimulation, the formation of a complex consisting 
of VEGFR-2, HSP90 and β3 integrin was shown to take place. Two parallel downstream 
signaling pathways subsequently contribute to FAK phosphorylation on tyrosines 397, 407 and 
861 and on serine 732, and result in cell migration. FAK is recruited to activated integrins 
resulting in its autophosphorylation (Parsons 2003) and the recruitment and activation of the Src 
kinase Pyk-2 (Le Boeuf et al. 2006). Pyk-2 and the Rho-associated coiled-coil-forming protein 
kinase ROCK, which becomes activated downstream of VEGFR-2 and Rho A then mediate the 
full activation of FAK (Le Boeuf et al. 2004). 
 
 
Figure 3: Schematic summary of the downstream signaling pathways induced by VEGFR-2 (Lamalice et al. 2007; Zachary 
2005). 
 
1.4.4 VEGF-A co-receptors  
Heparan sulfate and neuropilin (Nrp) are co-receptors of VEGF-A and can strongly increase the 
biological response of endothelial cells to the growth factor isoforms that they bind (Figure 2).  
In the early studies, VEGF-A is described as a heparin-binding protein. In vivo, VEGF-A 
isoforms comprising a heparin-binding domains encoded by exons 6 and 7 interact with 
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heparin-like domains of heparan sulfates found as a component of proteoglycans on cell 
surfaces, in the extracellular matrix and in the basement membrane of most mammalian tissues 
(Bernfield et al. 1999). A need of heparan sulfate proteoglycans (HSPGs) for the full activation 
of signaling pathways induced by VEGF-A, FGF-2 and PDGF-BB has been described (Gitay-
Goren et al. 1992; Rolny et al. 2002; Yayon et al. 1991).  
For VEGF-A165, it is known that the C-terminal region encoded by exon 7 and corresponding to 
amino acids 111-165 is essential not only for the interaction with heparin, but also for its full 
mitogenic potency, as it was shown using plasmin-generated VEGF-A165 fragments (Keyt et al. 
1996). Plasmin-mediated processing of VEGF-A165 gives rise to two shorter fragments, 
VEGF-A110 and VEGF-A111-165. VEGF-A110 is still able to bind to VEGFR-2 but is a less potent 
mitogen than VEGF-A165. Instead, its mitogenicity is comparable to that of VEGF-A121 (Keyt et 
al. 1996). In vitro experiments using human umbilical vein endothelial cells (HUVECs) showed, 
that heparin increases VEGF-A165 affinity to VEGFR-2 and also to Nrp-1, leading to increased 
VEGFR-2 phosphorylation and cell proliferation. The effect of VEGF-A121 by contrast is not 
potentiated by addition of heparin, underlining the importance of the presence of a heparin-
binding domain (Ashikari-Hada et al. 2005). For this potentiation, presentation of VEGF-A to 
VEGFR-2 by heparan sulfate on neighboring cells seems to be necessary, which mechanistically 
may prevent receptor downregulation by its internalization, and promote prolonged VEGFR-2 
signaling (Jakobsson et al. 2006). 
 
Nrp-1 and -2 are additional VEGF-A co-receptors. These transmembrane glycoproteins were 
originally discovered as adhesion proteins on neurons, where they are involved in axonal 
guidance as semaphorin-receptors (Schwarz and Ruhrberg 2010). Both Nrps are very similar in 
structure and consist of a large extracellular domain linked to a short cytoplasmic domain via a 
transmembrane domain. Nrp-1 binds to VEGF-A165 and VEGF-A121, while Nrp-2 binds to 
VEGF-A165 and VEGF-A145 (Gluzman-Poltorak et al. 2000; Pan et al. 2007; Soker et al. 1998). 
In porcine aortic endothelial cells co-transfected with Nrp-1 and VEGFR-2, chemoattraction 
towards VEGF-A165 is increased as compared to cells transfected with either receptor alone 
(Soker et al. 1998). The increased chemotactic response observed in co-transfected PAE cells 
was attributed to the formation of complexes between Nrp-1 and VEGFR-2 (Whitaker et al. 
2001), and it was demonstrated that complex formation can take place between receptors of one 
cell or between neighboring cells, and results in enhanced VEGFR-2 signaling under certain 
conditions (Soker et al. 2002). Whether Nrp-1 can signal on its own is still under discussion and 
may be cell type specific (Wang et al. 2003).  
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1.4.5 Crosstalk between VEGFR-2 and integrins in angiogenesis 
Early evidence shows that angiogenesis not only requires growth factor stimulation but is also 
dependent on outside-in signaling mediated by integrins. Integrins are heterodimeric 
transmembrane cell surface receptors for the extracellular matrix. By linking the extracellular 
matrix and the cell cytoskeleton, integrin outside-in signaling has a major impact on cell 
behavior, and integrin occupancy modulates cellular functions such as survival, cell-cycle 
progression, substrate adhesion, migration, and signaling via other cell surface receptors. 
Integrins are composed of one α and one β subunit that are non-covalently linked to each other, 
and the subunit composition determines the ligand specificity of a given integrin. Angiogenesis 
is a process that is profoundly dependent on the extracellular matrix, and so the prominent role 
that integrins play during vascular remodeling is not surprising. On quiescent endothelial cells, 
integrins α1β1, α2β1, α3β1, α5β1, α6β1, α6β4  and αvβ5 are expressed (Stupack and Cheresh 
2002), mediating the attachment to laminins, collagens, fibronectin or vitronectin. Angiogenic 
stimuli alter the integrin-expression profile and result in upregulation of α1β1 and α6β1 (Lee et 
al. 2006; Stupack and Cheresh 2002) as well as a dramatic upregulation of αvβ3 expression (Lee 
et al. 2006; Stupack and Cheresh 2002), thus allowing activated integrins to interact with 
proteins of the provisional matrix and matricryptic sites of extracellular matrix proteins that 
become exposed upon proteolytic processing (Stupack and Cheresh 2002). 
Early evidence of the importance of integrins specifically points to an essential role of αvβ3 in 
angiogenesis. The expression of this integrin is absent on quiescent vessels, but strongly 
upregulated in angiogenic vessels in the granulation tissue of human wounds and in the chick 
chorioallantoic membrane (CAM, Brooks et al. 1994a). αvβ3 is functionally required for 
angiogenesis, as inhibition by either function blocking antibodies or cyclic arginine-glycine-
aspartic acid (RGD)-peptides selectively induces apoptosis of activated endothelial cells (Brooks 
et al. 1994a; Brooks et al. 1994b). Ligation of αvβ3 hence promotes an important survival signal 
for activated endothelial cells that involves the inhibition of p53 binding to DNA (Stromblad et 
al. 1996).  
Importantly, integrin αvβ3 also plays a critical role in the full activation of VEGFR-2 (Soldi et 
al. 1999) and other receptor tyrosine kinases such as PDGF-receptor β, insulin receptor, and 
TGFβ type II receptor (Scaffidi et al. 2004; Schneller et al. 1997). In endothelial cells attaching 
to an αvβ3 ligand, VEGFR-2 signaling is markedly increased; the phosphorylation of VEGFR-2 
is stronger, and cells proliferate and migrate more compared to cells stimulated with VEGF-A165 
on ligands specific to other integrins. Integrin αvβ3 is activated by VEGF-A165-stimulation 
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downstream of VEGFR-2 via a signaling pathway that seems to involve PI3K and Akt (Byzova 
et al. 2000). Moreover, both receptors can be co-immunoprecipitated upon VEGF-A165 
stimulation (Hall et al. 2004; Hall and Hubbell 2004; Soldi et al. 1999). This interaction between 
VEGFR-2 and integrin αvβ3 was shown to involve the extracellular domains of the receptors, to 
be mediated by the integrin β3 subunit, and to require also the αv subunit (Borges et al. 2000). 
Mahabeleshwar and co-workers showed that the stimulation of either receptor leads to complex 
formation and to the mutual transactivation of the receptors resulting in increased 
phosphorylation of VEGFR-2 and β3 (Mahabeleshwar et al. 2007). Furthermore, in these 
complexes, VEGFR-2 associates with activated αvβ3 integrin in angiogenic cells, both in 
HUVEC stimulated with VEGF-A in vitro, and in vessels in biopsies taken from prostate cancers 
in vivo (Mahabeleshwar et al. 2008). Research done by this group indicates that 
autophosphorylation of VEGFR-2 upon VEGF-A stimulation recruits cSrc to the receptor and 
leads to interaction of VEGFR-2 with αvβ3. β3 is subsequently phosphorylated on two 
cytoplasmatic tyrosine residues by cSrc, which is necessary for the prolonged and full activation 
of VEGFR-2 (Figure 4). Furthermore, basal VEGFR-2 phosphorylation can be triggered by 
integrin αvβ3 ligation in endothelial cells even in the absence of VEGFR-2 and can start the 
angiogenic program in CAMs (Hall et al. 2004; Mahabeleshwar et al. 2007). The angiogenic 
program can also be activated by direct binding of VEGF-A165 to αvβ3 (Hall et al. 2004; 
Hutchings et al. 2003). 
 
 
Figure 4: Model of the molecular mechanisms of transactivation of VEGFR-2 and integrin αvβ3. VEGF-A binding to VEGFR-2 
(1) results in receptor autophorphorylation (2). cSrc is recruited to phosphorylated VEGFR-2 and activated (3), and mediates the 
phosphorylation of β3 (4), thereby activating integrin αvβ3 (5). Complex formation between the activated receptors (6) allows for 
their full activation and synergistic signaling (Somanath et al. 2009). 
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Silencing experiments, in which the expression of β-integrin subunits β1, β3 and β5 was 
downregulated, showed that the silencing of β3 integrin had the most profound effect on 
endothelial cell biology. HUVECs in which the expression of β3 was downregulated by siRNA 
were not capable of tube formation and phosphorylation of VEGFR-2 was reduced. Silencing of 
the other β-subunits resulted in less severe disfunction in these experiments (Mahabeleshwar et 
al. 2008), even though also integrins α1β1 and α2β1 have been shown to be crucial for 
angiogenesis in vitro and in vivo (Senger et al. 1997; Senger et al. 2002). 
 
However, the role of integrin αvβ3 as a pro-angiogenic modulator has recently been questioned. 
Even though the majority of mice deficient in αv integrins dies in utero, these mice still develop 
a vascular system, in which angiogenic sprouting and vascular remodeling takes place. Lethality 
is not caused by absence of vessel growth, but by heamorrhages in the brain and the interstitium 
(Bader et al. 1998). Similarly, deficiency in integrin β3 results in mortality, which in part is due 
to placental defects, and to hemorrhages. Nevertheless, mice surviving birth develop a normally 
vascularized retina indicative of functional angiogenesis (Hodivala-Dilke et al. 1999). This may 
result from compensatory mechanisms, as in these mice, the expression of VEGFR-2 is 
upregulated and enhanced phosphorylation is observed (Reynolds et al. 2004). By contrast, 
knock-in mice in which the tyrosine residues on integrin β3 were mutated, develop normally. 
However, the mutated β3 integrin is not capable to form complexes with VEGFR-2 and 
signaling is reduced. Also, pathological angiogenesis in response to subcutaneously implanted 
tumors is abolished (Mahabeleshwar et al. 2006). Importantly, the strictly anti-angiogenetic 
effect of RGD-mimetics was queried in a recent study, as low concentrations of these molecules 
currently in clinical trials for the inhibition of tumor angiogenesis were shown to promote 
angiogenesis (Reynolds et al. 2009). Thus, the molecular regulation of angiogenesis by integrin 
avβ3 is not entirely clear. 
 
1.4.6 Role of VEGF-A during wound healing 
VEGF-A-mediated signaling and the angiogenic response induced by VEGF-A are crucial for 
normal wound healing. In unwounded skin, VEGF-A expression is absent, but immediately after 
injury, VEGF-A is released by platelets and monocytes (Bottomley et al. 1999) and exerts an 
important function in the recruitment of monocytes into the clot. Also other inflammatory cell 
types are important sources of VEGF-A. Furthermore, hypoxia in the wound area induces 
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VEGF-A expression in keratinocytes, fibroblasts and dermal micorvessels (Connolly et al. 1989; 
Namiki et al. 1995; Senger et al. 1983). At the mRNA- and protein level, VEGF-A becomes 
upregulated in wounds at day 3 post wounding and declines around day 13. After three weeks, 
VEGF-A expression is absent again. The expression of VEGF-A is thus restricted both in time 
and space and parallels the time course and location of active wound angiogenesis (Bates and 
Jones 2003; Brown et al. 1992; Kishimoto et al. 2000). 
The importance of VEGF-A in tissue regeneration first became evident during a study 
employing diabetic mice, characterized by delayed wound closure. In these mice, VEGF-A 
mRNA is briefly upregulated on day one post-injury, but downregulated relative to control levels 
from day three on, which is the time granulation tissue formation normally starts. In wild type 
mice by contrast, VEGF-A expression is upregulated concomitantly with granulation tissue 
formation (Frank et al. 1995). Furthermore, in a pig wounding model, it was shown that 
application of VEGF-A neutralizing antibodies inhibits wound angiogenesis and granulation 
tissue formation (Howdieshell et al. 2001). By contrast, both topical application of VEGF-A 
protein as well as transfection of the skin with a plasmid encoding for VEGF-A improved the 
closure of wounds in diabetic mice (Galiano et al. 2004; Roth et al. 2006).  
 
1.5 Cellular and molecular mechanisms of angiogenesis 
1.5.1 Induction of angiogenesis and the role of VEGF-A 
Angiogenesis is the growth of new capillaries out of pre-existing ones and hence clearly 
distinctive from vasculogenesis, the formation of a primitive capillary plexus from precursor 
cells during early stages of development. Angiogenesis occurs in the adult in a very limited array 
of situations physiologically, among these are the female reproductive cycle and skin 
regeneration. Endothelial cells are among the most quiescent cell populations of the human body 
(Folkman 2006). Hence, angiogenesis requires activation of endothelial cells, involving a 
profound change in their genetic program. This re-programming allows endothelial cells to 
proliferate, to migrate towards angiogenic stimuli and to interact with provisorial and interstitial 
extracellular matrices (Cheresh and Stupack 2008). During the early stages of angiogenesis, this 
re-programming of endothelial cells is induced by VEGF-A. Internalization of vascular 
endothelial cadherin leads to the loosening of cell-cell junctions between endothelial cells (Potter 
et al. 2005), which is a prerequisite for cells to migrate. The disruption of cell-cell contacts also 
increases vascular permeability, thus permitting leakage of plasma proteins from the circulation, 
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to form a provisional matrix permissive for migration. VEGF-A signaling furthermore stimulates 
the turnover of focal adhesions, the reorganization of the cytoskeleton resulting in a loss of cell 
polarity, and stimulates proliferation (see above). Importantly, the growth factor also triggers the 
expression of proteases to degrade the basal membrane, the connective tissue or the provisional 
matrix being invaded and of an additional set of integrins that recognize substrates found in these 
tissues (Cheresh and Stupack 2008).  
 
1.5.2 Vascular guidance by tip cells and the role of tip cell 
selection 
Importantly, during the sprouting process, cells need guidance to determine their migration. In 
the developing mouse retina, but also ex vivo in rat aortic ring assays, it was demonstrated that 
the growing vessels are guided by a single cell that is peculiar by the dynamic extension and 
regression of multiple filopodia (Gerhardt et al. 2003). These cells are named tip cells and 
followed by a phalanx of lumen-bearing stalk cells. Due to their filopodia, tip cells are highly 
polar and capable of probing their environment for pro- and anti-angiogenic cues far from the 
cell body. Particularly, tip cells were shown to be enriched in VEGFR-2 that is prominently 
located to filopodia, rendering them thus capable to act as a sensor for VEGF (Gerhardt et al. 
2003). The tip cell phenotype is induced by VEGF-A, as topical VEGF-A increases the number 
of tip cells induced, while the application of VEGF-A-neutralizing antibodies in the developing 
mouse retina abolishes tip cell formation and extension of filopodia (Gerhardt et al. 2003). For 
ordered angiogenesis to take place, it is necessary to ensure that not all VEGF-A stimulated cells 
become tip cells, as that is the default fate for VEGF-A-stimulated endothelial cells (Bentley et 
al. 2008). This is accomplished by lateral inhibition mediated by delta-like ligand 4 (Dll4) and 
notch signaling. It was shown that VEGF-A-stimulated cells up-regulate the notch-ligand Dll4 
via the VEGFR-2/PI3K/Akt axis (Liu et al. 2003). Dll4 binds to and activates notch in 
neighboring cells Notch signaling in these cells downregulates the expression of VEGFR-2 
(Williams et al. 2006), hence making cells less responsive to VEGF-A, and leading to a 
decreased Dll4-expression. Cells with a strong notch signal therefore adapt to stalk cells 
(Hellstrom et al. 2007). In this way, cells that receive the stronger VEGF-A stimulus and express 
more Dll4 acquire the tip cell phenotype and laterally inhibit adjacent cells from doing the same 
(Bentley et al. 2008). For tip cell selection, but also for their guidance, VEGF-A-gradients are of 
crucial importance (Bentley et al. 2008). 
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1.5.3 The role of VEGF-A binding to the extracellular matrix in tip 
cell guidance 
For VEGF-A isoforms possessing a heparin-binding domain, VEGF-A localization within the 
extracellular matrix can be controlled and gradients can be established, which is not the case for 
diffusible VEGF-A isoforms. Disturbance of these gradients leads to vascular malformations, as 
demonstrated in mice selectively expressing one of the three main VEGF-A isoforms 
VEGF-A120, VEGF-A164 and VEGF-A188 (in mice, VEGF-As are one amino acid shorter than in 
humans, Ruhrberg et al. 2002; Stalmans et al. 2002). In the developing retina of mice that 
express exclusively the soluble isoform VEGF-A120, VEGF-A is no longer localized to 
astrocytes but distributed in a more diffuse pattern. Hence, the VEGF-A gradient is less steep in 
these mice. This is reflected by the extension of short filopodia not only in tip cells but also in 
stalk cells. The vessels are bigger as stalk cell proliferation is increased, branching is decreased 
and migration is impaired in mice expressing solely VEGF-A120 (Gerhardt et al. 2003; Ruhrberg 
et al. 2002). In contrast, expression of only the tightly matrix bound isoform VEGF-A188 has the 
opposite effect on the vascular network: vessels are very thin and hyperbranched. Mice which 
express only VEGF-A165, the VEGF-A isoform partially matrix bound and partially soluble, 
develop a normal retinal vasculature (Stalmans et al. 2002). Taken together, these results 
demonstrate that both tip cell migration and stalk cell proliferation are regulated by VEGF-A, 
but that tip cell migration is dependent on extracellular gradients, while stalk cell proliferation 
depends on local VEGF-A concentrations (Gerhardt et al. 2003). 
 
1.5.4 Maturation of the vascular network 
Newly induced vasculature is immature and characterized by high instability, leakiness, and high 
dependence on VEGF-A-signaling for its survival. Vessels mature by the recruitment of 
pericytes, a vascular mural cell type that covers the outside of the vessel and helps to build a 
novel basal membrane in which it is embedded (Armulik et al. 2005; Jain 2003). It was shown 
that pericytes become recruited to the novel vessel by PDGF-B, which in binding to the 
PDGFR-β induces the proliferation of pericytes and their migration along the nascent vessel 
(Hellstrom et al. 1999; Hoch and Soriano 2003). PDGF-B in turn is secreted by tip cells 
(Gerhardt et al. 2003) and sequestered to the growing vessel’s wall by binding to HSPGs 
(Abramsson et al. 2007). Between the two cell types, special cell-cell contacts are established, 
which allow communication between the cells (Armulik et al. 2005). Both endothelial cells and 
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pericytes constitute to a novel basement membrane, containing laminins, fibronectin, nidogen-1 
and perlecan (Stratman et al. 2009). Basement membrane synthesis is accompanied by altered 
integrin expression in both cell types and contributes to the regulation of the vessel’s diameter. 
Additionally, the basement membrane is stabilized by protease inhibitors released by vascular 
cells: endothelial cells secrete the soluble tissue inhibitor of metalloproteinase-2 (TIMP-2) while 
pericytes secrete TIMP-3, which becomes sequestered in the basal membrane due to heparin-
binding motifs (Saunders et al. 2006). Besides inhibiting several proteases, TIMP-3 was also 
shown to negatively regulate pro-angiogenic signaling induced by VEGF-A by competing with 
VEGF-A for VEGFR-2 (Qi et al. 2003). 
Homeostasis and quiescence of the endothelium are actively maintained by 
angiopoietin-1/tyrosine kinase with immunoglobulin and epidermal growth factor homology 
domain-2 (Ang1/Tie-2) signaling, a pathway that is also essential for the maturation of the 
vasculature (Armulik et al. 2005; Murakami and Simons 2009). Tie-2 is an endothelium-specific 
receptor tyrosine kinase and becomes activated upon binding of Ang1, which is constitutively 
expressed by perivascular and mural cells (Davis et al. 1996; Suri et al. 1996). Downstream 
signaling results in vessel stabilization and resistance to VEGF-A-induced leakiness (Gavard et 
al. 2008). 
 
1.6 Strategies aiming at the optimization of VEGF-A 
induced angiogenesis in tissue engineering 
1.6.1 Stabilization of the VEGF-A165 heparin-binding site in the 
proteolytic environment of the chronic wound 
In our laboratory, it was shown that VEGF-A165 becomes degraded in wound fluid obtained from 
chronic wounds because the activation of the serine-protease plasmin is enhanced in these 
wounds (Lauer et al. 2000). VEGF-A165 processing by plasmin gives rise to VEGF-A110, which 
is the receptor binding domain of the molecule, and VEGF-A111-165, which contains the heparin-
binding domain (Keyt et al. 1996; Lauer et al. 2000). Although VEGF-A110 retains its ability to 
bind to both VEGFR-1 and -2, its potency is markedly decreased as it retains no affinity to 
VEGF-A co-receptors that interact with the heparin-binding domain (Keyt et al. 1996). Upon 
prolonged incubation with plasmin or chronic wound fluid, VEGF-A is completely degraded 
(Lauer et al. 2000). Thus, the poor stability coupled with decreased potency of the growth factor 
may account for the lack of granulation tissue formation observed in chronic wounds.  
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In order to increase the stability of VEGF-A165 in non-healing skin lesions, several variants of 
this growth factor isoform in which the plasmin cleavage site of the protein was mutated were 
created. When the plasmin cleavage site was mutated from Arg110/Ala111 to either 
Arg110/Pro111 (VEGF-A165A111P) or to Lys110/Pro111, the mitogenic properties of the wild 
type protein were retained, and the potent proteins remain stable upon plasmin digest and in 
wound fluid obtained from chronic wounds (Lauer et al. 2002). Moreover, in vivo experiments 
were performed in diabetic (db/db) mice employing transfection of the skin by particle 
bombardment with plasmids carrying either VEGF-A165 or the plasmin resistant mutant 
VEGF-A165A111P prior to wounding (Roth et al. 2006). Db/db mice are characterized by a 
mutation in their leptin receptor gene (Bahary et al. 1990) and represent an established model for 
the study of impaired wound healing. Importantly, they also show increased plasmin activity in 
skin wounds (Roth et al. 2006). When VEGF-A165 or VEGF-A165A111P was expressed in skin of 
diabetic mice during regeneration, a well-vascularized granulation tissue was induced by day 12, 
which was not the case in animals receiving a control vector. In comparison to VEGF-A165, 
VEGF-A165A111P induced a more persistent vasculature that regressed later during healing, most 
likely due to the prolonged stability of VEGF-A165A111P protein at the wound site, which 
protected endothelial cells from apoptosis and resulted in more efficient recruitment of pericytes 
(Roth et al. 2006). For all experiments performed in this thesis, a VEGF-A165 variant in which 
the plasmin cleavage site was mutated from Arg110/Ala111 to Lys110/Pro111 was used 
(Figure 5). This isoform is referred to as VEGFmut henceforth. 
 
VEGF165 wild type  100  K C E C R P K K D R A R Q E N P C G P C  120 
        | | | | | | | | |     | | | | | | | | | 
VEGF165 mutant  100  K C E C R P K K D K P R Q E N P C G P C  120 
 
Figure 5: For experiments performed, a VEGF-A165 isoform was used, which is resistant to plasmin mediated processing 
due to a mutation in the major cleavage site from Arg110/Ala111 to Lys110/Pro111. This mutant is denoted as VEGFmut. 
 
1.6.2 Targeted delivery of VEGF-A for pro-anigogenic therapies 
In a large variety of animal models, delivery of VEGF-A in either plasmid or protein form to 
induce angiogenesis yielded promising results. However, most double-blinded, placebo 
controlled clinical trials in humans have been disappointing so far, as VEGF-A treatment failed 
to prove superior to sham treatments.  
Major challenges to overcome in the development of pro-angiogenic therapy using VEGF-A are 
the tight control of the dosage, the precise local administration and the timely limited exposure 
of the growth factor (Zisch et al. 2003). The proper local dose is essential for the induction of a 
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functional and mature vasculature, as VEGF-A acts physiologically in a very narrow range of 
concentrations (Ozawa et al. 2004). Elevated concentrations of VEGF-A result in the formation 
of excessive vasculature that is leaky, a fact that together with VEGF-A’s ability to induce 
vascular permeability contributes to the formation of edema, which is a major side-effect 
observed upon bolus injections. Furthermore, overdose or extended delivery can result in the 
formation of haemangioma-like structures. Also, this immature and dysfunctional vasculature 
regresses as the growth factor concentration decreases due to protein diffusion out of the site of 
application below a biologically effective dose (Zisch et al. 2003).  
To overcome these problems, Schense and Hubbell developed a delivery strategy in which 
recombinant proteins or peptides are covalently coupled to fibrin matrixes when applied to the 
place of action and released upon cell-mediated fibrin degradation (Schense and Hubbell 1999). 
Fibrin is a biopolymer forming naturally during wound healing, is non-toxic, and provides cues 
for degradation and invasion by cells. Thus, fibrin is a very attractive compound for tissue 
engineering applications.  
Its precursor, fibrinogen, consists of three pairs of disulfide-bond linked polypeptide chains. 
Fibrinogen is converted to fibrin by activity of the protease thrombin that cleaves off N-terminal 
fibrinopeptides A and B. Thereby, binding sites on the molecule are exposed, allowing for non-
covalent interactions with other fibrin molecules, resulting in the generation of double stranded 
protofibrils that laterally aggregate and built a network. This network is stabilized by covalent 
crosslinks formed between lysines and glutamines of distinct fibrin chains, a reaction that is 
catalysed by the transglutaminase factor XIIIa (Figure 6 A). Factor XIII is a heterotetrameric 
molecule that binds to fibrin(ogen) and is activated by thrombin to factor XIIIa (Mosesson et al. 
2001; Weisel 2004). Besides crosslinking fibrin molecules with each other, factor XIIIa also 
crosslinks α2-plasmin inhibitor or fibronectin to fibrin. The factor XIIIa substrate sequence of 
proteins that become bound to fibrin is known, and hence, by fusing a factor XIIIa substrate 
sequence to a recombinant protein, it is possible to incorporate it specifically into fibrin matrices. 
For this purpose, the substrate sequence of α2-plasmin inhibitor, NQEQVSPL, is used, as it is 
an especially efficient substrate of factor XIIIa (Schense and Hubbell 1999). Growth factors 
fused to this transglutaminase substrate sequence (denoted as TG henceforth) and incorporated 
into fibrin matrices are released once cells proteolytically degrade the matrix, and thereby they 
are available when needed by the cells (Figure 6 B). The liberation of growth factors from the 
matrix can be accelerated by inserting the engineered plasmin sensitive site LIKMKP denoted as 
PL between the TG sequence and the growth factor (Figure 6 C). Liberation under these 
circumstances is even more sensitive to the presence of cells (Ehrbar et al. 2005). 
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Figure 6: Fibrin as slow release matrix for the delivery of bioengineered VEGF-A proteins. (A) Fibrinogen is converted to fibrin 
by proteolytic processing by thrombin and aggregates to form a network. This network is covalently crosslinked by the activity of the 
transglutaminase factor XIIIa (Mosesson et al. 2001). (B) Expression of VEGFmut as a fusion protein with the factor XIIIa substrate 
sequence of α2-plasmin inhibitor (TG) allows for the covalent incorporation of the protein into fibrin matrices. (C) Comparison of 
differential release mechanisms of VEGFmut from fibrin gels. Soluble VEGFmut is thought to result in an uncontrolled burst release. 
Matrix-bound TG-VEGFmut is released once cells proteolytically degrade the matrix, and this release is more sensitive to the 
presence of cells, if a plasmin sensitive site (PL) is incorporated between the TG-site and VEGFmut (Ehrbar et al. 2005). 
 
The effect of matrix coupled VEGF-A121 has been investigated in vitro and in vivo by Zisch et al. 
and Ehrbar et al. They demonstrated that VEGF-A121 released from fibrin matrices remains 
active (Zisch et al. 2001) and that fibrin matrix bound VEGF-A121 is able to induce 
morphologically normal, hierarchical, well-developed vessels in a CAM assay. Matrix binding 
was shown to improve the effect of VEGF-A121 on vessel induction, as no unorganized capillary 
networks were observed. Moreover, it was shown in the mouse subcutaneous Teflon chamber 
implant model, that vessels induced by diffusible VEGF-A121 were leaky, whereas those induced 
by matrix bound VEGF-A121 did not leak (Ehrbar et al. 2004).  
Within the present study, plasmin resistant VEGF-A165 proteins were delivered to skin wounds 
using fibrin matrices in order to limit burst release of the growth factor.  
 
1.6.3 Amplification of VEGF-A165 induced signals 
An additional strategy to increase the angiogenic response of endothelial cells could be to 
co-stimulate VEGFR-2 and integrin αvβ3. As described above, this integrin plays a prominent 
role in VEGF-A stimulated angiogenesis, and co-stimulation can result in increased downstream 
signaling and integrin activation.  
For the generation of a bi-functional ligand consisting of VEGFmut and an integrin ligand, the 
design was inspired by a natural complex forming between VEGF-A165 and fibronectin. 
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Fibronectin is a 430 kDa rod-like protein composed of three different kinds of repeating modules 
(Figure 7 A) found in the blood and in the extracellular matrix. Fibronectin interacts with several 
extracellular matrix proteins such as collagen, fibrin and syndecan. Importantly, this molecule 
comprises various integrin-adhesion sites localized to fibronectin type III domains 9 (FNIII9) 
and 10 (Pankov and Yamada 2002) that primarily are recognized by integrin α5β1. Fibronectin 
binds to different growth factors including VEGF-A165. Activated thrombocytes were shown to 
be a source for a fibronectin/VEGF-A165 complex. The complex proved to amplify VEGF-A 
derived signaling in endothelial cells by binding to integrin α5β1 via the cell-binding domains 
FNIII9 and 10 on fibronectin, and to VEGFR-2 via VEGF-A165 (Wijelath et al. 2002, Figure 
7 A). The VEGF-A165-binding domain of fibronectin could be located to FNIII12-14. However, 
binding of VEGF-A165 to recombinant FNIII12-14 is not sufficient to increase the cellular 
response to the growth factor. Instead, the fibronectin cell binding domains FNIII9/10, which are 
a ligand for α5β1, have to be present in the recombinant VEGF-A165-binding protein to trigger a 
strong cellular response. The minimal fibronectin based construct permissive for synergistic 
downstream signaling in that context thus consisted of the cell binding type III domains 9 and 10 
as well as the VEGF-A-binding domains III12-14 (Wijelath et al. 2006). 
 
 
Figure 7: The design of a bi-functional protein for the induction of synergistic signaling between VEGFR-2 and integrin 
αvβ3  was inspired by nature. (A) A complex released from activated thrombocytes consisting of fibronectin and VEGF-A165 was 
shown to induce synergistic downstream signaling in endothelial cells by co-activation of VEGFR-2 and integrin α5β1 (fibronectin 
domain structure from Wierzbicka-Patynowski and Schwarzbauer 2003). (B) Generation of a bi-functional construct consisting of 
VEGF-A165mut and FNIII10 is thought to mimic this co-stimulation but to signal via VEGFR-2 and integrin αvβ3. This construct is to 
be delivered in fibrin matrices.  
 
Interestingly, different fibronectin fragments have distinct affinities to various integrins. Thus, 
large fragments comprising FNIII9 and 10 were shown to bind to integrin α5β1, whereas small 
fragments consisting of FNIII10 bound preferentially to integrin αvβ3 (Pytela et al. 1985).  
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FNIII10 is the location of the minimal site required to promote integrin-mediated attachment, the 
tripeptide RGD, which is recognized by both integrins. However, for enhanced activation of 
α5β1, additional portions of FNIII9 are required, that consist in a synergy site comprising a 
PHSRN sequence.  
To mimic the enhanced biological activity of fibronectin-bound VEGF-A165, the FNIII10 was 
fused to VEGFmut via a linker peptide, thus giving raise to FNIII10-linker-VEGFmut, referred 
to as FLV. The RGD-site of FNIII10 is a promiscuous ligand for various integrins. However, in 
the activated endothelium, integrin αvβ3 becomes strongly upregulated (Brooks et al. 1994a), 
thus the construct is thought to target VEGFR-2 and integrin αvβ3 for synergistic downstream 
signaling (Figure 7 B). 
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2 Hypothesis 
  
Previous investigations show that interactions between VEGF-A isoforms and the extracellular 
matrix are of crucial importance for the formation of a functional vascular network. VEGF-A 
isoforms bound to the extracellular matrix permit the formation of a growth factor tissue 
gradient, which is essential for the formation of tip cells and guidance of growing vessels. 
Furthermore, cells can discriminate between matrix bound and soluble VEGF-A, and both forms 
result in distinct downstream signaling. Finally, matrix binding of VEGF-A is considered 
important for the generation of local VEGF-A depots and can be used for the development of 
therapeutic strategies to pomote angiogenesis. 
 
In this thesis, the following questions were investigated: 
1. How does non-covalent binding of VEGF-A165 to fibrin influence wound angiogenesis as 
compared to covalent binding? To answer this question, the binding of a plasmin-resistant 
VEGF-A165 molecule (VEGFmut) was artificially increased by covalent coupling of the 
molecule to fibrin. To that end, VEGFmut was expressed as a fusion protein to a substrate 
sequence of the transglutaminase factor XIIIa, which under these conditions mediates the 
formation of covalent crosslinks between fibrin fibers and VEGFmut. VEGFmut covalently 
linked to a fibrin gel was delivered to full-thickness wounds of diabetic mice and its 
proangiogenic potential and tissue repair activities were examined.  
 
2. Does the simultaneous co-stimulation of integrin αvβ3 and VEGFR-2 by a bioengineered 
protein result in increased angiogenesis? To investigate this question, bi-functional fusion 
proteins comprising VEGFmut fused to fibronectin type III domain 10 were generated 
(FLV) in order to co-ligate VEGFR-2 and integrin αvβ3, and their biological activities were 
investigated in vitro and in vivo. 
 
The recombinant proteins generated can be used as experimental tools to gain new insights into 
the biology of growth factor-matrix interactions and to elucidate mechanisms underlying the 
increased cellular responses upon integrin and growth factor receptor co-stimulation. 
Furthermore, the use of the recombinant fusion proteins in combination with fibrin matrices 
might also represent a potential pro-angiogenic approach for the treatment of impaired wound 
healing conditions due to defective angiogenesis.  
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3 Results 
 
3.1 Design of VEGF-A based fusion proteins for the 
co-stimulation of VEGFR-2 and integrin αvβ3 
3.1.1 Domain organization of engineered VEGF-A proteins 
To allow for simultaneous activation of VEGFR-2 and integrin αvβ3, a novel fusion protein was 
designed based on the plasmin-resistant VEGFmut. As ligand for integrin αvβ3, FNIII10 was 
chosen, which due to its RGD binding site is a promiscuous integrin-ligand and is also 
recognized by integrin αvβ3. These functional domains were interconnected by a linker. 
Additional functional domains employed were the TG-site for factor XIIIa-mediated covalent 
coupling of the proteins to fibrin, and a plasmin-sensitive sequence for facilitated release of the 
protein from the fibrin gel upon cell invasion. Eight different constructs were cloned into 
expression vectors and purified as described in section 3.2. An overview on the domain 
organization is given in Figure 8. 
 
 
 
Figure 8: Domain organization of recombinant fusion proteins 
expressed and purified. Abbreviations: FNIII10: fibronectin type III 
domain 10, TG: transglutaminase substrate sequence of α2-plasmin 
inhibitor (NQEQVSPL), VEGFmut: plasmin-resistant variant of 
VEGF-A165, PL: plasmin-sensitive site (LIKMKP), L: linker. 
 
3.1.2 Design of the linker interconnecting FNIII10 and VEGFmut 
in the bi-functional constructs 
For the functionality of the system it is essential to choose a linker long enough to allow 
coincident stimulation of VEGFR-2 and integrin αvβ3. To estimate the required linker length, 
the diameters of both receptors were determined using Pdb-viewer, added and divided by two 
(Figure 9). 15% of the length was added as recommended by Crasto and Feng (2000).  
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The required linker length was calculated to be 112 angstroms. Assuming that one amino acid is 
3.25 angstroms long (Crasto and Feng 2000; Huston et al. 1988), the required linker is 34 amino 
acids long. 
 
 
 
Figure 9: The required length of the linker was 
roughly calculated by determining the diameters of 
the dimeric VEGFR-2 and αvβ3. The diameters d1 
and d2 were added and divided by two and additionally 
15% of the length was added. The required linker 
length is 112 angstroms. 
 
Furthermore, the amino acid sequence of the linker can influence the function of the recombinant 
fusion protein. In general, the linker should be flexible and have an extended conformation, 
while at the same time it should not interfere with folding of the protein. It is possible to search 
databases for natural linkers according to their length. These interconnect domains of native 
proteins with each other but have no enzymatic activity on their own. Another approach is the 
use of a repetitive GGGGS-linker, which is frequently and successfully used in the production of 
recombinant single-chain antibodies. Due to its high glycine content, this linker is very flexible, 
and hydrophilic serine residues promote an extended conformation (Huston et al. 1991). 
Additionally, it is unlikely to be immunogenic, and no protease cleavage site was predicted 
within the linker using the PeptideCutter tool available on the ExPASy Proteomics server (Swiss 
Institute of Bioinformatics, Lausanne). For the interconnection of FNIII10 and VEGFmut, the 
linker (GGGGS)6.5 was used. 
 
3.2 Production and identification of the recombinant fusion 
proteins 
3.2.1 Expression of GST-tagged proteins in E. coli 
3.2.1.1 Purification of FNIII10 and TG-FNIII10 
FNIII10 and TG-FNIII10 were purified as GST-fusion proteins. Figure 10 shows typical 
chromatograms and protein gels monitoring the purification processes. In the first step of 
purification (Figure 10 A), GST-fusion proteins were retained in the GSH-column, and proteins 
not binding to the column were found in the first peak. Upon addition of elution buffer, 
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GST-FNIII10 or GST-TG-FNIII10 was eluted from the column, represented by the second peak. 
Following thrombin mediated cleavage, a second step of purification was performed removing 
the protease and the cleaved-off tag from the sample (Figure 10 B). FNIII10 or TG-FNIII10 was 
found in the fractions collected from the first peak. The second peak represented GST, and the 
third set of peaks corresponded to thrombin (Figure 10 B). Samples from the peaks denoted in 
Figure 10 A and B were investigated by Coomassie stained reducing SDS-PAGE gels (Figures 
10 C and D). GST-FNIII10 and GST-TG-FNIII10 were detected at 35 kDa. The GST-tag was 
efficiently cleaved off by thrombin, and upon thrombin digest, GST was detected at 25 kDa and 
FNIII10 and TG-FNII10 at 12 kDa. Both final products revealed high purity. From 1 L of 
bacterial culture, 3 mg of pure recombinant FNIII10 and 10 mg of TG-FNIII10 were purified, 
respectively. Yields of all protein productions performed are summarized in Table 1. 
 
 
Figure 10: Purification of FNIII10 and TG-FNIII10 as GST-fusion proteins resulted in high yields and final products of good 
purity. (A) Chromatogram showing the first step of purification, capturing GST-FNIII10 and GST-TG-FNIII10 from the soluble 
fraction of bacterial lysates exploiting their GSH-binding affinity. (B) Chromatogram showing the second purification step, in which 
the sample was applied to a GSH-packed column and to a benzamidine (BA) column to remove GST and thrombin. (C, D) The 
purification process was monitored by SDS-PAGE and subsequent protein staining.  
 
3.2.1.2 Purification of TG-PL-FLV and VEGFmut as GST-fusion proteins 
For GST-TG-PL-FLV, the thrombin digestion was optimized first. The protein was completely 
digested within 8 hours by 1 U of thrombin per mg of protein. Figure 11 A shows a western blot 
using a primary antibody directed against VEGF-A monitoring the digestion of the protein over  
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time. Prior to thrombin digest, two bands were visible: GST-TG-PL-FLV at about 65 kDa, and a 
truncated form of GST-TG-PL-FLV, which had a molecular weight of about 50 kDa. Upon 
thrombin digest, TG-PL-FLV was detectable at 37 kDa, which corresponded well to its predicted 
molecular weight. Surprisingly, two additional bands became visible upon thrombin digestion. 
The band at about 25 kDa corresponded to a truncated form of TG-PL-FLV, and the other band 
was detected at 20 kDa. This latter band seemed to be another thrombin cleavage product 
resulting from processing of TG-PL-FLV because this 20 kDa band increased in intensity 
whereas the 37 kDa and the 25 kDa band decreased in intensity with prolonged thrombin 
incubation. Indeed, for GST-TG-PL-FLV, a second thrombin cleavage site was predicted by 
ExPASy Proteomic Server’s PeptideCutter tool (Swiss Institute of Bioinformatics), which is 
situated in the RGD domain of FNIII10. Cleavage in this site would give rise to linker-
VEGFmut, and the predicted molecular weight of this fragment is in agreement with a band at 
about 20 kDa on SDS-PAGE gels. 
 
 
Figure 11: GST-TG-PL-FLV was processed by thrombin to yield TG-PL-FLV, but purification was not possible due to the 
protein’s affinity to benzamidine. (A) Western blot using an antibody directed against VEGF monitoring the thrombin digest of 
GST-TG-PL-FLV over time using 1 U per mg of protein. (B) Coomassie blue stain and (C) VEGF-specific western blot on samples 
taken during the purification process. 
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TG-PL-FLV was attempted to be purified in two steps as described above and monitored by 
Coomassie blue staining and western blot (Figure 11 B and C). GST-TG-PL-FLV was detected 
on Coomassie blue stained SDS-PAGE gels at 65 kDa (Figure 11 C). The GST-tag was cleaved 
off by thrombin and detected at 25 kDa, while TG-PL-FLV was observed at 37 kDa. In the flow-
through, where TG-PL-FLV was expected, exclusively linker-VEGFmut was found in a band at 
20 kDa. TG-PL-FLV by contrast efficiently bound to benzamidine, which is used to remove 
thrombin from the sample. The identity of these bands was confirmed by western blot using an 
antibody directed against VEGF as primary antibody (Figure 11 C). Therefore, it was impossible 
to remove thrombin from the protein sample. Due to this benzamidine affinity, the purification of 
TG-PL-FLV following standard protocols was not possible. 
The production of VEGFmut as a GST-fusion protein was not feasible following this protocol 
either. During large-scale thrombin digest, the recombinant VEGFmut regularly precipitated. 
Thus, VEGF-based proteins were purified from bacterial inclusion bodies. 
 
3.2.2 Purification of VEGFmut-containing proteins from bacterial 
inclusion bodies 
3.2.2.1 Purification of VEGFmut by heparin affinity chromatography 
The purification of VEGFmut was done as described previously (Zisch et al. 2001). Briefly, 
bacterial protein expression of the recombinant protein was induced with IPTG for 3 hours, 
inclusion bodies were then harvested and solubilized, and VEGFmut was refolded in decreasing 
concentrations of urea and dimerized in a GSH redox system. The dimeric protein was then 
purified by heparin affinity chromatography and eluted with NaCl. 
To increase both yield and purity of the sample, two modifications of the original protocol were 
established. First, protein production was induced overnight, to increase quantity as well as 
purity, since the relative amount of contaminating protein is expected to decrease in inclusion 
bodies as the relative amount of recombinant protein increases (Carrio et al. 1998). Second, the 
sample was pre-cleared prior to purification by adjusting the pH to 3.5, at which most impurities 
precipitated (Fiebich et al. 1993). Prolonged induction time resulted in higher recombinant 
protein content in inclusion bodies as exemplified for the expression of TG-VEGFmut 
(Figure 12 A), and acetic precipitation increased the purity of the sample for both, VEGFmut and 
TG-PL-FLV as shown on Coomassie stained SDS-PAGE gels (Figure 12 B).  
Both modifications of the protocol were therefore included in subsequent protein productions. 
Results 
 
36 
 
Figure 12: Prolonged induction time and removal of acetic precipitable proteins from the sample resulted in higher content 
of target proteins in inclusion bodies and purer samples as monitored by SDS-PAGE and Coomassie blue staining. 
(A) Effect of induction time on recombinant protein content in inclusion bodies. (B) Pre-clearing by acetic precipitation. T – total, P – 
pellet, S – supernatant.  
 
The purification of VEGFmut following this modified protocol is shown in Figure 13. The 
solubilized inclusion bodies were enriched in monomeric VEGFmut detectable at 20 kDa (Figure 
13 A). The refolded, dimerized and pre-cleared protein sample contained good amounts of 
dimeric VEGFmut, and the dimeric VEGFmut is detectable at 37 kDa under non-reducing 
conditions on Coomassie blue stained SDS-PAGE gels (Figure 13 B). The sample denoted as 
supernatant in Figure 13 B was applied to a heparin column and eluted in one step after 
extensive washing (Figure 13 C). 
 
 
Figure 13: VEGFmut was purified according to the modified protocol, and the final protein product was of good purity and 
mainly composed of the dimeric protein. (A, B, D) Coomassie stained SDS-PAGE gels and (C) chromatogram monitoring the 
purification process. (E) Final product as detected by Coomassie stain and western blot. P – pellet, S – supernatant.  
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Investigation of obtained fractions by non-reducing SDS-PAGE and Coomassie blue staining 
identified several fractions highly enriched with dimeric VEGFmut (Figure 13 D). Similar 
fractions (B11 and B10) were pooled, and the final product exhibited good purity as shown by 
Coomassie blue staining and western blotting using an antibody raised against VEGF-A (Figure 
13 E). In several purifications, 2.1 mg of VEGFmut were obtained from 4 L of bacterial culture 
(Table 1). 
 
3.2.2.2 Purification of the engineered VEGF-proteins 
VEGF165wt, TG-VEGFmut, TG-PL-VEGFmut, FLV, TG-FLV and TG-PL-FLV were purified 
according to the optimized protocol as well. The final products are shown on non-reducing 
Coomassie blue stained SDS-PAGE gels in Figure 14, and the yields are summarized in Table 1. 
VEGF165wt was dimerized successfully and dimers were detected at 37 kDa. Several fractions 
enriched in the protein were pooled, and the final product is very pure (Figure 14 A). The yield 
from 3 L of bacterial culture was 6 mg. 
TG-VEGFmut was well dimerized and showed good purity (Figure 14 B). Similar fractions were 
pooled and frozen separately from fraction C8, in which the TG-VEGFmut content was higher. 
Dimeric TG-VEGFmut was visible at 36 kDa, and the final yield from 2 L of bacterial culture 
was 4.8 mg. 
Also of TG-PL-VEGFmut, several pure fractions were obtained. The dimeric protein was 
detected in a band at 37 kDa on a non-reducing SDS-PAGE gel (Figure 14 C). Fractions C3 and 
C5 were pooled and frozen separately from fraction C4. By this purification, 1.8 mg of TG-PL-
VEGFmut were obtained from a 2 L culture. 
Purification of FLV yielded one pure fraction, which was used for subsequent experiments 
(Figure 14 D). The final product consisted of dimeric FLV at 75 kDa, and monomers detected 
below 37 kDa. Also higher ordered structures were detectable. This purification yielded 1.1 mg 
of FLV from a 2 L culture. 
TG-FLV was detected at around 74 kDa in its dimeric form and at 37 kDa as a monomer. 
Fractions containing the dimeric protein were pooled. The resulting product was rather pure as 
judged by Coomassie blue staining; however, precipitates and monomers remained detectable 
(Figure 14 E). 200 µg of TG-FLV were purified from a 2 L bacterial culture. 
The longest construct, TG-PL-FLV, was visible at 75 kDa upon successful dimerization, while 
bands of the monomeric protein were detected at 35 kDa on non-reducing, Coomassie blue 
stained SDS-PAGE gels (Figure 14 F). Similar fractions (C2, C3, and C6) were pooled and 
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frozen separately from higher concentrated fractions C4 and C5. The final product mainly 
consisted of dimeric TG-PL-FLV, but monomers and precipitates were detected as well. The 
total yield was 1.3 mg from 6 L of bacterial culture. 
 
 
Figure 14: Purification of VEGF-constructs from bacterial inclusion bodies yielded pure protein preparations mainly 
consisting of dimeric proteins, but also containing higher ordered precipitates and monomers. Non-reducing, Coomassie 
blue stained SDS-PAGE gels showing the final product of (A) VEGF165wt, (B) TG-VEGF, (C) TG-PL-VEGF, (D) FLV (E) TG-FLV 
and (F) TG-PL-FLV. 
 
3.2.3 Protein expression in eucaryotic cells 
Especially expression of the bi-functional constructs in E. coli was a challenge because the 
dimerization was usually incomplete and a high amount of precipitates was present in the 
preparations. Thus, the constructs FNIII10, TG-FNIII10, VEGFmut, TG-VEGFmut, FLV and 
TG-FLV were subcloned into the eucaryotic expression vector pCEP-V97 and expressed 
according to a protocol established by professor Dr. Manuel Koch as His-tagged proteins in 
human embryonic kidney (HEK) 293-EBNA cells and purified from conditioned cell 
supernatants.  
The proteins obtained were investigated by Coomassie blue staining under reducing and non-
reducing conditions to asses overall purity and dimerization. Results are shown in Figure 15, and 
Table 2 summarizes final yields. FNIII10 and TG-FNIII10 run at around 15 kDa under both 
reducing and non-reducing conditions as these are monomeric proteins. Of FNIII10, 3.2 mg of 
protein were purified from 2.3 L of conditioned media, while 1.5 mg of TG-FNIII10 were 
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purified from 1.2 L of media. VEGFmut and TG-VEGFmut monomers were observed at 30 kDa 
and the dimers at 55 kDa. 715 µg of VEGFmut were obtained from 2 L of culture supernatant, 
and of TG-VEGFmut, 490 µg were purified from 2.2 L. FLV and TG-FLV dimers were found to 
run at 70 kDa, and monomers were observed at 45 kDa. The yield of FLV was 1100 µg from 
1.6 L of conditioned media, and 860 µg of TG-FLV were purified from 3.6 L.  
Comparison between reducing and non-reducing conditions revealed good dimerization for all 
engineered VEGF proteins. Remaining monomers seemed to be found exclusively in the 
TG-forms. Generally, proteins were of very good purity, and no precipitates were observed.  
 
 
Figure 15: Recombinant protein preparations purified from HEK293-EBNA cell supernatants were pure and well dimerized. 
On the Coomassie blue stained gel, the final products are shown. Loading: 2 µg/lane. 
 
 
3.2.4 Confirmation of the identity of recombinant proteins 
produced 
The identity of the purified proteins was confirmed by liquid chromatography followed by liquid 
chromatography tandem mass spectronomy (LC-MS/MS) and subsequent peptide mass finger 
printing (PMF). Analysis was performed at the Proteomic Core Facility at Ecole Polytechnique 
Fédérale de Lausanne, Switzerland by Diego Chiape or at Zentrale Bioanalytik at Zentrum für 
Molekulare Medizin, Köln, Germany by Dr. Stefan Müller and Andrea Grün. 
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3.2.5 Determination of protein concentrations  
As a first approach to determine protein concentrations of the obtained fractions expressed in 
E. coli, a BCA assay was performed. Working concentrations were determined by human 
VEGF-A specific ELISA, and concentrations were calculated in comparison to a VEGF-A 
standard curve. This has the major advantage that the concentration is already normalized for its 
VEGF-content and thus corresponds to the effective concentration. Often, the protein 
concentration determined using the ELISA was markedly lower than the concentration 
determined by BCA-assay (see Table 1). This discrepancy was particularly dramatic when 
determining protein concentrations of FLV, TG-FLV and TG-PL-FLV, and was not abolished 
when the concentration determined by ELISA was corrected taking into account the molecular 
weight of the proteins (for example, the molecular weight of TG-PL-FLV is approximately 
1.7 times higher than the molecular weight of VEGFmut, thus the concentrations obtained by 
ELISA might be too low). A reasonable explanation for this was the presence of aggregates 
particularly enriched in protein preparations containing the bi-functional constructs produced in 
E. coli. For this reason, protein concentrations determined by ELISA measurements were 
considered more precise than these determined by BCA assay, and these concentrations were 
used in subsequent experiments. The calculations of the molar concentrations were based on the 
concentrations obtained by ELISA and corrected for the molecular weight. Molecular weights 
were predicted using ExPASy’s ProtParam tool. For FNIII10 and TG-FNIII10, protein 
concentrations were determined by UV measurement and corrected by the extinction coefficient 
(labeled with an asterisk).  
 
For engineered VEGF proteins prepared from cell supernatants, there were also enormous 
differences in concentrations determined by BCA assay as compared to concentrations 
determined by human VEGF-A ELISA (Table 2). However, concentrations determined by 
ELISA appeared too low compared to intensities of protein bands observed on Coomassie blue 
stained gels, and again this effect was particularly prominent when comparing values obtained 
for bi-functional constructs. As in these purifications, neither precipitates nor contaminations 
were observed that could account for these discrepancies, the concentration was determined by 
BCA assay, and values obtained were corrected for the molar VEGF-content of the protein to 
determine the effective concentration. These corrected values were used for subsequent 
experiments characterizing the bioactivity of these proteins. The calculation of the molarity was  
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based on uncorrected concentrations determined by BCA-assay, and the molecular weight was 
predicted using the ProtParam tool (ExPASy). FNIII10 and TG-FNIII10 protein concentrations 
were determined by UV-spectrometry and corrected as described above.  
 
Proteins produced in E. coli        
Protein Molecular 
weight 
[kDa] 
Culture 
volume 
Fraction BCA 
[µg/mL] 
ELISA 
[µg/mL] 
ELISA 
corrected 
[µg/mL] 
Molarity 
[µM| 
Yield [µg] 
FNIII10 11.2 1 L  2250*   200.90 3000 
TG-FNIII10 12.48 1 L  3379*   270.65 10000 
VEGFwt (dimer) 38.59 1 L  25.6 54.54 54.54 1.41 1000 
VEGFwt (dimer) 38.59 2 L C4-C6 641.4 844.7 844.7 21.89 5000 
VEGFmut (dimer) 38.59 2 L B15 282.1 379.85 379.85 9.84 760 
 38.59  A15+B14 25.9 33.11 33.11 0.86 130 
VEGFmut (dimer) 38.59 2 L B11+B10 356.6 321.52 321.52 8.33 1280 
40.81 2 L C8 524.1 241.26 255.01 6.25 510 TG-VEGFmut 
(dimer) 40.81  C5-7+C10 1026.2 515.22 544.59 13.34 4300 
42.57 2 L C4 2899.9 671.55 740.72 17.40 1500 TG-PL-VEGFmut 
(dimer)   C3+C5 1410.4 79.8 88.02 2.07 350 
FLV (dimer) 63.44 2 L C5 910 340.8 560.28 8.83 1120 
TG-FLV (dimer) 66.21 2 L B12+B13 696.1 30.25 51.88 0.78 200 
67.96 2 L C5 3178.6 258.1 454.57 6.69 910 TG-PL-FLV (dimer) 
67.96  C4 1105 13.71 23.34 0.34 45 
TG-PL-FLV (dimer) 67.96 2 L C4+C5 390 32.05 56.46 0.83 225 
TG-PL-FLV (dimer) 67.96 2 L C4 1105 33.87 59.66 0.88 120 
Table 1: Summary of protein concentrations and yields of protein expression in E. coli. Protein concentrations were 
determined by BCA-assay or by VEGF-specific ELISA. The values obtained by ELISA were considered more precise and used in 
subsequent experiments (see text for details). Asterisks indicate the determination of protein concentration by UV-spectrometry.  
 
 
Proteins produced in HEK293-EBNA cells      
Protein 
Molecular 
weight 
[kDa] 
Supernatant  
volume 
BCA  
[µg/mL] 
BCA 
corrected 
 [µg/mL] 
ELISA  
[µg/mL] 
Molarity  
[µM] 
Yield 
 [µg] 
FNIII10 11.96 2.3 L 679*   56.77 3200 
TG-FNIII10 13.35 1.2 L 600*   44.96 1500 
VEGFmut (dimer) 42.71 2.0 L 188.17 188.17 85.45 4.41 710 
TG-VEGFmut (dimer) 44.93 2.2 L 188.81 179.48 89.47 4.20 490 
FLV (dimer) 67.56 1.6 L 302.06 190.9 18.75 4.47 1100 
TG-FLV (dimer) 70.33 3.6 L 333.55 202.46 19.07 4.74 860 
Table 2: Summary of yield and concentration of proteins purified from HEK293-EBNA cell supernatants. Concentrations 
obtained by the BCA-assay were in agreement with the intensity of bands observed on Coomassie-blue stained gels and 
calculations of the molarity are based on these concentrations. Asterisks indicate the determination of protein concentrations by UV-
spectrometry. 
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3.2.6 Endotoxin test 
The endotoxin content of recombinant protein samples was determined by Dr. Gabriela Bald in 
the laboratories of Bayer Schering Pharma (Wuppertal, Germany) by the LAL-test. The 
endotoxin contents of individual preparations are given in Table 3.  
It was evident, that proteins obtained from HEK293-EBNA cells showed a very low endotoxin 
content as compared to proteins produced in E. coli. In general, the endotoxin content seemed to 
increase with increasing molecular weight of the constructs.  
 
Endotoxin content of protein preparations 
Construct Expression system Purification EU/µg 
FNIII10 HEK His-tag 0.0035 
FNIII10 E. coli, cytosol GST-tag 0.026 
TG-FNIII10 E. coli, cytosol GST-tag 11.6 
VEGFwt E. coli, inclusion bodies Heparin affinityC4-6 2.55 
VEGFmut HEK His-tag 0.01 
VEGFmut E. coli, inclusion bodies Heparin affinity B11+10 a) 0.56 
VEGFmut E. coli, inclusion bodies Heparin affinity B11+10 b) 21.5 
TG-VEGFmut E. coli, inclusion bodies Heparin affinity C8 2.35 
TG-VEGFmut E. coli, inclusion bodies Heparin affinity C5-7+10 15.15 
TG-PL-VEGFmut E. coli, inclusion bodies Heparin affinity C4 13.4 
FLV HEK His-tag  0.15 
FLV E. coli, inclusion bodies Heparin affinity C5 69.5 
TG-FLV E. coli, inclusion bodies Heparin  31000 
Table 3: Summary of the endotoxin content of recombinant protein preparations as determined by the LAL-test. 
 
The endotoxin limit for the planned animal experiments was calculated as suggested by Malyala 
and Singh (2004) as follows:  
 
 
 
As all recombinant proteins produced in E. coli show an endotoxin content markedly above this 
value, exclusively proteins produced in HEK293-EBNA cells were used for animal 
experimentations. 
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3.3 Functional characterization of recombinant proteins 
3.3.1 Covalent incorporation of engineered VEGF-proteins into 
fibrin matrices 
3.3.1.1 Retention of proteins produced in E. coli equipped with a 
TG-sequence in fibrin gels 
Recombinant VEGF proteins were to be delivered to wounds in fibrin gels. To test the 
functionality of the TG-site, fibrin gels were formulated from 10 mg/mL fibrinogen containing 
either VEGFmut, TG-VEGFmut, TG-PL-VEGFmut, FLV or TG-PL-FLV and were washed for 
two days with shaking at 37°C. The gels were then degraded by plasmin incubation, and the 
lysate was investigated by western blot analysis using an antibody raised against VEGF-A. As 
shown in Figure 16, the soluble variants VEGFmut and FLV could not be detected by this 
approach. In contrast, the constructs containing the TG-sequence were readily identified by 
western blot. For TG-VEGFmut, TG-PL-VEGFmut and TG-PL-FLV, several prominent bands 
were detected, which is indicative for the presence of fibrinopeptides still coupled to the growth 
factor.  
In regard to the constructs containing a plasmin cleavage site, this result is surprising, as the 
construct should be released without fibrinopeptides, therefore, one single band would be 
expected. Possibly, the digestion was incomplete.  
 
 
Figure 16: Bioengineered VEGF-proteins comprising a TG site are retained in fibrin gels upon washing. VEGF-specific 
western blot on lysates of fibrin gels formulated with various VEGF proteins after washing, non-reducing conditions. 
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Furthermore, VEGF concentrations in the wash buffer were determined at different time points 
of washing by ELISA in two independent experiments using 2 U/mL or 10 U/mL of factor XIII 
(Figure 17). Factor XIIIa used in these experiments was provided by Baxter. 
 
 
Figure 17: Prolonged retention of VEGF-variants comprising a TG-site produced in E. coli in fibrin gels. Graphs monitoring 
the release of proteins from fibrin gels formulated with 2 U/mL (A, B) or 10 µg/mL (C, D) of factor XIIIa provided by Baxter, as 
compared to the release from fibrin gels crosslinked with 10 U/mL of factor XIII obtained from CSL Behring (E). 
 
Under both conditions, the soluble form VEGFmut was entirely released during the first 8 hours 
of washing, whereas both TG-VEGFmut and TG-PL-VEGFmut were retained at a minimum of 
70 % in the matrix (Figure 17 A and C). These results are in good agreement with data published 
previously (Ehrbar et al. 2004; Ehrbar et al. 2005). The results obtained for the bi-functional 
constructs tested were similar. Also in these experiments, the non-coupled form was largely 
released in a burst release within the first 8 hours of washing. TG-PL-FLV was retained by 
approximately 60 % during washing (Figure 17 B and D). Furthermore, the release of FLV 
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appeared to be delayed from fibrin gels formulated with 10 U/mL factor XIIIa. However, 
additional experiments would be necessary to confirm this tendency. 
The same experiment was repeated using a different, commercially available factor XIIIa, 
obtained from CSL Behring as Fibrogamin. For fibrin gels formulated, 10 U/mL of factor XIIIa 
were used. Release kinetics of the VEGF-isoforms investigated (Figure 17 E) were very similar 
to those observed using factor XIII obtained from Baxter (Figure 17 C and D). The soluble 
VEGFmut is released during the first hours of washing, whereas only around 20 % of both 
TG-VEGFmut and TG-PL-VEGFmut produced in E. coli were found in the washing buffer at 
the time points indicated. 
 
3.3.1.2 Release of proteins produced in HEK293-EBNA cells from fibrin 
gels 
The release of engineered VEGF proteins produced in the eucaryotic expression system from 
fibrin gels was investigated in similar experiments as described above. Release kinetics from 
fibrin matrices formulated with either 2 U/mL (Figure 18 A and B) or 10 U/mL (Figure 18 C 
and D) factor XIIIa from CSL Behring closely resembled the release observed from fibrin gels 
formulated with proteins produced in E. coli.  
 
Figure 18: The release kinetics of proteins produced in HEK293-EBNA cells closely resemble those of proteins produced 
in E. coli. Graphs showing the release of VEGF proteins from fibrin gels formulated with 2 U/mL (A, B) or 10 U/mL (C, D) factor 
XIIIa (CSL Behring). 
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The soluble proteins VEGFmut and FLV were quickly released during the first hours of 
washing. By contrast, TG-VEGFmut and TG-FLV, which become covalently bound to fibrin by 
factor XIIIa, were retained in the gel by up to 85 %. Interestingly, the retention of TG-FLV was 
similar to the retention of TG-VEGFmut observed in these experiments, which was unlike in 
previous experiments employing proteins obtained from inclusion bodies. A likely explanation 
for this is the absence of aggregates in the final product obtained from HEK293-EBNA cells, as 
aggregates may fail to become incorporated into fibrin gels due to misfolding possibly resulting 
in an inaccessible TG-site. 
 
3.3.2 HUVEC attachment to TG-FNIII10 is partially dependent on 
integrin αvβ3 
To assess the bioactivity of TG-FNIII10 produced in E. coli, cell attachment assays using human 
umbilical vein endothelial cells (HUVECs) were performed (Figure 19 A). When HUVECs were 
allowed to attach to various concentrations of TG-FNIII10, attachment proved to be dependent 
on the concentration of the ligand plated. The difference in attachment observed between 
0.01 µM and 0.1 µM of TG-FNIII10 plated was significant (p<0.05). Pre-treatment of cells with 
function-blocking integrin specific antibodies prior to seeding revealed that adhesion of cells to 
fibronectin was not influenced by anti-αvβ3, but partially inhibited by anti-α5  (p<0.05, Figure 
19 B). By contrast, anti-αvβ3 strongly inhibited attachment to TG-FNIII10 by 30 % (p<0.05), 
whereas pre-incubation with anti-α5 had a less pronounced effect on attachment to this 
fibronectin domain (Figure 19 C).  
By this experiment, it was shown that indeed αvβ3 is targeted by FNIII10, as intended by the 
expression of the bi-functional constructs containing FNIII10 and VEGFmut. 
 
 
 
Figure 19: HUVEC attach to TG-FNIII10 in a concentration dependent manner, and attachment is partially dependent on 
integrin αvβ3. Graphs summarize the investigation of cell attachment to TG-FNIII10. (A) Cells were seeded on increasing 
concentrations of TG-FNIII10. (B, C) Cells were incubated with integrin adhesion-blocking anti-integrin antibodies and seeded on 
fibronectin or TG-FNIII10. Significance was accepted for p<0.05 and p-values were determined by paired t-tests. 
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3.3.3 FLV and FNIII10 promote cell attachment and spreading of 
HUVECs  
In order to investigate cell attachment and spreading of HUVECs on the recombinant proteins 
produced in HEK293-EBNA cells, microscopy slides were coated with FNIII10, VEGFmut, 
FLV and poly-L-lysine as a negative control. The coating density employed took into account 
that FLV as a dimeric protein comprises two FNIII10-sites per molecule, and for this reason, 0.4 
µM of FNIII10 and 0.2 µM of FLV and VEGFmut were used for the coating, thus providing 
equal amounts of functional domains. Cells were allowed to attach for two hours, fixed and 
stained for actin filaments and the focal adhesion protein vinculin (Figure 20 A).  
On poly-L-lysine, cells remained rounded and no spreading was observed. Cells on VEGFmut 
behaved similar. On FNIII10 by contrast, various degrees of spreading were observed. While 
only few cells were rounded, most cells were well attached to the substrate and spread. Some 
cells also showed stress fibers and focal adhesion assembly indicated by vinculin staining. On 
FLV, cell spreading observed was maximal, and cells were enriched in stress fibers ending in 
vinculin-positive focal adhesion sites. Cells in five random fields of view were counted per 
condition. Low cell numbers on poly-L-lysine and VEGFmut indicated weak attachment to these 
substrates (Figure 20 B). By contrast, cell numbers on FLV and FNIII10 were approximately 
6fold higher than on poly-L-lysine.  
These results indicate that cell attachment and cell spreading are promoted by FNIII10 and FLV, 
and that spreading on FLV is more efficient than on FNIII10.  
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Figure 20: FLV promotes cell attachment and spreading. (A) Confocal images of HUVECs seeded on poly-L-lysine, FNIII10, 
VEGFmut or FLV, stained for F-actin (red), vinculin (green) and nuclei (blue). Scale bars: 30 µM. (B) Graph summarizing the 
quantification of adherent cells in five random fields of view.  
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3.3.4 Recombinant VEGF-proteins produced in E. coli promote 
VEGFR-2 phosphorylation 
To answer the question if the designed proteins were biologically active in vitro, they were tested 
for their ability to promote VEGFR-2 phosphorylation. Serum starved HUVECs in 3.5 cm dishes 
were stimulated for 5 minutes with 1.3 nM of commercial VEGF165 (Invitrogen), VEGF165wt, 
VEGFmut, TG-VEGFmut, TG-PL-VEGFmut, FLV and TG-PL-FLV produced in E. coli 
(corresponding to 50 ng/mL effective VEGFmut concentration). By western blotting, VEGFR-2 
phosphorylation was detected by a primary antibody raised against phosphotyrosine 1175 in 
VEGFR-2 (Figure 21), which is one of the major autophosphorylation sites of the receptor 
(Takahashi et al. 2001). By contrast, no phosphorylation of this residue was observed in 
non-stimulated cells or upon stimulation with 4.46 nM FNIII10 (corresponding to 50 ng/mL). 
Detection of VEGFR-2 on the same blot indicated equal loading. These data clearly showed that 
the engineered VEGF proteins produced are active. 
 
 
Figure 21: Recombinant VEGF-proteins purified from inclusion bodies promote VEGFR-2 phosphorylation. Western blot anti 
phospho-VEGFR-2 and anti VEGFR-2 on lysates obtained from HUVECs stimulated with 1.3 nM (50 ng/mL) of VEGF proteins or 
4.46 nM (50 ng/mL) FNIII10.  
 
3.3.5 VEGFR-2 phosphorylation is induced by VEGF-proteins 
produced in eucaryotic cells 
3.3.5.1 The activity of bi-functional proteins is reduced as compared to 
VEGFmut-proteins as determined by western blot 
The activity of recombinant proteins produced in HEK293-EBNA cells was tested by assessing 
their ability to promote VEGFR-2 phosphorylation on tyrosine residue 1175 following 
stimulation with 1.17 nM (corresponding to 50 ng/mL effective VEGFmut concentration) of 
recombinant VEGF proteins. Additionally, phosphorylation of the VEGFR-2 downstream 
signaling molecules Erk 1/2 was investigated. Representative western blots are shown in  
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Figure 22. At all time points investigated, VEGFmut and TG-VEGFmut constructs induced a 
stronger VEGFR-2 phosphorylation than FLV or TG-FLV, while autophosphorylation of 
VEGFR-2 on tyrosine 1175 was strongest upon stimulation with commercial VEGF-A165 
(denoted as VEGF com). For Erk 1/2, analysis proved difficult, as the kinase seemingly became 
activated once the media were changed for stimulation. However, as a tendency, Erk 1/2 became 
activated upon stimulation with commercial VEGF165, VEGFmut and TG-VEGFmut at all time 
points investigated. Upon stimulation with FLV and TG-FLV, phosphorylation of Erk 1/2 
remained at background levels, and only after 30 minutes of stimulation a slight increase in 
phosphorylation was detectable. The same blots were reprobed for total VEGFR-2 and β-actin as 
loading controls, and indicated similar loading.  
 
Figure 22: VEGF-constructs purified from HEK293-EBNA cell supernatants promote VEGFR-2 phosphorylation, but no 
synergistic signaling was observed upon stimulation with bi-functional constructs. Western blot on HUVEC lysates 
stimulated with engineered VEGF proteins for the time indicated, detecting phosphorylation of VEGFR-2 and Erk 1/2 and showing 
loading controls.  
 
In summary, no increase in phosphorylation was detected neither on the receptor level nor on the 
level of downstream signaling molecules Erk 1/2 upon stimulation with FLV as compared to 
stimulation with VEGF. 
 
3.3.5.2 The overall VEGFR-2 phosphorylation detected by ELISA 
reproduces phosphorylation on tyrosine 1175 
VEGFR-2 becomes phosphorylated at multiple tyrosine residues upon VEGF-stimulation. To 
clarify whether phosphorylation of tyrosine 1175 reflects the phosphorylation state of overall 
VEGFR-2, phosphorylation was investigated by an ELISA detecting all phosphorylated 
tyrosines of VEGFR-2 captured by a VEGFR-2 specific primary antibody (Figure 23).  
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A dose response was determined in a first experiment. HUVECs were stimulated for 15 minutes 
with 0.02, 0.23, 1.17 and 2.34 nM (corresponding to 1, 10, 50 and 100 ng/mL effective VEGF-A 
concentration, respectively) of commercial VEGF, VEGFmut, TG-VEGF, FLV and TG-FLV. 
Under these conditions, higher concentrations of commercial VEGF-A165, VEGFmut, 
TG-VEGFmut, FLV and TG-FLV resulted in higher VEGFR-2 phosphorylation (Figure 23 A). 
Phosphorylation was maximal for stimulation with either 50 or 100 ng/mL. Also in this ELISA, 
stimulation with the bi-functional constructs led to a markedly decreased VEGFR-2 
phosphorylation as compared to phosphorylation induced by VEGF-isoforms investigated. 
Stimulation with commercial VEGF-A, VEGFmut or TG-VEGF led to an increase of up to 
140 % in VEGFR-2 phosphorylation, while FLV and TG-FLV increased phosphorylation by 
maximally around 20% as compared to non-stimulated controls.  
Furthermore, the time-course of VEGFR-2 phosphorylation was investigated upon stimulation 
with 1.17 nM (corresponding to 50 ng/mL effective VEGF-A concentration) VEGF proteins in 
an independent experiment (Figure 23 B). Commercial VEGF-A165 induced a dramatic increase 
of VEGFR-2 phosphorylation within 5 minutes of stimulation. Phosphorylation decreased over 
time, but still remained high 30 minutes after stimulation (50fold increase over non-stimulated 
control). VEGFmut and TG-VEGFmut triggered a less dramatic increase in VEGFR-2 
phosphorylation, but the signal was elevated during the time investigated and showed a 50 % 
increase over non-stimulated controls. Again, upon stimulation with FLV and TG-FLV, 
phosphorylation was low, and a maximal increase of 11 % over non-stimulated controls was 
observed.  
However, when comparing the signal intensities detected for phosphorylated VEGFR-2 obtained 
in this experiment to the data generated when investigating the VEGFR-2 dose response, it was 
evident that signal intensities differed markedly between both experiments. In general, the 
VEGFR-2 phosphorylation upon stimulation with VEGFmut and TG-VEGFmut was much lower 
in the second experiment as compared to the first one, as can be seen by direct comparison of the 
phosphorylation triggered by stimulation with 50 ng/mL of the proteins for 15 minutes 
determined in both experiments (Figure 23 C).  
By this ELISA, it could be ruled out that reduced VEGFR-2 phosphorylation upon stimulation 
with FLV or TG-FLV as compared to stimulation with VEGFmut or TG-VEGFmut is specific to 
tyrosine 1175. The results obtained by western blotting hence reflect well overall VEGFR-2 
phosphorylation.  
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Figure 23: Detection of overall VEGFR-2 phosphorylation by ELISA confirmed reduced phosphorylation levels upon 
stimulation with FLV and TG-FLV as compared to VEGFmut and TG-VEGFmut. Graphs showing the phosphorylation of 
VEGFR-2 upon stimulation with VEGF proteins from a commercial source or produced in HEK293-EBNA. (A) Dose response and 
(B) time response of VEGFR-2 phosphorylation. (C) Comparison of VEGFR-2 phosphorylation detected in the two separate 
experiments upon stimulation with 1.17 nM (50 ng/mL) of the proteins for 15 minutes.  
 
3.3.6 VEGFmut and FLV bind to VEGFR-2 with high affinities: 
Surface plasmon resonance binding studies 
One possible reason for the lower VEGFR-2 phosphorylation observed upon stimulation with 
these proteins might be an altered conformation inhibitory to interaction with the receptor. To 
characterize the binding of the bi-functional constructs to VEGFR-2 in comparison to binding of 
VEGFmut to the receptor, surface plasmon resonance (SPR) biosensor binding studies were 
carried out in collaboration with professor Dr. Stefan Höning. Representative sensograms are 
shown in Figures 24 A and B. Association rate constants ka, dissociation rate constants kd and 
the resulting equilibrium dissociation constant KD are summarized in Table 4. 
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VEGFmut bound to immobilized VEGFR-2 Fc with an association rate constant ka = 1.34106 ± 
2.63105 M-1s-1. This value is comparable with the association rate constant ka = 3.71106 ± 
0.7105 M-1s-1 published in the literature for VEGF-A165 (Cunningham et al. 1999). For FLV, 
ka = 2.31105 ± 5.69104 M-1s-1 was determined. Binding of FLV to VEGFR-2 Fc was markedly 
weaker than binding of VEGFmut, but FLV still bound the receptor with high affinity. The 
decreased affinity of FLV to the receptor was not due to too low concentrations of FLV 
employed, as shown in the western blot performed on reduced protein samples used for the SPR 
binding studies (Figure 24 C). 
Due to the high affinity both molecules showed to VEGFR-2 Fc, determination of the 
dissociation rate constant was difficult and not precise under the experimental conditions used, 
as seen by the lack of a drop in the sensograms shown in Figures 24 A and B at the end of 
injection, indicating that all recombinant protein injected remains bound to the receptor. The 
dissociation rate constant determined was kd = 110-3 s-1 for both molecules. Cunningham et al. 
measured kd = 1.3410-4 ± 01910-4 s-1 for VEGF-A165. Based on these values, for VEGFmut 
KD = 7.8110-10 ± 1.8710-10 M, and for FLV, KD = 4.5510-9 ± 1.1610-9 M were calculated, and 
for VEGF165, 3.71 10-11 ± 4.9  10-11 M are published. Due to differences in kd, KD determined 
for VEGFmut compared less well to the KD published for VEGF-A165.  
 
Figure 24: SPR biosensor binding studies revealed high affinity binding of VEGFmut and FLV to VEGFR-2. (A) Sensogram 
illustrating the binding of VEGFmut to VEGFR-2-Fc. (B) Sensogram describing the binding of FLV to VEGFR-2-Fc. (C) Western blot 
anti-VEGF-A on 200 ng of the protein samples used for the experiments.
 
 
 ka [M-1s-1] kd [s-1] KD [M] 
VEGFmut 1.34106 ± 2.63105  110-3 7.8110-10 ± 1.8710-10 
FLV 2.31105 ± 5.69104 110-3 4.5510-9 ± 1.1610-9 
VEGF165 (Cunningham et al. 1999) 3.6106 ± 0.7105 1.3410-4 ± 0.1910-4 3.71 10-11 ± 4.9  10-11 
Table 4: Table summarizing kd, ka and KD determined as compared to values found in the literature. 
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For an appropriate description of the dissociation kinetics, additional experiments would be 
necessary. However, experiments performed clearly affirm specific binding of both, VEGFmut 
and FLV, to VEGFR-2 Fc, and the association rate constant of VEGFmut is comparable to that 
of VEGF-A165. Performed experiments thus provide the answers required for this work. 
 
3.4 In vivo characterization of engineered VEGF proteins 
applied to wounds in fibrin matrices 
Subsequent experiments explored the angiogenic properties of recombinant proteins produced in 
HEK293-EBNA and delivered in fibrin gels in vivo, using full thickness skin wounds as a 
clinically relevant model. Punch biopsy wounds were created on the back of male db/db mice, 
and fibrin gels supplemented with 0.468 µM (corresponding to 20 µg/mL effective VEGFmut 
concentration) of either soluble VEGFmut, TG-VEGFmut, TG-FLV, or no growth factor were 
allowed to polymerize in situ. After gel formation, the wounds were covered by a piece of 
non-adherent Adaptic® and a semipermeable wound dressing to prevent drying of the gels 
(Figure 25). Tissue samples were collected on day 10 and 14/15 post wounding.  
 
 
Figure 25: Schematic overview of the wounding procedure and the optimized wound care applied.  
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3.4.1 Cellular invasion of fibrin gels and induction of angiogenesis 
in day 10 and day 15 wounds 
To get a first impression on angiogenesis and the wound healing response upon the described 
treatment, wounds from a total of 6 mice were harvested on day 10 and 15 post injury. The 
overall histology of these wounds was investigated by hematoxylin and eosin (H&E) stained 
paraffin sections, and Masson’s Trichrome (TM) staining was performed to distinguish the 
extracellular matrix and to highlight erythrocytes (Figure 26).  
Based on this histological analysis, the fibrin gel was always evident in day 10 wounds. In some 
day 15 wounds, it could still be seen, even thought it largely became substituted by granulation 
tissue. The fibrin gel seemed to be incorporated by the regenerating tissue, as cells invaded the 
fibrin gel under all conditions investigated. This was particularly evident in day 10 wounds, 
where the hyperproliferative epithelium of the wound margins seemed to migrate over the gel, 
whereas the gel was integrated in the cell-rich granulation tissue that formed beneath the 
epithelium (Figure 26). Fibrin alone had little effect on angiogenesis. Upon inclusion of 
diffusible VEGFmut in fibrin gel, some vascular structures filled with erythrocytes were visible. 
Vascular structures were more numerous and showed increased vessel diameters in wounds 
treated with the matrix bound proteins TG-VEGFmut or TG-FLV. 
Also 15 days post wounding, in some of the wounds the fibrin matrix was still detectable, and 
became replaced by the granulation tissue (Figure 26). Furthermore, on day 15, the angiogenic 
response detected was more pronounced in wounds treated with TG-VEGFmut than with 
VEGFmut, but decreased as compared to day 10 wounds. Also in wounds treated with TG-FLV, 
erythrocyte numbers were increased as compared to the fibrin treated control. In wounds with 
the matrix-bound growth factors, TG-VEGFmut and TG-FLV, the granulation tissue appeared 
highly cellular with a dense extracellular matrix. 
For both time points, plain fibrin matrices resulted in the weakest response in angiogenesis and 
granulation tissue formation. In contrast, VEGFmut, TG-VEGFmut and TG-FLV seemed to 
stimulate granulation tissue formation when compared to the control. Both granulation tissue 
formation and angiogenesis appeared slightly higher on both day 10 and day 15 when fibrin gels 
contained soluble VEGFmut. Granulation tissue formation and angiogenesis was most 
pronounced in fibrin matrices formulated with TG-VEGFmut and TG-FLV. 
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Figure 26: Investigation of skin wounds treated with recombinant VEGF proteins in a fibrin gel revealed that matrix bound 
isoforms were particularly efficient at inducing angiogenesis. Wound sections from day 10 and day 15 wounds were stained 
with H&E and Masson’s Trichrome staining. Magnifications shown: 1.5x (scale: 1000 µm), 10x, 20x (scales 100 µm). Abbreviations 
used: e – epidermis, g – granulation tissue, F – fibrin, sc – subcutaneous fat tissue, pc – panniculus carnosus. Frames and dashed 
frames highlight area of interest, on which was focused in higher magnification. 
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3.4.2 TG-VEGFmut and TG-FLV induce a prominent angiogenic 
response, but differ in their potency to recruit pericytes 
For a more sophisticated analysis of the wound healing response, cryosections were prepared 
from the wounds of 12 mice sacrificed on day 10 or 14 after wounding treated as described 
above. Sections were probed for CD31, an endothelium-specific marker, and for desmin, in the 
wound mainly expressed by pericytes. The effect of these treatments on the wound healing 
response was assessed histomorphometrically, and distance between the epithelial tips, the 
amount of granulation tissue and the distance between the ends of the panniculus carnosus 
determined are summarized in Figure 27.  
When compared to fibrin only treated control wounds, wound closure was accelerated upon 
treatment with fibrin plus diverse VEGF proteins (Figure 27 A). Whereas 4 out of 6 wounds 
treated with fibrin were still open on day 10, 1 out of 6 treated with VEGFmut/fibrin and 1 out 
of 7 treated with TG-FLV/fibrin showed incomplete epithelialization by day 10. All 7 wounds 
treated with TG-VEGF/fibrin were closed by this time.  By day 14 post injury, all wounds 
revealed complete reepithelialization. 
Although at day 10 post injury the mean deposition of granulation tissue was increased in 
VEGF-isoform treated wounds versus fibrin alone treated wounds, this difference was not 
statistically significant (Figure 27 B).  Furthermore, wound contraction was not significantly 
altered at day 10 or day 15post injury in VEGF-isoform treated wounds versus control wounds 
(Figure 27 C). 
 
 
Figure 27: Accelerated wound closure and a tendency toward increased amounts of granulation tissue were evident in 
wounds treated with recombinant VEGF proteins. Morphometric analysis of wound healing on CD31/desmin stained 
cryosections at day 10 and 14 post injury, treated with either fibrin alone, VEGFmut/fibrin, TG-VEGFmut/fibrin or TG-FLV/fibrin. 
Graphs summarize (A) distance between ends of epithelial tips, (B) area of granulation tissue, (C) distance between ends of 
panniculus carnosus. Each data point represents the wound tissue of a different mouse. 
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The vascular response during granulation tissue formation was investigated in cryosections co-
stained for CD31 and desmin and quantified in a semiquantitative fashion. Statistical 
significance was accepted for p-values <0.05 in the paired student’s t-test. Representative images 
of wound tissue 10 days post injury are shown in Figure 28, and the quantification is 
summarized in Figure 29. 
Wounds treated with fibrin only showed few short capillaries invading the granulation tissue 
(Figures 28 and 29). Generally, these sparse vascular structures were associated with desmin 
positive perivascular cells. 
When soluble VEGFmut was incorporated into the fibrin gel, the length of vascular structures 
appeared slightly increased when compared to control wounds (Figure 28), however the mean 
area within the granulation tissue that stained positive for CD31 was similar to that observed in 
control wounds (Figure 29 A, B). Wounds treated with fibrin showed an average of 7.2 % of 
granulation staining positive for CD31, and wounds treated with VEGFmut 6.5 %. Also the area 
staining positive for desmin was comparable to that observed in control wounds (Figure 
29 D, E).  
The most prominent increase in the density and length of vascular structures within the 
granulation tissue was found in wounds treated with TG-VEGFmut in fibrin (Figures 28 and 
29 A, B), where an average area of 18.8 % of the granulation tissue stained positive for CD31. 
Despite the dramatically increased vascular network, vascular structures were covered with 
abundant desmin positive perivascular cells (Figure 29 C, D). The density of perivascular cells 
associated with vascular structures was comparable to fibrin only treated wounds as well as 
VEGFmut/fibrin gels (Figure 29 E). The relative area covered by endothelial cells or pericytes 
was significantly increased as compared to the other treatment options (Figure 29 B, D). 
Also TG-FLV loaded fibrin gels significantly increased the density of vascular structures within 
the granulation tissue when compared with control wounds or wounds treated with VEGFmut, as 
an average of 12.5 % of the granulation tissue was found positive for CD31 (Figure 28 and 
29 B).  
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Figure 28: Treatment of skin wounds with the matrix bound variants TG-VEGFmut and TG-FLV in fibrin gels induced more 
vessels as compared to the fibrin only control and to soluble VEGFmut. CD31/desmin stained cryosections of day 10 wounds 
treated as indicated. Magnifications shown: 10x, 20x. Scale bar 100 µm. Abbreviations: e – epidermis; g – granulation tissue; sc –
subcutaneous fat tissue; pc – panniculus carnosus; F – fibrin gel. Arrow indicates direction of wound edge. 
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Figure 29: Quantification of the angiogenic response within the granulation tissue of day 10 and day 14 wounds reveals a 
significantly increased angiogenesis in wounds treated with TG-VEGF and TG-FLV in fibrin gels. (A, B) Graphs show the 
result of the quantification of CD31 positive areas. (C, D) Graphs summarize the quantification of desmin positive areas. (E) Graph 
indicating the ratio of CD31 to desmin positive areas. Each data point represents the wound tissue of a different mouse. Statistical 
significance was tested by paired t-tests and accepted for p<0.05.  
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Interestingly, the increased vascularity found in wounds treated with TG-FLV was not 
accompanied with proportional recruitment of perivascular cells, as the area covered by pericytes 
was similar in wounds treated with fibrin only or soluble VEGFmut (Figure 29 C, D) Thus, the 
ratio of vascular structures to desmin positive perivascular cells expressed as the ratio of CD31 
signal to desmin signal was significantly increased when compared to wounds treated gels 
containing VEGFmut or TG-VEGFmut (Figure 29 E). In control wounds, as well as in wounds 
treated with VEGFmut or TG-VEGFmut in fibrin, around 5 endothelial cells are found per 
pericyte, while in the TG-FLV treated wounds, this ratio of endothelial cells to pericytes is 
increased to 12 (Figure 29 E). 
At day 14 post injury, all treatment options revealed a reduced vascular network when compared 
to day 10 post injury wounds, indicating vascular remodeling and regression following wound 
closure (Figure 29). 
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4 Discussion 
 
4.1 Covalent binding of VEGF-A165 to fibrin matrices is 
superior to soluble VEGF-A165 to induce sustained 
angiogenesis during wound repair 
This study aims at the optimization of angiogenesis induced by bioengineered VEGF-A variants 
in combination with advanced delivery strategies. To this end, the produced VEGF-A proteins 
VEGFmut, TG-VEGFmut and TG-FLV were delivered to full-thickness wounds in diabetic 
mice, which represent a well-established model for impaired wound healing characterized by 
delayed angiogenesis. The vessel growth was compared to wounds treated with a fibrin gel only. 
In this setting, growth factors comprising the TG-peptide become covalently bound to fibrin 
during coagulation. This delivery strategy allows for cell-demanded, locally controlled release in 
a sustained manner, hypothesized to be critical for the induction of a functional vasculature.  
Wounds treated with fibrin in combination with the various VEGF-A proteins showed 
accelerated wound closure by day 10 post-wounding as compared to wounds treated with fibrin 
alone. This observation is in agreement with previous studies, in which the delivery of VEGF-A 
to wounds either as a protein, as a plasmid or by genetically modified cells accelerated 
re-epithelialization (Brem et al. 2009; Michaels et al. 2005; Romano Di Peppe et al. 2002; Roth 
et al. 2006). Major differences between the various treatments were observed in the induction of 
angiogenesis, as the vessel density at day 10 in wounds treated with the matrix-bound forms was 
significantly increased as compared to wounds treated with fibrin only. Importantly, soluble 
VEGFmut did not increase angiogenesis over control levels. 
Previous reports underline the importance of matrix coupling for the induction of a functional 
and well-organized vasculature. Ehrbar et al. showed in a CAM assay, that soluble VEGF-A121 
induced many brush-like vessels and altered the hierarchical organization of the vessels. An 
increase in intussusception and abrupt vessel diameter changes were observed. By contrast, 
vascular networks induced by TG-VEGF-A121 appeared well organized and showed none of 
these abnormalities. Furthermore, Teflon chambers filled with fibrin with soluble VEGF-A121 
and subcutaneously implanted induced non-functional, leaky vessels in mice, which were not 
observed upon delivery of TG-VEGF-A121 in the same model (Ehrbar et al. 2004). By contrast, 
in the wounding experiments performed in this study, no obvious vascular disorganization upon 
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treatment with soluble VEGFmut was detectable. As described, VEGFmut is a mutated form of 
VEGF-A165, and thus, the intrinsic capability of VEGF-A165 to interact with fibrin (Sahni and 
Francis 2000) may prevent vessel abnormalization. However, a more likely explanation for this 
phenomenon may consist in different time points chosen for the read-out of the experiments. In 
the experiments performed by Ehrbar et al., early angiogenic effects were detected. Alterations 
in the vasculature of the CAM were detected after two days of exposure to VEGF-A 
functionalized fibrin matrices. Also the mouse experiments performed by this group were 
terminated after 4 days (Ehrbar et al. 2004). By contrast, wounding experiments conducted 
during this study were terminated after 10 days. In these experiments, diabetic mice 
characterized by a delayed wound healing response caused by reduced angiogenesis were 
investigated as a clinically relevant model. In diabetic mice, the angiogenic response is generally 
sparse, and therefore, tissue harvest was performed at the time point of maximal vessel growth. 
In untreated wounds, the maximum angiogenic response was observed between days 8 and 11 
following wounding (Roth et al. 2006). Therefore, by the experiments performed, it could not be 
excluded that an abnormal vessel growth took place during the induction of angiogenesis at 
earlier time points of the treatment with soluble VEGFmut. By the time of tissue harvest, 
normalization of the vasculature may have taken place following a decrease in local VEGFmut-
concentrations, and by the recruitment of pericytes. The weak angiogenic response observed 
upon treatment with soluble VEGFmut suggests an earlier depletion of the growth factor depot 
by a burst release of the growth factor. This was surprising, as VEGF-A165 is thought to bind to 
fibrinogen and fibrin with high affinity (Sahni and Francis 2000), and for this reason has been 
frequently delivered as admixture to fibrin glue in various systems. As also the in vitro 
experiments investigating the release kinetics of VEGFmut showed that the soluble VEGFmut 
was quickly washed out of the fibrin gels, the delivery of VEGF-A165 by simple addition of the 
growth factor to the gel may need to be reconsidered. 
 
A major advantage of the delivery system employed here is the tight control of local VEGF-A 
doses. VEGF-A is a very potent inducer of angiogenesis, and physiologically induces 
angiogenesis in a very narrow concentration range. This was shown in a series of elegant 
experiments, in which myofibroblasts engineered to express various concentrations of VEGF-A 
were implanted into muscle of mice. In this setting it was demonstrated, that not the total 
VEGF-A dose delivered was critical for the induction of a functional vasculature, but that rather 
the local dose in the microenvironment determined the outcome of vessel growth (Ozawa et al. 
2004). Control over the local VEGF-A dose upon delivery of the growth factor covalently 
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coupled to fibrin gels is accomplished by cell-controlled release from the matrix. The 
engineered, covalently fibrin bound VEGF-A is specifically released upon matrix degradation by 
proteases located to the cell surface. By this approach, the natural storage function of the 
extracellular matrix is mimicked, and cell demanded release kinetics allow for a controlled and 
prolonged releases at low concentrations (Zisch et al. 2001). Importantly, in wounds of diabetic 
mice, elevated plasmin concentrations were detected (Roth et al. 2006), and the stability of the 
fibrin gel within the wounds initially was not clear. However, this was a critical parameter, as 
fibrinolysis is directly linked to the controlled release of VEGF-A from the gel. Results of the 
wounding experiments performed indicated, that the fibrin gels employed were stable within the 
wound for at least 10 days, as the gels were microscopically still detectable at the wound site at 
this time point. This system thus represents a delivery mode, which might be beneficial for the 
treatment of human non-healing wounds enriched in proteases as well. 
Additionally, the covalent coupling of VEGF-A to fibrin matrices not only functions as feedback 
controlled local growth factor depot, but also provides a steep local VEGF-A-gradient between 
the gel and the surrounding wound tissue. The formation of gradients depends on extracellular 
matrix-VEGF-A interactions mediated by VEGF-A isoforms equipped with a heparin-binding 
site during development. In mice solely expressing the soluble variant VEGF-A120, guidance 
during the post-natal vascularization of the retina was severely impaired. Similar effects were 
observed when the extracellular VEGF-A gradient in wild-type mice was disturbed by injections 
of VEGF-A120 protein (Gerhardt et al. 2003; Ruhrberg et al. 2002; Stalmans et al. 2002). 
Importantly, in the delivery system applied here, the incorporation of TG-VEGFmut and 
TG-FLV into fibrin gels by factor XIIIa is incomplete as shown by in vitro release experiments 
performed in this study. Approximately 10-15 % of the growth factor remained soluble. As also 
VEGF-A165 is thought to retain some diffusibility within the tissue (Houck et al. 1992; Park et al. 
1993), it may be possible that low amounts diffusing out of the fibrin gel could locally activate 
endothelial cells, thus prime the angiogenic response, and provide local gradients guiding cells 
into the gel. The induced tip cells may sense VEGF-A localized within the fibrin gel far from the 
cell body by the extension of multiple, highly dynamic filopodia enriched in VEGFR-2 
(Gerhardt et al. 2003). They then guide invasion of the gel in the direction of transcellular 
gradients, with highest VEGF-A-concentrations at the filopodial tips. Furthermore, the 
membrane-anchored MMP, MT1-MMP, was shown to be expressed in tip cells during 
angiogenesis (Yana et al. 2007). Localization of this protease to filopodia would allow for a 
highly localized matrix degradation and release of VEGF-A at the tip of the migrating cell, and 
allow for gradient shaping in collaboration with interstitial flow (Fleury et al. 2006; Helm et al. 
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2005). However, these possible mechanisms of gradient formation and guidance were not 
investigated within this study and remain to be elucidated in detail in the future. 
 
Many previous experiments, in which VEGF-A was delivered into wounds either employed 
genetically modified cells engineered to over-express VEGF-A, or delivered VEGF-A protein 
daily in high doses to the wound (Galiano et al. 2004; Roth et al. 2006). The delivery approach 
chosen here has the major advantage that it is effective in diabetic mice upon one single 
application. Furthermore, it provides advantages for the clinical use, as overcomes security 
concerns when using genetically modified cells in patients, it is more feasible in wound care as 
daily application of the growth factor is not necessary, and more cost efficient, as lower doses of 
VEGF-A are delivered.  
 
4.2 FNIII10 fusion to VEGF-A165 promotes enhanced cell 
attachment and spreading in vitro compared to FNIII10 
and VEGF-A165 alone 
Another approach towards the optimization of angiogenesis aimed at the activation of synergistic 
signaling downstream of αvβ3 and VEGFR-2 by a novel fusion molecule consisting of 
VEGFmut and FNIII10 interconnected by a linker and denoted FLV. The design of this molecule 
was motivated by findings from various in vitro and in vivo models indicating that integrin αvβ3 
is required for the full activation of VEGFR-2 (Mahabeleshwar et al. 2006; Soldi et al. 1999). 
Ligation of this integrin was interpreted to be critical for angiogenesis, as its inhibition by RGD-
mimetics or specific antibodies counteracted vessel growth (Brooks et al. 1994b). It was 
demonstrated that VEGF-A stimulation results in activation of αvβ3, and that the functional 
consequence of this crosstalk is enhanced migration on αvβ3 substrates (Byzova et al. 2000), in 
which FAK and SAPK2 are involved (Masson-Gadais et al. 2003). Endothelial cell migration 
proved to depend on a sustained activation of Erk, which in turn was abolished in CAMs by 
treatment with integrin αvβ3 inhibitors (Eliceiri et al. 1998). Work by Mahabeleshwar et al. 
demonstrated that the molecular interplay between both receptors is of a reciprocal nature, as 
ligand binding of the integrin triggered basal VEGFR-2 activation and vice versa. Upon 
stimulation, a complex comprising αvβ3 and VEGFR-2 is formed (Soldi et al. 1999), in which 
both receptors are phosphorylated and αvβ3 integrin is activated (Byzova et al. 2000; 
Mahabeleshwar et al. 2006). For the formation of a VEGFR-2/αvβ3 complex, the tyrosine 
Discussion 
 
66 
residues on the β3 cytoplasmic tail which become phosphorylated upon integrin activation are 
critical, as in endothelial cells obtained from DiYF knock-in mice, in which these tyrosine 
residues are mutated, showed severe defects in various in vitro and ex vivo angiogenesis assays. 
Endothelial cells failed to form tubes in matrigel, also outgrowth from aortic rings as well as 
migration on αvβ3-ligands was impaired, and no sustained Erk-activation was detected in 
response to VEGF-stimulation (Mahabeleshwar et al. 2006). Nevertheless, these mice developed 
normally. 
 
To test whether the FNIII10 subunit indeed is a specific ligand for integrin αvβ3, cell attachment 
assays were performed using TG-FNIII10 as attachment substrate. The TG-sequence consists of 
only 8 amino acids, and these 8 amino acids were considered to have a smaller effect on the 
overall conformation of the FNIII10 domain than the expression of FNIII10 outside of the 
context of full-length fibronectin. The cell attachment assays performed firstly indicated that 
attachment of HUVECs to TG-FNIII10 correlated with the concentration of the recombinant 
protein plated, and secondly showed, that this attachment could be reduced by 30 % by function 
blocking antibodies raised against integrin αvβ3. This antibody was more efficient in inhibiting 
attachment to TG-FNIII10 than a function-blocking antibody directed against the α5 integrin 
subunit. On full-length fibronectin by contrast, the αvβ3 function blocking antibody had no 
inhibitory effect on cell attachment, but attachment was reduced upon pre-treatment with the α5 
function blocking antibody proving the functionality of this antibody. This was to be expected, 
because αvβ3 is the major integrin binding to the RGD site on FNIII10 in the absence of the 
synergy site on FNIII9 (Danen et al. 1995). On full-length fibronectin by contrast, binding to the 
RGD-site on the FNIII10 domain is preferentially mediated by integrin α5β1, even though this 
site is recognized by many different integrins. Integrin α5β1 recognizes the so called synergy 
site on FNIII9 in addition to the RGD-site localized in FNIII10, which in turn is required for 
efficient binding of cells to fibronectin allowing near maximum cell adhesion (Aota et al. 1994; 
Grant et al. 1997). By this experiment, it was shown that indeed αvβ3 is targeted by FNIII10, as 
intended by the expression of the bi-functional constructs containing FNIII10 and VEGF-A165. 
 
Another functional question concerning the bi-functional proteins was, whether their RGD-site 
within the FNIII10 domain was functional. During the expression of the protein as GST-tagged 
fusion protein, it seemed that GST-TG-PL-FLV had another thrombin cleavage site besides the 
one employed to cleave the tag off the protein, as thrombin-mediated cleavage resulted in 
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additional cleavage products. Indeed, for this protein, a cleavage site within the RGD-site is 
predicted, which seemingly is not processed by thrombin digestion of GST-TG-FNIII10, as cells 
can still attach to this protein. Thus, it seemed possible that the RGD-site was non-functional in 
the bi-functional proteins. To answer this question, HUVECs were allowed to attach to 
microscopy slides coated with the bi-functional protein FLV. Interestingly, cell attachment and 
spreading on FLV was enhanced as compared to attachment and spreading to FNIII10 or 
VEGFmut alone. On FLV, cells appeared maximally spread and showed many stress fibers 
ending in well-established focal contacts. By contrast, on FNIII10, less advanced cell spreading 
was observed, cells showed fewer focal contacts and stress fibers, and some cells remain 
rounded. On VEGFmut, cells did not spread. This was surprising, as Hutchings et al. observed 
good cell spreading on VEGF-A165 as compared to spreading on poly-L-lysine, and the 
formation of numerous membrane protrusions resulting in stellate-like cell shapes (Hutchings et 
al. 2003). As their VEGF-A concentration plated was lower and the time during which cells were 
allowed to attach was shorter, this difference most likely is due to the use of different primary 
endothelial cells, namely human umbilical arterial endothelial cells and bovine retinal 
endothelial cells in these experiments.  
 
In summary, a clear synergism in the promotion of cell spreading on the novel hybrid protein 
FLV was shown. These data apparently conflict with other in vitro results obtained in this study, 
as VEGFR-2 and Erk 1/2 phosphorylation upon stimulation of adherent subconfluent HUVECs 
with FLV was reduced as compared to the stimulation with VEGFmut, thus no synergism could 
be detected under these conditions. However, integrins are mechanosensors, which can 
distinguish soluble ligands from sequestered ligands. This idea is based on the observation, that 
soluble RGD-mimetics raised against αvβ3 induce apoptosis endothelial cells (Brooks et al. 
1994b). Binding to soluble ligands does not permit the generation and transmission of force to 
the actin cytoskeleton, and does not support integrin activation (Cheresh and Stupack 2008). The 
in vitro experiments performed within this study underscored thus the importance of the proper 
presentation of the molecule to endothelial cells to allow for functional signaling. Apparently, 
sequestered FLV was capable to produce synergistic signaling towards enhanced cell spreading, 
while no synergism was observed when FLV was applied to the cells in solution. Future 
investigations should therefore investigate synergistic VEGFR-2 and Erk1/2 signaling in cells 
plated to immobilized FLV.  
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4.3 Covalent binding of FLV to fibrin is not superior to 
covalently fibrin-bound VEGF-A165 in the induction of 
wound angiogenesis 
Based on the literature it was hypothesized that the collaboration between integrin αvβ3 and 
VEGFR-2 may be beneficial for the promotion of wound angiogenesis as well, and might result 
in improved tissue regeneration due to a better perfusion in wound healing impaired mice. To 
investigate this question, the hybrid protein consisting of the FNIII10 domain and VEGFmut was 
fused to a substrate sequence for the transglutaminase factor XIIIa and delivered to full thickness 
lesions in diabetic mice covalently bound to a fibrin gel. In this wound healing model, the 
angiogenesis induced by fibrin-bound TG-FLV was significantly increased over control levels. 
However, in wounds treated with TG-FLV, the area covered by vascular structures was reduced 
as compared to wounds treated with TG-VEGFmut, thus no synergistic signaling could be 
detected. By the in vitro stimulation of HUVECs with bi-functional fusion proteins it was 
demonstrated that both FLV and TG-FLV were biological active, as they triggered the 
phosphorylation of VEGFR-2 and downstream signaling partner Erk 1/2. Yet, also in this 
experiment, the bi-functional proteins they failed to induce increased or sustained activation of 
VEGFR-2 and Erk 1/2 phosphorylation upon stimulation as compared to the stimulation with 
VEGFmut.  
The most important question at this point was to determine, whether the bi-functional protein 
was still able to interact with the VEGFR-2 or if the presence of FNIII10 within the same 
molecule would interfere with VEGFR-2 binding. SPR binding studies demonstrated, that FLV 
bound to immobilized VEGFR-2-Fc with high affinity. As compared to VEGFmut, the affinity 
was slightly decreased. However, it is not clear if differences in binding affinity between 
VEGF-A isoforms to VEGFR-2 directly translate into differences in their signaling capabilities. 
Even though VEGF-A121 showed a reduced binding to VEGFR-2 as compared to VEGF-A165, 
both isoforms induced comparable phosphorylation and endothelial cell migration, yet 
endothelial sprouting from spheroids was decreased upon stimulation with VEGF-A121 (Pan et 
al. 2007). By contrast, experiments performed by another group indicated that VEGF-A165 
stimulation of HUVECs induced a stronger and sustained phosphorylation of MEK and ERK as 
compared to VEGF-A121, while VEGF-A121 appeared to activate Src, which was not the case for 
VEGF-A165 (Zhang et al. 2008). Also VEGF-A165b binds to VEGFR-2 with the same affinity as 
VEGF-A165. Both molecules differ only by their 6 C-terminal amino acids (Woolard et al. 2004). 
However, VEGF-A165b does not induce VEGFR-2 phosphorylation and does not promote 
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angiogenesis (Cebe Suarez et al. 2006). Thus, the interaction strength of VEGF-A with 
VEGFR-2 does not forcedly correlate with the signaling output. By contrast, the interplay of 
VEGF-A isoforms with co-receptors might have a stronger effect on the signaling than their 
actual affinity to VEGFR-2, as co-receptors may optimize VEGF-A presentation to the receptor 
and enhance their binding. This view is supported by the finding that VEGF-A165b only weakly 
binds to HSPGs, and retains no affinity to Nrp-1, which may attribute to the more transient 
signaling observed downstream of VEGFR-2 (Cebe Suarez et al. 2006; Grunewald et al. 2010). 
Another possible explanation for the lack of synergism may be that the density of RGD-ligands 
within the clot is very high, as fibrin possesses two RGD-sites within its Aα chain (Henschen et 
al. 1983), which are recognized by integrin αvβ3 expressed on endothelial cells (Cheresh 1987). 
For this reason, the addition of additional integrin ligands may not further induce angiogenic 
signaling. Also, too many integrin ligands may have adverse effects on cell migration, as they 
can slow focal adhesion dynamics, as cells attach too strongly (Cheresh and Stupack 2008). By 
contrast, there is strong evidence based on experiments performed by Hall et al. that additional 
integrin αvβ3 ligands within the fibrin gel can promote angiogenic sprouting in the absence of 
growth factors. In these experiments, the 6th Ig-like domain of the cell adhesion molecule L1 
(L1Ig6), which contains a RGD site and is a specific ligand for integrin αvβ3 (Blaess et al. 
1998), was expressed as a fusion to the factor XIIIa substrate sequence and incorporated into 
fibrin matrices. These L1Ig6 functionalized fibrin gels promoted HUVEC process extension 
from microcarrier beads and angiogenesis in the CAM (Hall et al. 2004). The presence of 
additional integrin αvβ3 ligands is thus unlikely to hinder angiogenesis. 
It appears more likely, that for the detection of synergistic signaling, a lower concentration of the 
growth factor should be delivered to wounds within the fibrin gels. In the experiments 
performed, 1.6 µg of each protein (effective VEGF-A concentration) were delivered to one 
wound. In combination with the targeted delivery system employed, it seems reasonable that this 
dosage induced the maximal angiogenic response possible, and that doses below a saturation 
level should be investigated for the detection of synergistic signaling. Importantly, the 
physiological density of the vascular network induced is tightly regulated. Thus, the biological 
activity of TG-FLV to promote angiogenesis in vivo observed most likely was to be attributed to 
its presentation in a covalently matrix bound form, while synergistic effects remain to be 
elucidated in future experiments. 
 
Discussion 
 
70 
4.4 Recombinant fusion proteins composed of various 
protein domains raise the possibility of synergistic 
signaling and novel biological functions  
The availability of recombinant cloning techniques allows the combination of various functional 
domains to assemble novel molecules with altered or additional properties. Within this study, 
bioengineering strategies were employed first to improve the delivery of VEGF-A165 for 
biomedical applications, second to potentiate the biologic activity of the growth factor, and third 
to fine-tune the angiogenic response induced by VEGF-A165 in non-healing wounds. This section 
will compare the bioengineering strategies employed in this study to other possible, published 
strategies, in which similar outcomes were targeted by molecular modifications of biologically 
active molecules. 
 
The targeted delivery and the controlled release of potent growth factors to the desired site of 
treatment is recognized to be critical for positive outcome of treatments using recombinant 
proteins. In this study, VEGF-A165 was fused to the α2-plasmin inhibitor substrate sequence of 
factor XIIIa, and this fusion allows specific covalent binding of the protein to fibrin by the 
crosslinking activity of factor XIIIa. As detailed above, this VEGF-A165 form delivered in fibrin 
gels proved to be more efficient in the induction of angiogenesis in chronic wounds than soluble 
VEGF-A165, and these results were in agreement with investigations on the induction of 
angiogenesis with matrix-bound VEGF-A121 (Ehrbar et al. 2004). In previous studies, the 
delivery of other growth factors in covalent binding to fibrin proved to have superior biological 
effects as compared to the soluble growth factor in fibrin gels in various in vitro and in vivo 
models. A fibrin-bound form of β nerve growth factor induced increased neurite process 
extension from embryonic chick dorsal root ganglia (Sakiyama-Elbert et al. 2001), and fibrin-
bound bone morphogenic protein-2 promoted healing in critical size cranial defects (Schmoekel 
et al. 2005), respectively. Further, the delivery of growth factors by the covalent binding of 
heparin-binding peptides to fibrin (Sakiyama-Elbert and Hubbell 2000), as well as the delivery 
of DNA via covalently bound DNA-nanoparticles (Trentin et al. 2006) is feasible by this 
approach.  
Similarly, also other growth factors engineered for improved matrix binding have been shown to 
be more potent as compared to soluble ones due to their prolonged retention time. To accomplish 
prolonged retention of growth factors in tissues, another strategy consists in their fusion to a 
collagen-binding domain. As connective tissue mainly consists of collagen, this should increase 
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residence and bioavailability of the growth factor. Fusion of a collagen-binding domain to 
VEGF-A was shown to prolong its residency in muscle or wound tissue (Ishikawa et al. 2006; 
Yan et al. 2010), and similarly, collagen-binding HGF, PlGF and FGF variants were designed 
(Kitajima et al. 2007; Lin et al. 2006; Pang et al. 2010). 
 
The second strategy employed in this study aimed at the potentiation of the biologic activity of 
VEGF-A165. To this end, a VEGF-A165 variant with a cell adhesion site naturally found in 
fibronectin, the FNIII10 domain was designed, aiming at increased angiogenic signaling by co-
stimulation of VEGFR-2 and integrin αvβ3. In the approach employed here, FNIII10 was fused 
to the N-terminus of VEGF-A165, and both functional domains were interconnected by a linker 
calculated to be long enough to allow simultaneous interaction of both ligand domains with their 
respective receptors. The finding that this bi-functional protein retains the ability to bind to 
VEGFR-2 and to induce its activation in vitro is in agreement with previous reports, indicating 
that the N-terminal modification included is permissive for the bioactivity of the VEGF-A 
molecule (Backer and Backer 2001). The most important finding of this study was, that these 
hybrid proteins indeed have the potential to induce synergistic signaling. FLV was shown to 
promote cell adhesion of HUVECs to a greater extend than both functional domains alone. On 
FLV, HUVECs were maximally spread, showed many stress fibers and focal contacts. Also on 
FNIII10, spreading was efficient, but stress fiber organization and focal contact formation were 
dramatically reduced as compared to cells on FLV. On VEGF-A165 by contrast, no spreading was 
observed. Thus, the fusion of cell-binding domains to growth factors can promote increased cell 
spreading.  
This phenomenon was also observed using a very similar hybrid protein design, in which FGF-1 
or -2 were directly fused to the fibronectin type III domains 9 and 10 (FNIII9/10). Also these bi-
functional fusion proteins increased cell attachment to the hybrid construct over cell attachment 
observed on FNIII9/10 alone (Jang and Chung 2004; Jeon et al. 2009). Besides, FGF1-FNIII9/10 
promoted increased proliferation, Erk1/2 phosphorylation and osteoblastic differentiation in a 
human osteosacroma cell line compared with cells seeded on FNIII9/10 or FGF1 alone (Jeon et 
al. 2009). These results indicate, that the assembly of multiple functional domains in new fusion 
proteins may not only have an additive effect on biologic responses, but also can result in novel 
biological responses not observed in response to the single domains.  
 
The third bioengineering strategy employed aimed at the fine-tuning of the angiogenic response, 
as pro-angiogenic therapies for chronic wounds and other treatments require the induction of a 
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mature, persistent, non-leaky and well organized vasculature. The highly proteolytic 
environment of non-healing wounds constitutes an additional challenge for the treatment with 
recombinant protein formulations, as it requires a stabilization of the growth factor delivered. 
Previous work by Roth et al. showed that gene delivery of a plasmin-stabilized mutant 
VEGF-A165 form to skin lesions on the back of diabetic mice resulted in sustained vascular 
ingrowth due to pericyte recruitment and reduced apoptosis, most likely due to the increased 
persistence of the stabilized VEGF-A165 in the wound (Roth et al. 2006). Similarly, the delivery 
of a mutant form of VEGF-A165 covalently linked to fibrin gels in the same wound healing 
model proved to induce mature vessels abundantly covered with pericytes. Thus, the 
combination of a stable VEGF-A165 isoform and targeted delivery is a good strategy for the 
induction of mature vessels.  
An alternative approach using bioengineered VEGF-molecules aimed at the induction of a 
mature vasculature by specific targeting of VEGFR-2. It was hypothesized, that VEGF-A’s 
ability to recruit inflammatory cells and to induce vascular leakage might delay mature vessel 
formation during wound healing. This consideration motivated Zheng et al. to design a chimeric 
VEGF-ENZ7 molecule. VEGF-E is a potent, Orf-virus encoded VEGF-family member binding 
specifically to VEGFR-2, and thus incapable to act as a chemoattractant for inflammatory cells, 
as this response is mediated by VEGFR-1 signaling. For humanization, non-essential portions of 
VEGF-ENZ7 were replaced by sequences from PlGF-1 (Zheng et al. 2007). When injected 
subcutaneously, this novel molecule accelerated wound closure and angiogenesis in full 
thickness wounds on diabetic mice, and this was attributed to the absence of tissue edema and 
the lack of a sustained infiltration of inflammatory cells (Zheng et al. 2007).  
Furthermore, Ang1 is an emerging compound for the promotion of therapeutic angiogenesis. In 
binding to its receptor, the receptor tyrosine kinase Tie-2, Ang1 is known to promote vascular 
maturation, to prevent vascular leakage, and to contribute to angiogenic vascular growth 
(Asahara et al. 1998; Gamble et al. 2000). Ang1 binding to its receptor is mediated by its 
C-terminal fibrinogen-like domain, and a coiled-coil domain and a superclustering domain in the 
N-terminus of the protein accomplish the formation of bioactive oligomers. For its use as pro-
angiogenic drug however, difficulties concerning its purification as a recombinant protein had to 
be overcome. Due to its superclustering domain, the purified protein tends to form aggregates 
reducing its bioavailability. For this reason, the natural oligomerization domains of Ang1 were 
replaced by the coiled-coil domain of the cartilage oligomeric matrix protein (COMP). This 
modification resulted in the preferential formation of COMP-Ang1 pentamers (Cho et al. 2004). 
In endothelial cells, this bioengineered protein promoted the protection from apoptosis, the 
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induction of migration, tube formation and sprouting to a greater extend than native Ang1 in 
vitro. Interestingly, COMP-Ang1 induced an angiogenic response similar to that observed upon 
stimulation with VEGF-A in the corneal micropocket assay, while native Ang1 didn’t promote 
angiogenesis. A major benefit of COMP-Ang1 in comparison to VEGF-A in the induction of 
angiogenesis was the formation of a non-leaky vasculature (Cho et al. 2004).  
These examples indicate, that the optimization of the molecular properties of bioactive 
compounds by recombinant techniques may provide additional benefits for pro-angiogenic 
therapies. 
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5 Perspectives 
 
The overall objective of the present study was the amelioration of wound angiogenesis in 
response to recombinant VEGF-A165 by optimizing bioavailability and potency of the growth 
factor.  
 
One major finding was, that VEGF-proteins engineered for the covalent binding to fibrin had a 
superior effect on the induction of angiogenesis in vivo compared to soluble VEGF-A165. 
However, the hypothesized superiority of a bi-functional protein comprising FNIII10 fused to 
VEGF-A165 targeting integrin αvβ3 and VEGFR-2 for synergistic pro-angiogenic signaling was 
not detectable in this wound healing model. One possible reason may be that the amount of 
VEGFmut and FLV delivered covalently bound to fibrin matrices induced maximum wound 
angiogenesis, as the amount of recombinant proteins delivered to wounds was high. Thus, future 
experiments should be performed to determine the optimal dose of recombinant matrix bound 
VEGF-proteins to be delivered. Also, it is likely that for the distinction of synergistic signaling 
in response to bi-functional proteins, a lower concentration range might be required. 
Also, when HUVECs were stimulated with soluble VEGF-A165 or FLV, no synergistic signaling 
was detected on the level of VEGFR-2 or Erk1/2 phosphorylation. By contrast, when HUVECs 
were plated on the immobilized ligands, cell spreading in response to FLV was markedly 
enhanced as compared to cell spreading on FNIII10 or VEGF-A165. These results indicate, that 
for the detection of synergistic signaling, the presentation of the immobilized ligand is crucial, 
and future experiments thus will focus on differences in cellular signaling in cells plated on 
VEGF-A165 or FLV. The signaling output under this condition may be very different. 
Furthermore, even though the functional domains FNIII10 and VEGF-A165 are biologically 
active and can bind to their respective ligands as shown by cell attachment assays and by surface 
plasmon resonance measurements, respectively, the direct proof of simultaneous binding of both 
receptors to both ligands is still lacking. This evidence might be obtained by the performance of 
crosslinking experiments, during which the ligands are covalently crosslinked to cell surface 
receptors. The crosslinked complexes can be investigated for the presence of αvβ3 and 
VEGFR-2 by western blot. These experiments are currently ongoing. 
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The delivery system employed and the fusion proteins generated provide the possibility to study 
the impact of VEGF-A interactions with the extracellular matrix in angiogenesis and the role of 
the VEGFR-2 – integrin αvβ3 crosstalk. Additionally, the combination of fibrin matrices with 
protease stabilized VEGF-A proteins holds promising potential also for various pro-angiogenic 
therapeutic approaches, such as the treatment of healing-impaired wounds. 
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6 Materials and methods 
 
6.1 Chemicals 
Used chemicals were of analytical purity grade and obtained from Roth (Karlsruhe, Germany), 
Sigma Aldrich (St. Louis, USA), Riedel de Haen (Seelze, Germany), Applichem (Darmstadt, 
Germany) or Merck (Darmstadt, Germany) unless specified otherwise.  
 
6.2 Special equipment  
Chromatograph: ÄKTApurifier™ (GE Healthcare, Fairfield, USA) 
UV spectrometer:  NanoDrop-1000 (Thermo Fisher Scientific Inc., Waltham, USA) 
ELISA plate readers:  VICTOR3 (Perkin Elmer, Waltham, USA) 
 Safire2 (Tecan, Männedorf, Switzerland) 
Electrophoresis systems: PROTEAN II Electrophoresis Cell (Bio-Rad Laboratories GmbH, 
Munich, Germany) 
 XCell SureLock™ Mini-Cell (Invitrogen, Paisley, UK) 
Western blotting systems:  Mini Trans-Blot® cell (Bio-Rad) 
XCell II™ Blot Module (Invitrogen) 
Microscopes:   Leica DM 4000B (Leica Camera AG, Solms, Germany) 
    Nikon eclipse E 800 (Nikon, Melville, USA) 
    Nikon A1 (Nikon, Melville, USA) 
 
6.3 Bacterial cell culture 
6.3.1 Escherichia coli (E. coli) strains  
E. coli strains used for cloning 
DH5α was purchased from Invitrogen and used for routine subcloning. This strain has several 
mutations that make it particularly useful for cloning and DNA-amplification, such as reduced 
homologous recombination to stabilize the insert and a reduced endonuclease activity that allows 
for higher yields. The genotype is F- φ80lacZ∆M15 ∆ (lacZYA-argF)U169 recA1 endA1 
hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λ-. 
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SCS110 was purchased from Stratagene (Santa Clara, USA) and is also a strain used for plasmid 
amplification due to its endonuclease deficiency. Additionally, it carries mutations in the DNA 
methylases Dam and Dcm, so the DNA isolated from these cells can be digested using 
methylation-sensitive restriction enzymes. The genotype is rpsL, (Strr), thr, leu, endA, thi-1, 
lacY, galK, galT, ara, tonA, tsx, dam, dcm, supE44, d(lac-proAB), [F' traD36, proAB, lacIqD 
M15]. 
 
E. coli strains used for protein expression 
BL21 was purchased from GE Healthcare and is deficient in the proteases lon and ompT and 
hence a strain commonly used for the expression of recombinant proteins. The genotype is B F-, 
dcm, ompT, hsdS (rB-, mB-), gal [malB+]K-12(λS). 
BL21(DE3)pLys was obtained from Stratagene. As compared to BL21, the expression of 
recombinant proteins is more tightly controlled. The genome contains a T7 polymerase gene 
under the control of lacUV5. Expression of the T7 polymerase is induced by the addition of 
IPTG. Furthermore, this strain carries the plasmid pLysS encoding for the T7 lysozyme, a T7 
RNA polymerase inhibitor to prevent leaky expression of the target gene in uninduced cells. The 
genotype is B, F-, dcm, ompT, hsdS(rB-mB-), galλ(DE3) [pLysS Camr]. 
 
6.3.2 General culture conditions 
For the culture of E. coli, sterile plastic ware and sterile technique was used. E. coli propagated 
for cloning purpose or for the expression of recombinant proteins were cultivated in liquid 
cultures in Lysogeny broth (LB), Super optimal broth with catabolite repression (SOC) or 
2x yeast extract and tryptone (YT) medium as specified, at 37°C under shaking at 180 rpm using 
the appropriate selection antibiotics obtained by Applichem when indicated (Table 5). 
For the selection of clones, liquid cultures were plated on LB agar plates and allowed to grow 
overnight at 37°C. For the investigation of the clones (for example for the detection of an insert 
during cloning or for the identification of a good protein producer), liquid cultures were 
inoculated from a single colony. Plates were stored at 4°C for up to 3 weeks.  
 
LB   SOC   2x YT  Antibiotics  
0.5 % Yeast extract  0.5 % Yeast extract  1.6 % Tryptone  Ampicillin 0.1 mg/mL 
1 % Tryptone  2 % Tryptone  1 % Yeast extract  Chloramphenicol  0.03 mg/mL 
1 % NaCl  10 mM NaCl  0.5 % NaCl    
(1.5% Agar)  2.5 mM KCl       
   10 mM MgCl2       
   10 mM MgSO4       
   20 mM Glucose       
Table 5: Media and antibiotics used for the culture of E. coli. 
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6.3.3 Generation of chemical competent bacteria using calcium 
chloride (Cohen et al. 1972) 
A single colony of bacteria was picked form a plate, transferred into 100 mL of LB and grown to 
an OD600 of 0.4. Cells were harvested by centrifugation at 4°C and the pellet was resuspended in 
30 mL of ice-cold 80 mM MgCl2, 20 mM CaCl2 solution. Following another centrifugation step, 
the pellet was resuspended in 4 mL of 0.1 M CaCl2. For the preparation of a frozen stock, 
140 µL of DMSO were added to the suspension and incubated for 15 minutes on ice. An 
additional 140 µL of DMSO were added, and cells were dispensed into working aliquots, snap-
frozen in liquid nitrogen, and stored at -80°C until use (Sambrook 2001). 
 
6.3.4 Transformation of chemical competent bacteria 
For transformation, cells were rapidly thawed, and 10 ng of plasmid DNA or 10 µL of ligation 
assays were added to 100 µL of cell suspension. After an incubation on ice of 15 minutes, cells 
were heat shocked in a 42°C water bath for 2 minutes and allowed to recover in SOC-medium 
with shaking for 1 hour at 37°C prior to plating on LB-agar plates containing the appropriate 
antibiotics for the selection of transformants. 
 
6.3.5 Generation of bacterial frozen stocks 
To overnight cultures of positive clones in LB containing selection antibiotics, 30 % sterile 
glycerol were added to a total volume of 1 mL, and cultures were stored at -80°C. 
 
6.4 Culture of eucaryotic cells 
6.4.1 Eucaryotic cells  
Human embryonic kidney (HEK) 293-EBNA cells were a kind gift from professor Dr. Manuel 
Koch. This cell line constitutively expresses the Epstein Barr Virus EBNA1 gene from the vector 
pCMV/EBNA. EBNA1 binds to EBV origin of replication (oriP) on eucaryotic expression 
vectors (Frappier and O'Donnell 1992). 
Human umbilical vein endothelial cells (HUVECs) were obtained from either Promocell 
(Heidelberg, Germany) or Lonza (Basel, Switzerland).  
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6.4.2 General culture conditions 
Cell culture and experiments using cultured cells were performed under a laminar flow hood, 
applying sterile solutions and devices and using sterile technique. In general, media and 
solutions applied to the cells were pre-warmed to room temperature or to 37°C. Cells were 
cultured in cell culture plastic ware obtained from BD (Franklin Lakes, USA) in a cell culture 
incubator adjusted to 37°C and 5 % CO2. Media were supplemented with 100 U/mL penicillin 
(Biochrom, Berlin, Germany), 100 µg/mL streptomycin (Biochrom) and 0.05 mg/mL ascorbic 
acid (Sigma-Aldrich). 
 
6.4.2.1 Culture of HEK293-EBNA cells 
HEK 293-EBNA were cultured on collagen I coated flasks in DMEM (Invitrogen) supplemented 
with 10 % FCS (PAA, Pasching, Austria).  
 
6.4.2.2 Culture of HUVECs 
HUVECs were cultured according to the protocol from the supplier and using the growth media 
recommended by the supplier, either endothelial cell growth medium 2 (Promocell) or EGM®-2 
BulletKit® (Lonza). These media are defined as they do not contain bovine brain extract, and the 
final serum concentration is 2 %. Cells were grown in culture flasks coated with either collagen I 
(BD, 50 µg/mL in 0.02 M acetic acid) or gelatin (Sigma Aldrich, 0.01% in water). At 70-90% 
confluency, cells were subcultured as recommended by the supplier. HUVECs were used for 
experiments between passages 5 and 7.  
 
6.5 General protein biochemical methods 
6.5.1 Determination of protein concentration 
6.5.1.1 Determination of protein concentration by spectrometry 
The concentration of a protein solution can be determined by its absorbance at 280 nm, but needs 
to be corrected by the extinction coefficient. The extinction coefficient is protein specific and 
was predicted based on the amino acid composition of the protein of interest at the ExPASy 
Proteomics Server (Swiss Institute of Bioinformatics, Lausanne, Switzerland), using the 
ProtParam tool. Concentrations of FNIII10-constructs were determined by this approach using a 
NanoDrop 1000 spectrometer. However, in proteins lacking tryptophan residues, this prediction 
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is very imprecise, hence other ways to determine protein concentrations are required, such as the 
bicinochoninic acid (BCA) assay or protein-specific enzyme-linked immunosorbent assays 
(ELISA). 
 
6.5.1.2 Determination of protein concentration by the BCA assay 
The BCA protein assay kit (Pierce, Thermo Fisher Scientific, Waltham, USA) is based on the 
reduction of Cu+2 to Cu+1 by proteins, and the colorimetric detection of CU+1 by complexation 
with BCA. The absorbance of the complex at 562 nm is proportional to the protein concentration 
over a wide range of concentrations, and protein concentration is determined in comparison to a 
bovine serum albumin (BSA) standard curve. Protein concentrations of the VEGF-variants or of 
cell lysates were determined using the microplate procedure as described by the supplier. 
 
6.5.1.3 Determination of protein concentration by VEGF specific ELISA 
A VEGF-A sandwich ELISA, either from R&D (Minneapolis, USA, Quantikine Human VEGF 
immunoassay) or Peprotech (Hamburg, Germany, Human VEGF ELISA Development Kit), was 
used for the determination of concentrations of proteins purified form E. coli and for the 
investigation of the release kinetics of proteins from fibrin gels in comparison to a 
VEGF-standard curve following the manufacturer’s manual. 
 
6.5.2 Sodium dodecylsulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
SDS-PAGE is a method to separate proteins according to their molecular weight in a 
polyacrylamide gel. SDS is negatively charged and binds to proteins in a constant ratio, so that 
the charge of a SDS-protein complex is proportional to its mass. Interaction with SDS 
denaturates proteins and prevents their interaction. Subjected to an electric field, the negatively 
charged proteins migrate to the anode. During their migration in the gel, large proteins are 
retained stronger in the polyacryleamide gel than small ones and do not migrate as far. Proteins 
are first concentrated in a stacking gel with large pore sizes and then separated in a separating 
gel (Laemmli 1970). Gels for SDS-PAGE were purchased from Invitrogen (NuPAGE system), 
and NuPAGE® Novex® Bis-Tris precast gels were run using the XCell SureLock® Mini-Cell 
system in MES/SDS running buffer.  
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Alternatively, the gels were prepared manually and run with the mini PROTEAN II 
electrophoresis Cell system (Bio Rad) using Tris/glycine/SDS as running buffer. When preparing 
polyacrylamide gels, the separating gel (Table 6) was cast first, and overlaid with isopropanol to 
obtain a straight border. Once the separating gel had polymerized, the isopropanol was removed, 
the stacking gel (Table 6) was cast on top, and the comp creating the gel pockets for the samples 
was placed in the gel.  
Prior to electrophoresis, loading buffer (Table 6) was added to the samples (either recombinant 
proteins produced or cell lysates), and the mixture was boiled for five minutes at 94°C. In 
reducing gels, the loading buffer contained β-mercaptoethanol as a reducing agent, thus allows 
visualization of VEGF monomers.  
A protein marker consisting of stained proteins of known size purchased from Bio Rad or 
Fermentas (Thermo Fisher Scientific), was included on each gel to estimate the molecular weight 
of given bands.  
 
Stock solutions for SDS-PAGE gels 
 4x Tris-Cl/SDS pH 8.8 4x Tris-Cl/SDS pH 6.8  
Tris Base 182 g 30.25 g  
SDS 4 g 2 g  
HCl Adjust pH to 8.8 Adjust pH to 6.8  
Acrylamide/Bis-acrylamide (Acr/Bis-Acr), 4 K 30% solution, 
37.5:1 (Applichem) 
10% ammonium persulfate (APS) (Sigma) 
N,N,N,N-tetramethylethylenediamine (TEMED) (Fluka) 
H2O To 1 L To 500 mL   
 
Composition of 3 polyacrylamide gels of 1mm thickness: 
Separating gel Acrylamide concentration (%)  Stacking gel  
Stock solution (mL) 5 6 7 7.5 8 9 10 12 13 15  Stock solution mL 
Acr/Bis-Acr 2.5 3 3.5 3.75 4 4.5 5 6 6.5 7.5  Acr/Bis-Acr 0.65 
Tris-Cl/SDS pH 8.8 3.75 3.75 3.75 3.75 3.75 3.75 3.75 3.75 3.75 3.75  Tris-Cl/SDS pH 6.8 1.25 
H2O 8.75 8.25 7.75 7.5 7.25 6.75 6.25 5.25 4.75 3.75  H2O 3.05 
10% APS 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05  10% APS 0.025 
TEMED 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01  TEMED 0.005 
(Current Protocolls in Cell Biology, 2007 37:6.1.1-6.1.38. John Wiley & Sons, Inc.) 
 
Running buffers and loading buffer 
MES/SDS  Tris/glycine/SDS  4x Laemmli loading buffer 
2.5 mM MES  2.5 mM Tris, pH 8.3  8 %  SDS 
2.5 mM  Tris base, pH 7.3  19.2 mM glycine  0.2 M Tris pH 6.8 
0.005 %  SDS  0.01% SDS  40 %  Glycerol 
0.05 mM EDTA     0.01 %  Bromphenol blue 
      (5% β-mercaptoethanol) 
Table 6: Solutions and buffers used for SDS-PAGE.  
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6.5.3 Protein detection on SDS-PAGE gels 
For the detection of proteins separated by SDS-PAGE, the gels were stained using the 
Coomassie blue based stain SimplyBlue™ SafeStain (Invitrogen) according to the manufacture’s 
instructions. Alternatively, staining was performed using Coomassie blue. Gels were covered 
with the Coomassie blue solution (Table 7) and stained for 2 hours with shaking. Background 
staining was removed by washing with a destain solution (Table 7) for several hours or over 
night. 
 
Coomassie blue  Destain solution 
0.01 % Coomassie blue R-250  10 % MeOH 
50 %  MeOH  10 % Acetic acid 
5 %  Acetic acid    
Table 7: Composition of Coomassie blue and destain solution. 
 
6.5.4 Immunoblotting of proteins 
6.5.4.1 Western blot transfer 
Following SDS-PAGE, separated proteins were transferred onto polyvinylidene fluoride 
(PVDF)-membranes purchased from Bio Rad or Millipore (Billerica, USA) in order to make 
them accessible for immunodetection by antibodies. For the transfer, either XCell IITM Blot 
Module with Bicine/Bis Tris buffer supplemented with 10 % methanol (Invitrogen) or the mini 
TransBlot system (Bio Rad) with Tris/Glycine as transfer buffer containing 20 % methanol were 
used (Table 8). 
The PVDF membrane was activated in methanol for one minute, and both the PVDF membrane 
and the gel were washed in the transfer buffer. As mentioned, proteins are charged negatively 
due to interaction with SDS and migrate toward the anode within an electric field. Thus, the 
orientation in the module was as follows:  
 kathode 
 sponge 
 watson filter paper 
 SDS-polyacrylamide gel 
 PVDF membrane 
 watson filter paper 
 sponge 
 anode 
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The transfer was performed at 30 V for 75 minutes in the Invitrogen system, or at 80 V for 60 
minutes in the Bio Rad system, respectively.  
 
Transfer buffers    
Bicine/ Bis Tris  Tris/Glycine 
1.25 mM  Bicine  2.5 mM Tris, pH 8.3 
1.25 mM Bis Tris, pH 7.2  19.2 mM Glycine 
0.05 mM  EDTA  20 % Methanol 
10 % Methanol    
Table 8: Transfer buffers used for western blot transfers. 
 
6.5.4.2 Immunodetection of proteins 
Following the transfer to PVDF, unspecific binding sites on the membrane were blocked by 
incubation in 5 % non-fat milk (Bio Rad or Roth, Karlsruhe, Germany), 1 % BSA (Sigma or 
PAA) in TBS containing 0.1 % Tween-20 (TBS-T) for at least one hour with shaking. Specific 
proteins were detected using the primary antibodies given in Table 9. 
 
Antigen Host species Supplier  Dilution Diluent Incubation time 
VEGF A20 Rabbit (polyclonal) Santa Cruz Biotechnology 1:2000 2.5 % milk 1 hr 
VEGFR-2 phosphotyrosine 1175 Rabbit (monoclonal) Cell signaling Technology 1:1000 5 % BSA o/n 
Flk-1 (A3) Mouse (monoclonal) Santa Cruz Biotechnology 1:500 5 % milk 1 hr 
Phospho-p44/42 MAPK (Erk1/2) Rabbit (monoclonal) Cell Signaling Technology 1:1000 5 % BSA o/n 
β-actin Mouse (monoclonal) Santa Cruz Biotechnology 1:1000 5% milk 1 hr 
Table 9: List of primary antibodies used for western blot experiments. 
 
For detection of the primary antibodies, the membrane was washed 3x10 minutes in TBS-T, and 
then incubated with horse radish peroxidase (HRP)-coupled secondary antibodies diluted 1:1000 
in 5 % milk for one hour. For detection of glutathione-S-transferase (GST)-tagged proteins, an 
antibody directly coupled to HRP is available, so no secondary antibody was required (Table 
10). Following additional extensive washes, the membrane was incubated with an enhanced 
chemiluminescence (ECL) system containing luminol (PIERCE or PerkinElmer, Table 10). The 
HRP mediated oxidation of luminol generates a luminescence signal detected by imposing a 
Röntgen film on the membrane. The film was then developed using an AGFA (Mortsel, 
Belgium) developing machine. 
 
HRP-coupled antibodies  Supplier  ECL used Supplier 
Goat anti mouse HRP Dako  PerkinElmer 
Swine anti Rabbit HRP Dako  
Western Lightning Plus, enhanced  
chemiluminescence substrate  
Goat anti mouse HRP Bio Rad  ECL Western Blotting Substrate PIERCE 
Goat anti rabbit HRP Bio Rad    
Anti GST-HRP GE Healthcare    
Table 10: Secondary antibodies and ECL solutions used. 
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6.6 Cloning and cloning strategy 
Proteins to be expressed were composed from different protein domains and were cloned in 
subsequent steps into expression vectors by recombinant DNA techniques. The DNA encoding 
for functional domains of the fusion proteins was amplified by polymerase chain reaction (PCR). 
The PCR product and the vector into which the sequence is to be cloned were subsequently 
digested with two restriction endonucleases. Specific PCR primers defining the sequence to be 
amplified were designed and obtained from Microsynth (Balgach, Switzerland). The sequences 
of these primers and detailed cloning procedures are given in section 6.6.1.  
Initially, the sequences encoding protein domains were cloned into the bacterial expression 
vector pGEX-4T-1. The sequence encoding for VEGFmut was amplified from pcDNA3.1, 
FNIII10 was amplified from pFH157, whereas sequences encoding for the transglutaminase 
substrate sequence TG, the plasmin sensitive site PL and for the linker were ordered as 
oligonucleotides from Microsynth. 
 
6.6.1 DNA and amino acid sequences of protein domains used and 
cloning into the bacterial expression vector pGEX-4T-1 
The protein domains cloned into pGEX-4T-1 in subsequent steps are shown in Figure 30, and 
were separated by different restriction sites.  
 
 
TG: transglutaminase substrate sequence 
PL: plasmin-sensitive site 
FNIII10: fibronectin type III domain 10 
L: linker (GGGGS)6.5 
VEGF165mut: plasmin-resistant VEGF-A165 
isoform  
(Arg110/Ala111  Lys110/Pro111) 
Figure 30: Cloning strategy employed and localization of restriction sites within the construct. 
 
Sequence of VEGFmut with the mutated plasmin cleavage site shown in red 
GCA CCC ATG GCA GAA GGA GGA GGG CAG AAT CAT CAC GAA GTG GTG AAG TTC ATG GAT GTC TAT CAG CGC AGC 
TAC TGC CAT CCA ATC GAG ACC CTG GTG GAC ATC TTC CAG GAG TAC CCT GAT GAG ATC GAG TAC ATC TTC AAG 
CCA TCC TGT GTG CCC CTG ATG CGA TGC GGG GGC TGC TGC AAT GAC GAG GGC CTG GAG TGT GTG CCC ACT GAG 
GAG TCC AAC ATC ACC ATG CAG ATT ATG CGG ATC AAA CCT CAC CAA GGC CAG CAC ATA GGA GAG ATG AGC TTC 
CTA CAG CAC AAC AAA TGT GAA TGC AGA CCA AAG AAA GAT AAG CCA AGA CAA GAA AAT CCC TGT GGG CCT TGC 
TCA GAG CGG AGA AAG CAT TTG TTT GTA CAA GAT CCG CAG ACG TGT AAA TGT TCC TGC AAA AAC ACA GAC TCG 
CGT TGC AAG GCG AGG CAG CTT GAG TTA AAC GAA CGT ACT TGC AGA TGT GAC AAG CCG AGG CGG TGA 
 
A P M A E G G G Q N H H E V V K F M D V Y Q R S Y C H P I E T L V D I F Q E Y P D E I E Y I F K P 
S C V P L M R C G G C C N D E G L E C V P T E E S N I T M Q I M R I K P H Q G Q H I G E M S F L Q 
H N K C E C R P K K D K P R Q E N P C G P C S E R R K H L F V Q D P Q T C K C S C K N T D S R C K 
A R Q L E L N E R T C R C D K P R R  
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Sequence of FNIII10 with the RGD site shown in red 
GTT CCG AGG GAC CTG GAA GTT GTT GCT GCG ACC CCC ACC AGC CTA CTG ATC AGC TGG GAT GCT CCT GCT GTC 
ACA GTG AGA TAT TAC AGG ATC ACT TAC GGA GAA ACA GGA GGA AAT AGC CCT GTC CAG GAG TTC ACT GTG CCT 
GGG AGC AAG TCT ACA GCT ACC ATC AGC GGC CTT AAA CCT GGA GTT GAT TAT ACC ATC ACT GTG TAT GCT GTC 
ACT GGC CGT GGA GAC AGC CCC GCA AGC AGC AAG CCA ATT TCC ATT AAT TAC CGA ACA GAA 
 
V P R D L E V V A A T P T S L L I S W D A P A V T V R Y Y R I T Y G E T G G N S P V Q E F T V P G 
S K S T A T I S G L K P G V D Y T I T V Y A V T G R G D S P A S S K P I S I N Y R T E 
 
Sequence of the oligonucleotide encoding for TG-PL with TG shown in italic and PL underlined 
TCG GTC GGA TCC AGC GCT AAC CAG GAG CAG GTG AGC CCC CTG AGG CCT CTG ATC AAG ATG AAG CCC GCC GGC 
GAA TTC TTG ATG 
 
S V G S S A N Q E Q V S P L R P L I K M K P A G E F L M 
 
Sequence of the oligonucleotide encoding for the linker 
T ATA CTC GAG GGT GGC GGA GGG TCT GGA GGC GGT GGG TCC GGC GGT GGG GGA TCA GGG GGA GGC GGT TCG GGA 
GGT GGG GGC TCG GGC GGT GGG GGA AGT GGT GGA GGT CCC GGG TTT A 
 
G G G G S G G G G S G G G G S G G G G S G G G G S G G G G S G G G 
 
Sequence of TG-PL-FLV with the distinct functional domains highlighted as follows: 
TG PL FNIII10 linker VEGFmut 
AAC CAG GAG CAG GTG AGC CCC CTG AGG CCT CTG ATC AAG ATG AAG CCC GCC GGC GAA TTC GTT CCG AGG GAC 
CTG GAA GTT GTT GCT GCG ACC CCC ACC AGC CTA CTG ATC AGC TGG GAT GCT CCT GCT GTC ACA GTG AGA TAT 
TAC AGG ATC ACT TAC GGA GAA ACA GGA GGA AAT AGC CCT GTC CAG GAG TTC ACT GTG CCT GGG AGC AAG TCT 
ACA GCT ACC ATC AGC GGC CTT AAA CCT GGA GTT GAT TAT ACC ATC ACT GTG TAT GCT GTC ACT GGC CGT GGA 
GAC AGC CCC GCA AGC AGC AAG CCA ATT TCC ATT AAT TAC CGA ACA GAA GTC GAC CTC GAG GGT GGC GGA GGG 
TCT GGA GGC GGT GGG TCC GGC GGT GGG GGA TCA GGG GGA GGC GGT TCG GGA GGT GGG GGC TCG GGC GGT GGG 
GGA AGT GGT GGA GGT CCC GGG GCA CCC ATG GCA GAA GGA GGA GGG CAG AAT CAT CAC GAA GTG GTG AAG TTC 
ATG GAT GTC TAT CAG CGC AGC TAC TGC CAT CCA ATC GAG ACC CTG GTG GAC ATC TTC CAG GAG TAC CCT GAT 
GAG ATC GAG TAC ATC TTC AAG CCA TCC TGT GTG CCC CTG ATG CGA TGC GGG GGC TGC TGC AAT GAC GAG GGC 
CTG GAG TGT GTG CCC ACT GAG GAG TCC AAC ATC ACC ATG CAG ATT ATG CGG ATC AAA CCT CAC CAA GGC CAG 
CAC ATA GGA GAG ATG AGC TTC CTA CAG CAC AAC AAA TGT GAA TGC AGA CCA AAG AAA GAT AAG CCA AGA CAA 
GAA AAT CCC TGT GGG CCT TGC TCA GAG CGG AGA AAG CAT TTG TTT GTA CAA GAT CCG CAG ACG TGT AAA TGT 
TCC TGC AAA AAC ACA GAC TCG CGT TGC AAG GCG AGG CAG CTT GAG TTA AAC GAA CGT ACT TGC AGA TGT GAC 
AAG CCG AGG CGG TGA  
 
N Q E Q V S P L R P L I K M K P A G E F V P R D L E V V A A T P T S L L I S W D A P A V T V R Y Y 
R I T Y G E T G G N S P V Q E F T V P G S K S T A T I S G L K P G V D Y T I T V Y A V T G R G D S 
P A S S K P I S I N Y R T E V D L E G G G G S G G G G S G G G G S G G G G S G G G G S G G G G S G 
G G P G A P M A E G G G Q N H H E V V K F M D V Y Q R S Y C H P I E T L V D I F Q E Y P D E I E Y 
I F K P S C V P L M R C G G C C N D E G L E C V P T E E S N I T M Q I M R I K P H Q G Q H I G E M 
S F L Q H N K C E C R P K K D K P R Q E N P C G P C S E R R K H L F V Q D P Q T C K C S C K N T D 
S R C K A R Q L E L N E R T C R C D K P R R 
 
 
Cloning into pGEX-4T-1  
1. Amplification of the sequence encoding for VEGFmut from from pcDNA3.1 using 
forward primer AAT GTC GAC TC GAG CCC GGG GCA CCC ATG GCA GAA GGA 
GGA GG and reverse primer TAT TGC GGC CGC TCA CCG CCT CGG CTT GTC ACA 
TCT GC and cloning into pGEX-4T-1 as SalI/NotI digest gives rise to pGEX-4T-1-
VEGFmut. 
 
2. Amplification of the sequence encoding for FNIII10 from pFH157 using forward primer 
CGC GGT GAA TTC GTT CCG AGG GAC CTG GAA GTT G and reverse primer CGC 
GCC GTC GAC TTC TGT TCG GTA ATT AAT GGG C, and cloning into pGEX-4T1 as 
EcoRI/SalI digest gives rise to pGEX-4T-1-FNIII10. 
 
3. Amplification of the ordered oligonucleotide encoding for the TG-PL peptide using 
forward primer TCG GTC GGA TCC AGC GCT AAC and reverse primer CAA GAA TTC 
GCC GGC GGG CTT. The sequence was cloned into pGEX-4T-1 as BamHI/EcoRI digest, 
which results in pGEX-4T-1-TG-PL. 
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4.  Amplification of the sequence encoding for FNIII10 from pFH157 using forward primer 
CGC GGT GAA TTC GTT CCG AGG GAC CTG GAA GTT G and reverse primer CGC 
GCC GTC GAC TTC TGT TCG GTA ATT AAT GGG C, and cloning into pGEX-4T-1-
TG-PL as EcoRI/SalI digest gives rise to pGEX-4T-1-TG-PL-FNIII10. 
 
5. Digest of pGEX-4T-1-TG-PL-FNIII10 with StuI and NaeI gives rise to pGEX-4T-1-TG-
FNIII10. 
 
6. Amplification of the sequence encoding for VEGFmut from pcDNA3.1 using the forward 
primer AAT GTC GAC CTC GAG CCC GGG GCA CCC ATG GCA GAA GGA GGA 
GG and the reverse primer tat TGC GGC CGC TCA CCG CCT CGG CTT GTC ACA 
TCT GC and cloning into pGEX-4T-1-TG-PL-FNIII10 as SalI/NotI digest gives rise to 
pGEX-4T-1-TG-PL-FNIII10-VEGFmut. 
 
7. The linker was ordered as oligonucleotide T ATA CTC GAG GGT GGC GGA GGG TCT 
GGA GGC GGT GGG TCC GGC GGT GGG GGA TCA GGG GGA GGC GGT TCG 
GGA GGT GGG GGC TCG GGC GGT GGG GGA AGT GGT GGA GGT CCC GGG 
TTT A, and amplified using forward primer ACT TCT ATA CTC GAG GGT GGC and 
reverse primer AAC TGT AAA CCC GGG ACC TCC A. Subsequent cloning as 
XhoI/XmaI digest into pGEX-4T1-TG-PL-FNIII10-VEGFmut gives rise to pGEX-4T-1-
TG-PL-FNIII10-linker-VEGFmut. 
 
8. Digest of pGEX-4T-1-TG-PL-FNIII10-linker-VEGFmut with NaeI and StuI gives rise to 
pGEX-4T-1-TG-FNIII10-linker-VEGFmut. 
 
9. Digest of pGEX-4T-1-TG-PL-FNIII10-linker-VEGFmut with Eco47III and NaeI gives rise 
to pGEX-4T-1-FNIII10-Linker-VEGFmut. 
 
10. Digest of pGEX-TG-PL-FNIII10-VEGF with NaeI and SmaI gives rise to pGEX-4T-1-
TG-PL-VEGFmut 
 
11. Digest of pGEX-4T-1-TG-PL-FNIII10-VEGFmut with StuI and SmaI gives rise to pGEX-
4T-1-TG-VEGFmut. 
 
6.6.2 Protein expression vectors used for cloning 
pGEX-4T-1 is a bacterial expression vector obtained from GE Healthcare. Target protein over-
expression is controlled by the strong tac promoter, inducible by IPTG. The vector further 
encodes for an N-terminal GST tag separated from the target protein by a thrombin cleavage site 
(Figure 31 A).  
pRSET is a bacterial expression vector from Novagen (Merck, Darmstadt, Germany) and 
contains a gene encoding for resistance to ampicillin. Target genes are expressed under the 
control of the strong T7 bacteriophage promoter. The vector used for protein expression in 
E. coli, a kind gift from professor Dr. Andreas Zisch, University Hospital Zurich, was a modified 
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vector, from which the multiple cloning site along with the his-tag was removed, and contained 
VEGF165wt as an insert (Figure 31 B). 
pCEP-V97 is an episomal eucaryotic expression vector based on the vector pCEP4 from 
Invitrogen and was a kind gift from professor Dr. Manuel Koch, Institut für Biochemie II, 
medizinische Fakultät, Universität zu Köln. The vector carries a cytomegalovirus promoter and 
the Epstein-Barr virus replication origin for high level protein expression and high-copy 
replication. For selection in bacteria, an ampicillin-resistance is encoded. pCEP-V97 differs from 
pCEP4 in the organization of its multiple cloning site, and it further encodes for puromycin 
resistance, a sorting signal targeting the recombinant protein for secretion, and a C-terminal 
poly-histidine tag that can be cleaved off by factor X (Figure 31 C).  
 
Figure 31: Vector maps of vectors used. (A) pGEX-4T-1 and (B) pRSET are bacterial expression vectors, and (C) pCEP-V97 is 
an eucaryotic expression vector. See text for details.  
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6.6.3 Polymerase chain reaction (PCR) 
The PCR reaction is divided into three distinct steps, namely denaturation of the DNA double-
strand, annealing of the primers, and extention, that usually are repeated for a total of 35 cycles. 
Additional steps are included to denature the double-strand prior to the first cycle and for 
extension of the construct. DNA is denatured at 94°C, and extention using Pfx50 (Invitrogen), a 
DNA-polymerase with 5’3’ proofreading activity, is performed at 68°C. The annealing 
temperature is primer specific and was calculated using the program OligoCalculator (University 
of Pittsburgh), while the extention time depends on the length of the expected PCR product. 
PCR-programs are summarized in Table 11. The templates were amplified in a standard PCR 
reaction mixture composed of 5 µM of each primer, 4 ng/µL of the template and 5 U Pfx in 1x 
polymerase buffer. 
 
PCR-programs used for the amplification of the indicated functional domains: 
 
TG-PL   FNIII10    TG-PL-FLV   
time temp.  time temp.  time temp.  
1’ 94°C  1’ 94°C  1’ 94°C  
15’’ 94°C  15’’ 94°C  15’’ 94°C  
30’’ 60°C 35 cycles 30’’ 60°C 35 cycles 30’’ 60°C 35 cycles 
30’’ 68°C  1’ 68°C  1’ 68°C  
5’ 68°C  5’ 68°C  5’ 68°C  
         
VEGF   linker      
time temp.  time temp.     
1’ 94°C  1’ 94°C     
15’’ 94°C  15’’ 94°C     
30’’ 56°C 35 cycles 30’’ 58°C 35 cycles    
1’ 68°C  30’’ 68°C     
5’ 68°C  5’ 68°C     
Table 11: PCR-programs used. 
 
6.6.4 DNA agarose gel electrophoresis 
To evaluate proper PCR amplification of the inserts or successful digest of the host vector, DNA 
fragments were routinely investigated by DNA agarose gel electrophoresis. Gels were 
formulated with 0.5 or 2 % (w/v) agarose in TAE (for digested vectors or PCR-products, 
respectively). Agarose was dissolved in the buffer by repeated boiling, the solution was chilled 
and supplemented with GelRed (1:10000, Biotium) or ethidium bromide (0.5 µg/ml) for the 
visualization of DNA under UV-light. Electrophoresis was performed at 80 V. 
Bands of the PCR product or the digested vector corresponding to the expected size were cut out 
of the gel using a scalpel and purified using the Wizard SV Gel and PCR Clean-up Kit by 
Promega (Madison, USA) or the E.Z.N.A. Gel Purification Kit by Omega bio-tek (Norcross, 
USA). 
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6.6.5 DNA restriction digest and 5’ dephosphorylation of the 
vector 
The PCR product and the vector were digested for 8 hours using the appropriate enzymes 
obtained from Promega, Invitrogen or New England Biolabs (Ipswich, USA, Table 12), and 
conditions as recommended by the supplier. A standard digest comprised 10 µg of vector and 
3 µL of the enzyme, or all obtained PCR-product and 0.3 µL of the enzyme in a total volume of 
20 µL.  
 
Restriction endonucleases    
BamHI (Promega) 
Eco47III (Promega) 
NaeI (New England Biolabs) 
NdeI (New England Biolabs) 
NheI (New England Biolabs) 
Not I (New England Biolabs) 
SalI (New England Biolabs) 
SmaI (Promega) 
StuI (Invitrogen) 
XhoI (New England Biolabs) 
XmaI (New England Biolabs) 
 
Table 12: Restriction endonucleases used for cloning procedures. 
 
After each digest, the restriction endonuclease was heat-inactivated for 15 minutes at 65°C. The 
digested vector was then purified by running on an agarose gel, and the digested PCR-product 
was directly purified using Wizard SV Gel and PCR Clean-up Kit (Promega). The second digest 
was performed in the same way.  
The double-digested vector was dephosphorylated on the 5’ end if enzymes creating cohesive 
ends were used for the digest in order to prevent auto-ligation of the vector by addition of 5 µL 
shrimp alkaline phosphatase (Promega) for 30 minutes at 37°C. Both vector and insert were 
purified one last time. 
 
6.6.6 DNA ligation 
Digested vector and inserts were ligated by T4 ligase (New England Biolabs) in three different 
molar ratios (1:1, 1:3, 1:6) using 100 ng of vector and 1 µL of the enzyme in a total volume of 
20 µL per reaction. The ligation was allowed to take place for at least 16 hours at 4°C.  
Competent E. coli were transfected with 10 µL of the ligation assay and plated onto LB-agar 
plates containing selection antibiotics. From the colonies formed, small liquid cultures were 
inoculated, from which the plasmid DNA was isolated using the E.Z.N.A. Plasmid Miniprep 
Kit I (Omega bio-tek). Presence of an insert was first verified by PCR followed by DNA agarose 
gel electrophoresis, and the correct DNA sequence was validated by sequencing by either 
Fasteris (Geneva, Switzerland) or SEQLAB (Göttingen, Germany). 
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6.6.7 Subcloning  
Due to problems with purification of the VEGF-containing constructs as GST-fusion proteins, 
constructs containing VEGF were subcloned into a modified pRSET vector for the production 
from inclusion bodies and subsequent purification by heparin affinity. As the obtained batches 
were of insufficient purity for the bi-functional constructs, constructs FNIII10, TG-FNIII10, 
VEGFmut, TG-VEGFmut, FLV and TG-FLV were then subcloned into pCEP-V97 comprising a 
C-terminal His-tag for eucaryotic expression.  
For subcloning of VEGF-containing constructs into the modified pRSET vector, the vector was 
NdeI/BamHI digested in order to remove the insert VEGF165wt. Other, VEGFmut containing 
inserts were inserted as NdeI/BamHI digest. For amplification of VEGFmut, the forward primer 
G GAA TTC CAT ATG GCA CCC ATG GCA GAA GGA was used, for constructs containing 
the TG-sequence, the primer G GAA TTC CAT ATG AAC CAG GAG CAG GTG AGC was 
used and for sequences starting with the FNIII10 sequence, G GAA TTC CAT ATG AAC CAG 
GAG CAG GTG AGC was used. The reverse primer was always CGC GGA TCC TCA CCG 
CCT CGG CTT GTC ACA TCT. 
The constructs FNIII10, TG-FNIII10, VEGFmut, TG-VEGFmut, FLV and TG-FLV were 
subcloned into pCEP-V97 as BamHI/NheI digests, and amplified using a combination of the 
following primers: FNIII10 forward C GGT GCT AGC A GTT CCG AGG GAC CTG GAA 
GTT GTT G; FNIII10 reverse CGC GCC GGA TCC TTC TGT TCG GTA ATT AAT GGA 
AAT TG; VEGFmut reverse GA TAT T GGA TCC CCG CCT CGG CTT GTC ACA TCT GCA 
AG; VEGF forward: C GGT GCT AGC A GCA CCC ATG GCA GAA GGA GGA GGG CAG; 
TG-sequence forward GT ATG CTA GCA AAC CAG GAG CAG GTG AGC CCC CTG.  
 
6.7 Recombinant protein expression in bacteria 
Generally, protein expression was induced with isopropyl β-D-1-thiogalactopyranosidase 
(IPTG). IPTG is a mimetic of allolactose not metabolizable by bacteria. IPTG binds to and 
inhibits the lac-repressor, thus allowing for the expression of target genes under the lac promoter. 
Protein expression from the expression vector pGEX-4T-1 is directly induced by IPTG in BL21. 
In BL21(DE3)pLysS cells, IPTG by contrast induces the expression of the T7 RNA polymerase 
under the control of a lac promoter, and T7 polymerase in turn binds to the T7 promoter on 
pRSET vector constructs, leading to the expression of the target gene. Additionally, in the latter 
system, the leaky expression of the target gene is reduced by the expression of pLysS, that 
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encodes for T7 lysozyme, an inhibitor of T7 polymerase (Davanloo et al. 1984; Moffatt and 
Studier 1987; Studier and Moffatt 1986). In general, after transformation of bacteria and 
selection of positive clones, a good producer of the recombinant proteins was identified by 
induction of protein expression and SDS-PAGE followed by protein staining on the lysate. 
 
6.7.1 Expression and purification of GST-tagged proteins 
BL21 were transfected with pGEX-4T-1 vectors encoding for the proteins to be produced, and 
GST-tagged proteins were purified from the bacterial cytosol. For large-scale production, a 5 mL 
liquid culture was inoculated in 2xYT containing ampicillin and grown overnight. 1L of 2xYT 
with ampicillin was inoculated with this culture and grown at 37°C with shaking until the OD600 
was about 0.6. At this density, protein expression was induced by addition of 0.6 mM IPTG, and 
bacteria were grown for 6 hrs at 22°C. The bacteria were collected by centrifugation and lysed 
by addition of 45 ml phosphate buffered saline (PBS) containing protease inhibitors, 50 mg 
lysozyme (Merck), and sonication. 500 U of DNAse (Sigma Aldrich) and 1% Triton-X-100 were 
added, and lysis was performed on a spinning wheel at 4°C for 30 min. The lysate was cleared 
by centrifugation and filtration, and 0.1% NaN3 was added.  The GST-fusion proteins were 
purified using an ÄTKA-FPLC system and a GSH-column. Elution from the column was 
accomplished by addition of 50 mM Tris-HCl, 10 mM reduced GSH, pH 8. The protein was 
subsequently digested by 20 U of thrombin (Sigma Aldrich) per mg of recombinant protein 
while removing GSH from the sample by dialysis against PBS. A second step of purification was 
performed using a GST column and a benzamidine column in order to remove GST and 
thrombin from the sample (Table 13). The protein was concentrated by membrane filtration 
(Amicon ultra filter systems by Millipore), and the buffer was exchanged to tris buffered saline 
(TBS). The protein concentration was then determined by absorbance measurement at 280 nm 
using a NanoDrop1000 spectrometer and corrected by division by the extinction coefficient. 
Purity of the protein solution was verified by SDS-PAGE and protein staining, and the protein’s 
identity was confirmed by LC-MS/MS and MALDI-TOF. 
 
Buffers and solutions   Columns  Enzymes  
PBS containing complete protease inhibitor (Roche)  GSTPrep FF 16/10 20 mL, GE Healthcare Lysozyme, VWR 
Running and wash buffer: PBS  HiTrap Benzamidine FF, 1 mL, GE Healthcare DNAse, Merck 
Elution buffer: 50 mM Tris-HCl, 10 mM reduced GSH, 
pH 8-8.6 
  Bovine thrombin, Sigma Aldrich 
TBS: 135 mM NaCl, 18 mM Tris-HCl, pH 7.4    
Table 13: Buffers and columns used for the purification of GST-tagged proteins. 
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6.7.2 Thrombin processing of GST-VEGFmut and GST-TG-PL-FLV 
To investigate whether the GST-tag could be removed from GST-VEGFmut and GST-TG-PL-
FLV by thrombin mediated cleavage, thrombin digestion of these proteins was performed using 
1 U of thrombin per mg of recombinant protein and monitored over time by western blotting 
using a primary antibody directed against VEGF-A. 
 
6.7.3 Purification of recombinant proteins from bacterial 
inclusion bodies 
For the purification of VEGF-isoforms from inclusion bodies, sequences encoding for these 
isoforms were cloned into a modified pRSET. BL21(DE3)pLys were transfected with pRSET 
vectors containing VEGF isoforms. A 3 ml culture of a good producer in LB containing 
ampicillin and chloramphenicol was grown. 1 L of LB with ampicillin was inoculated with this 
culture and grown at 37°C until an OD600 of 0.8. Protein expression was induced by addition of 
1 mM IPTG and bacteria were grown over night.  
The culture was harvested by centrifugation, dissolved in lysis buffer completed with 10 mg 
lysozyme and lysed for 20 minutes at room temperature. 50000 U of DNAse were added to the 
lysate and incubated overnight at 4°C. The inclusion bodies containing VEGF-A variants were 
collected by centrifugation and solubilized in extraction buffer containing 8 M urea. Proteins 
were refolded by subsequential dialysis against decreasing concentrations of urea and dimerized 
using a redox-system consisting of reduced and oxidized GSH. After removal of GSH from the 
sample by dialysis, the pH of the sample was set to 3.5. At this pH, many proteins precipitate, 
whereas VEGF-A remains soluble (Fiebich et al. 1993). The precipitate was removed by 
centrifugation. VEGF constructs were purified by heparin affinity chromatography after 
adjusting the pH of the sample to 6.5 and the NaCl concentration to 0.4 M, Bound proteins were 
eluted in one step with 1 M NaCl, 20 mM Tris pH 7.4 (Table 14). Obtained fractions were 
investigated by SDS-PAGE followed by protein staining, and similar fractions were pooled, 
aliquoted, and stored at -80°C.  
Subsequent investigations to confirm the identity of the obtained proteins included western 
blotting, LC-MS/MS and MALDI-TOF. Protein concentration was determined by a BCA-assay 
using a BSA standard curve (PIERCE, Thermo Scientific) and working concentrations were 
determined by ELISA (Quantikine ELISA, R&D Systems) compared to a VEGF-A standard 
curve. 
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Buffers required   Column used 
Lysis buffer 50 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA  HiTrap™ Heparin, 5 mL, GE Healthcare 
Column equilibration 50 mM Tris, 150 mM NaCl   
Wash buffer 4 M urea, 20 mM Tris pH 8, 150 mM NaCl, 2 mM EDTA   
Extraction buffer 8 M urea, 20 mM Tris pH 8, 150 mM NaCl, 10 mM DDT   
Folding buffers 6 M urea, 50 mM Tris pH 7.5, 150 mM NaCl, 2 mM EDTA 
4 M urea, 50 mM Tris pH 7.5, 150 mM NaCl, 2 mM EDTA 
2 M urea, 50 mM Tris pH 7.5, 150 mM NaCl, 2 mM EDTA 
  
Dimerization buffer: 
 
2 M urea, 50 mM Tris pH 7.5, 150 mM NaCl, 2 mM EDTA, 
0.5 mM oxidized GSH, 5 mM reduced GSH 
  
Elution buffer 50 mM Tris, 1 M NaCl   
Table 14: Buffers and column used for the purification of VEGF-proteins from bacterial inclusion bodies. 
 
6.7.4 Endotoxin test  
Endotoxins, also called lipopolysaccharides (LPS), are components of the outer membrane of 
Gram-negative bacteria. They are frequently released during normal cell division but particularly 
during lysis of bacteria. Endotoxins are recognized by the immune system, and hence have very 
strong biological effects when they enter the blood stream of humans or laboratory animals, 
including fever and endotoxin shock (Gorbet and Sefton 2005). As these side effects can 
severely impair the outcome of in vivo experiments, it is essential to deliver protein solutions 
devoid of endotoxins. Endotoxin testing of recombinant proteins was performed in the 
laboratories of Bayer Schering Pharma with kind support by Dr. Gabriella Bald, Dr. Felix 
Oehme and Dr. Burkhard Fugmann using the Limulus Amebocyte Lysate (LAL) test. This test 
represents the standard method for endotoxin detection and quantification in the pharmaceutical 
industry and is based on the property of the blood cell lysate of the horseshoe crab Limulus 
polyphemus to gel in the presence of endotoxin. 
 
6.8 Expression of recombinant proteins in HEK293-EBNA 
cells 
For protein expression in HEK293-EBNA cells, the constructs FNIII10, TG-FNIII10, VEGFmut, 
TG-VEGFmut, FLV and TG-FLV were subcloned into the eucaryotic expression vector 
pCEP-V97, which encodes for a signal sequence targeting the recombinant protein for secretion 
and a C-terminal poly-histidine tag. Recombinant protein expression is under the control of EBV 
origin of replication. HEK cells were transfected using the Fugene HD transfection reagent 
(Roche) according to the supplier’s instructions. Transfectants were selected by the puromycin-
resistance encoded on the plasmid and propagated after secretion of the recombinant proteins to 
the cell supernatant was confirmed by western blot analysis. Cells were seeded into collagen-
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coated triple flasks and serum deprived. Conditioned medium was collected every third day and 
stored at -20°C until purification. 
For purification, a gelatin sepharose column was used as a pre-column, and the his-tagged 
proteins were purified using a Ni Sepharose™ (GE Healthcare) packed column. Prior to 
purification, 1 mM PMSF, 0.07 % Tween-20, and 10 % Na2HPO4 were added to the supernatant. 
The proteins were eluted from the column by applying increasing concentrations of imidazol in 
20 mM Tris (Table 15), and the fractions were investigated by SDS-PAGE and Coomassie blue 
staining. Subsequently, fractions containing the recombinant proteins were pooled and dialyzed 
against TBS prior to aliquoting and storage at -80°C. 
 
Buffers for protein purification from HEK cell supernatant  Column beds (GE Healthcare) 
wash buffer:  20 mM Tris pH 8, 150 mM NaCl  Gelatin Sepharose™ 4B  
elution buffers: 5-250 mM Imidazol, 20 mM Tris pH 8, 150 mM NaCl  Ni Sepharose™ 6 Fast Flow  
Table 15: Buffers and column beds used for the purification of his-tagged proteins from conditioned cell supernatants.  
 
6.9 Functional characterization of recombinant proteins 
6.9.1 Cell attachment to TG-FNIII10 in presence and absence of 
integrin-specific inhibitors 
The protocol applied to assess cell attachment was modified from a basic protocol given in 
Current Protocols in Cell Biology (1998, 9.1.1-9.1.11, John Wiley & Sons, Inc.). 
Wells of a 96 well ELISA plate were coated for one hour at room temperature with 0.001 to 
25 µM TG-FNIII10 and subsequently blocked with 0.2% heat-inactivated BSA in PBS for one 
hour at 37°C. After washing the wells with HBSS, 3.5x104 HUVECs in 100 µL M-199 were 
plated per well and allowed to attach for 45 minutes. As a positive control, cells were plated on 
wells coated with 0.05 µg/µL full-length fibronectin (final coating per well: 5 µg), which served 
to define 100 % cell attachment. Non-adherent and loosely attached cells were removed by 
washing, and cells were then fixed with 5 % glutaraldehyde for 20 minutes. The cells were 
washed with water and stained with crystal violet for one hour (Table 16). Crystal violet binds to 
DNA and thereby allows quantification of cells. Following extensive washing, the dye was 
solubilized with 10 % acetic acid, and absorbance was measured at 570 nm. Each assay was 
performed in triplicate, and results were obtained in three independent assays. 
To test whether integrin αvβ3 was involved in the observed attachment, the cell attachment 
assay was performed using integrin function blocking antibodies. Wells of a 96-well ELISA 
Materials and methods 
 
95 
plate were coated with 25 µM TG-FNIII10 or 5 µg fibronectin per well and subsequently 
blocked with 0.2 % BSA in PBS for one hour at 37°C. A cell suspension containing 35x104 cells 
per ml was prepared and incubated with either 5 µg/mL function blocking anti-integrin αvβ3 or 
anti-integrin α5 (Table 16) or without inhibitor for 20 minutes at 37°C. 100 µL of the cell 
suspension were plated per well, and cells were allowed to attach for 45 minutes. The readout 
was then performed as described above. 
 
Buffers and media   Antibodies   Proteins 
M199 Invitrogen  anti-integrin αvβ3 Chemicon, MAB1976Z  Fibronectin  
HBSS with calcium and magnesium  Invitrogen  anti-integrin α5 Abcam, JBS5  (Millipore) 
PBS Amimed      
0.1 % (w/v) crystal violet in 200 mM MES       
Table 16: Buffers, media and antibodies used for cell attachment studies. 
 
6.9.2 Cell spreading assay  
To test cell spreading to the recombinant proteins produced in HEK293-EBNA, the chambers of 
a 8-chamber slide (Lab-Tek™ Chamber Slide™, Nunc, Thermo Scientific) were coated 
overnight at 4°C with 0.1 % poly-L-lysine, 0.4 µM FNIII10, 0.2 µM FLV or 0.2 µM VEGFmut. 
FLV was plated at a lower molarity, as the molecule comprises two FNIII10 sites. Unspecific 
binding sites were blocked with heat-inactivated BSA, and 80000 serum-starved HUVECs were 
plated per condition in M199 supplemented with 0.1 % BSA. Cells were allowed to attach for 2 
hours, washed once with TBS and fixed in 3 % PFA for 15 minutes. The cells were 
permeabilized with 0.2 % of Triton-X 100 in PBS for 10 minutes, and unspecific binding sites 
were blocked for 30 minutes with 10 % normal goat serum in PBS. The primary antibody 
directed against vinculin was diluted 1:500 in 1% BSA and incubated for 1 hour at room 
temperature. Following several rinses with PBS, the secondary antibody in combination with 
phalloidin and 1 µg/mL 4',6-diamidino-2-phenylindole (DAPI) was applied to the cells for one 
hour. Antibodies used are summarized in Table 17. Cells were mounted in evanol.  
 
Antibodies and dyes    
Vinculin MAB 3574  1:500 Chemicon 
Alexa 488 goat anti mouse IgG1 1:500 Invitrogen 
Alexa Fluor 594 phalloidin 1:100 Invitrogen 
Table 17 : Antibodies used for vinculin and actin co-staining.  
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6.9.3 Investigation of VEGFR-2 activation and downstream 
signaling by western blot 
The activation of VEGFR-2 in response to VEGF-containing constructs was determined by 
western blot using a phospho-specific primary antibody recognizing phosphorylation of 
tyrosine 1175 on VEGFR-2. Furthermore, phosphorylation of downstream signaling target 
Erk 1/2 was investigated using the antibodies specified in table 9. HUVECs were grown to 
confluence in 6-well plates and starved for 4 hours with M199 medium containing 0.1 % BSA. 
Then, they were stimulated with 50 ng/mL effective VEGF dose in M199 medium for 5 minutes 
at 37°C. After washing in M199 medium, cells were lysed on ice in Laemmli loading buffer (see 
Table 6) supplemented with β-mercaptoethanol, sodium orthovanadate, and protease inhibitors 
(Sigma Aldrich). The lysate was sonicated and boiled, and samples were subjected to SDS-
PAGE.  
Alternatively, lysis was performed in RIPA buffer (Table 19) supplemented with protease 
inhibitors (Sigma) and phosphatase inhibitors (PhosStop, Roche) according to the 
manufacturer’s recommendations. Protein concentration was determined by BCA assay, and 
equal amounts of protein were loaded on gels and separated by electrophoresis.  
After detection of the phosphorylated proteins, the blot was stripped and re-probed with a pan 
specific VEGFR-2 antibody (Flk-1 sc-6251, Santa Cruz) as loading control. Alternatively, equal 
loading was verified by detection of β-actin. 
 
RIPA buffer  Stripping buffer 
50 mM 
1% 
0.25% 
150 mM 
1 mM 
Tris-HCl, pH 7.4 
NP-40 
Sodium-deoxycholate 
NaCl 
EDTA 
 0.2 M 
0.1 % 
1 % 
pH 2.2 
Glycine 
SDS 
Tween-20 
Table 19: Buffers used for the determination of protein phosphorylation. 
 
6.9.4 Determination of VEGFR-2 phosphorylation by ELISA 
During western blotting, one single phosphotyrosine on VEGFR-2 was probed. In order to detect 
overall VEGFR-2 phosphorylation, an ELISA was performed, during which a ELISA plate is 
coated with a VEGFR-2 specific capture antibody, and the phosphorylated tyrosines are detected 
by an HRP-coupled secondary tyrosine-specific antibody (Human Phospho-VEGF R2/KDR 
DuoSet IC, R&D Systems). HUVECs in passage 6 were cultured in T25 flasks and lysed in 
500 µL of lysis buffer. Following a brief centrifugation, total protein concentration was 
determined by BCA assay, and lysates were stored at -80°C until further use. The ELISA was 
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performed according to the manufacturer’s recommendations (Table 20) after equalizing total 
protein concentration. The positive control supplied with the kit consisted of phosphorylated 
VEGFR-2 and was used to create a standard curve. The concentration of phosphorylated 
VEGFR-2 in the samples was calculated according to this standard curve, and values were 
expressed as percent increase over a non-stimulated control.  
 
Materials and buffers required 
Elisa plate NUNC MaxiSorp, 96 well 
Wash buffer 0.05 % Tween 20 in PBS 
Block buffer 1 % BSA, 0.05 % NaN3 in PBS, pH 7.2 
Diluent 20 mM Tris, 137 mM NaCl, 0.05 % Tween20, 0.1 % BSA, pH 7.2 
Lysis buffer 1% NP-40, 20 mM Tris (pH 8.0), 137 mM NaCl, 10 % glycerol, 2 mM EDTA, 
1 mM sodium orthovanadate, proteas inhibitor cocktail (Sigma) 
Substrate solution Tetramethylbenzidine (GE Healthcare) 
Stop solution  2 N H2SO4 
Table 20: Materials and buffers used for the phospho-VEGFR-2 ELISA by R&D Systems. 
 
6.9.5 Surface plasmon resonance (SPR) biosensor binding studies 
SPR-based biosensor analysis represents a common method for the determination of binding 
affinities for proteins and was employed in this work to investigate the binding of VEGFR-2 to 
VEGFmut and FLV in collaboration with Prof. Dr. Stefan Höning, Institut für Biochemie I, 
Uniklinikum Köln. All experiments were run on a BIAcore 3000 using a CM5 sensor surface 
(Table 18). First, protein A was covalently coupled to the surface by using EDC/NHS as 
activating reagents and with HBS-N as the running buffer. The degree of coupling was set to 
approximately 1200 resonance units (RU). Non-specific binding was blocked by inactivation of 
remaining reactive groups with ethanolamine. Subsequently, VEGFR-2 fused to the Fc fragment 
of IgG (VEGFR-2 Fc, R&D Systems) was immobilized on the protein A surface to a density of 
~ 650 RU. The following binding experiments with VEGFmut and FLV as analytes in TBS were 
performed at a flow rate of 50 µL/min and with concentrations ranging from 20 to 160 nM. 
Between different experimental cycles, the bound proteins were stripped from the sensor surface 
with 10 mM glycine, 200 mM NaCl, pH 1.8. The rate constants for the interaction were 
determined with the evaluation software supplied by the manufacturer. 
 
Materials and reagents used for SPR studies 
Biacore 300 sensor  GE Healthcare  Protein A GE Healthcare 
Biacore sensor chip CM5 GE Healthcare  VEGFR-2 Fc chimera R&D Systems 
Priming buffer: HBS-N buffer GE Healthcare  Stripping buffer 10 mM glycine, 200 mM NaCl pH 1.8. 
EDC/NHS GE Healthcare    
Table 18: Materials and reagents used for Biacore binding studies. 
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6.10 Fibrin gel formulation  
Fibrin gels used in this study were well defined, as protein preparations of high purity were used.  
For the treatment of skin wounds, stiff fibrin gels were formulated characterized by a high 
fibrinogen concentration and a high degree of crosslinking in order to prolong their residency 
within the wound. Fibrin gels were formed in TBS at the final concentrations given in Table 21. 
 
Component Final concentration  Buffers required 
Fibrinogen 10 mg/mL  TBS  
Thrombin 2 U/mL  135 mM NaCl 
Factor XIII 10 U/mL  18 mM  Tris-HCl, pH 7.4 
Aprotinin 17 µg/mL    
CaCl2 2.5 mM  TBS CaCl2 (40x) 
VEGF isoforms 20 µg/mL  100 mM CaCl2 in TBS 
Table 21: Composition of fibrin gels. 
 
6.10.1 Protein stock preparation 
0.25 g of human fibrinogen, depleted of plasminogen, von Willebrand factor and fibronectin 
(Enzyme Research Laboratories, Swansea, UK) was resuspended in 7 ml of sterile Millipore 
water, pre-warmed to 37°C, and dissolved for one hour at 37°C with repeated shaking. The 
protein solution was then filtered twice and dialyzed against TBS. The osmolarity was confirmed 
to be between 290 and 315 mosm/L, and the concentration of the protein solution was determined 
by NanoDrop measurement and normalized by dividing by the extinction coefficient.  
Thrombin from human plasma (Sigma) was resuspended in sterile water at a final concentration 
of 200 U/mL. 
Human Factor XIII was either a gift from Baxter (Deerfield, USA) or obtained as Fibrogamin by 
CSL Behring (King of Prussia, USA), and a stock of 200 U/mL was prepared in sterile water.  
Aprotinin (Roche) was prepared at a stock concentration of 17 mg/mL in sterile water. 
All protein solutions (Table 22) were aliquoted and stored at -80°C until use. 
 
Protein Supplier Order number Stock concentration 
Human fibrinogen, plasminogen, 
vWF and fibronectin depleted 
Enzyme Reseach Laboratories FIB3 variable, 20-30 mg/mL 
Thrombin from human plasma Sigma T4393 200 U/mL 
Fibrogamin (factor XIII) CSL Behring 1250 E FXIII 200 U/mL 
Aprotinin Roche 236624 17 mg/mL 
Table 22: Protein stock solutions for the preparation of fibrin gels. 
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6.10.2 Functionalization of fibrin matrices: incorporation and 
release of VEGF proteins 
Retention and release recombinant of VEGF proteins in fibrin matrices was tested in order to 
confirm covalent binding of TG-tagged proteins to fibrin. 50 µl fibrin gels, functionalized with 
2 µg of recombinant protein from E. coli or 0.2 µg from HEK293-EBNA cells, were formulated 
at a final concentration of 10 mg/mL fibrinogen, 2 U/mL thrombin, 2 or 10 U/mL factor XIII and 
2.5 mM CaCl2 in TBS. After formation, fibrin gels were washed at 37°C in 10 mL TBS with 
0.1% BSA. Aliquots were taken from the wash buffer at various time points, and the VEGF 
concentration in the wash buffer was determined by ELISA using the VEGF ELISA 
development kit by Peprotech. 100 % release was defined as 2 µg, or 0.2 µg, of each construct in 
10 mL wash buffer, and the amount of protein released from the fibrin gels was expressed 
relative to this value.  
In some experiments, the washed fibrin gels were digested with 0.02 U of plasmin in 20 µL TBS 
at 37°C until degradation was complete. 20 µL aliquots of this solution were then subjected to 
non-reducing SDS-PAGE and western blot analysis. 
 
6.11 Wounding of db/db mice 
The performed animal investigation was approved by Landesamt für Natur, Umwelt und 
Verbraucherschutz NRW. For wounding experiments, male BKS.Cg-m +/+ Leprdb/J (db/db) 
mice 12-14 weeks of age were used (Charles River Laboratories, Wilmington, USA). This 
mouse strain is considered a representative animal model for type-2 diabetes and is characterized 
by impaired wound closure and reduced angiogenesis during skin regeneration. Diabetes was 
confirmed by determination of blood glucose levels prior to experiments. The blood glucose 
level in these mice was above 300 mg/dL whereas in wildtype mice it is 100 mg/dL.  
Under Ketanest/Rompun anesthesia, the back of the mice was shaved, and washed with ethanol. 
On the back of the mice, four full thickness punch biopsy wounds with a diameter of 6 mm were 
created, removing the epidermis, the dermis and the underlying fat tissue. 80 µL fibrin gels at a 
final concentration of 10 mg/mL fibrinogen, 2 U/mL thrombin, 10 U/mL factor XIII, 17 µg/mL 
aprotinin, 2.5 mM CaCl2, and 20 µg/mL of either VEGFmut, TG-VEGFmut or TG-FLV proteins 
were formed directly in the wound site. A control was a fibrin gel without growth factors. After 
polymerization of the gel, the gel was covered with a piece of Adaptic (Johnson + Johnson 
wound management, Norderstedt, Germany), and a semipermeable hydrofilm (Hartmann, 
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Heidenheim, Germany) was placed on the wound side in order to keep the gel moist. The 
hydrofilm was fixed to the skin. For recovery from anesthesia, mice were placed on a heating 
plate until fully awake. Following surgery, the mice were kept in individual cages lined with 
tissues and received Tramal (Grunenthal, Aachen, Germany) as analgesia via the drinking water. 
Materials needed for the surgery are summarized in Table 23. 
 
Anesthetic   Surgery tools  
0.1%  Rompun (Bayer, Leverkusen, Germany)  6 mm biopsy punches Stiefel (NC, USA) 
10 mg/mL Ketavet (Pfizer, Berlin, Germany)  Scissors Fine Science Tools (Heidelberg, Germany) 
0.9 %  NaCl  Tweezers Fine Science Tools 
     
Animal care   Wound dressing  
Bepanthen eye cream Bayer  Adaptic Johnson & Johnson 
Tramal, 40 mg/kg bw Grunenthal (Aachen, Germany)  Hydrofilm Hartmann 
GlycoMen GlycO’ Menarini (Florence, Italy)    
GlycoMen Sensor Menarini (Florence, Italy)    
Heating plate     
Table 23: Materials required for the punch biopsy wounding of mice. 
 
6.11.1 Tissue harvest 
Mice were sacrificed by carbon dioxide asphyxiation on day 10 or 14/15 post wounding. The 
wound tissue was harvested, and either paraffin sections or cryosections were prepared.  
For paraffin sections, wounds were fixed in formalin, embedded in paraffin and cut into 6 µm 
thick sections. Sections were stained with hematoxylin and eosin (H&E) or Masson’s Trichrome 
(TM) stain. H&E is commonly used in histology for overview sections. Eosin stains eosinophilic 
structures like cytoplasm and protein pink, and erythrocytes red. Hematoxylin stains basophilic 
structures such as nucleic acids blue to purple. The TM stain was developed to distinguish cells, 
in particular erythrocytes, from connective tissues. Keratin and muscle fibers stain red, collagen 
stains green, cytoplasm stains pink, and nuclei can be identified by their black shading. 
Sectioning and staining was performed according to established standard protocols at the 
histology core facility of the dermatology compartment of the University Hospital of Cologne.  
For cryosections, wounds were embedded in OCT compound (TissueTek) and frozen. 10 µm 
thick sections were fixed in cold acetone and used for immunohistochemistry.  
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6.11.2 Staining for CD31 and desmin 
Wound sections were blocked in 10% normal goat serum and probed with antibodies directed 
against desmin (Dako Glostrup, Denmark, 1:100 in 1% BSA), a marker for pericytes, and CD31 
(BD Pharmingen, 1:1000 in 1% BSA), a marker for endothelial cells (Table 24). Primary 
antibodies were detected with Alexa Flour® 488 or 594 coupled secondary antibodies 
(Invitrogen, 1:500 in 1% BSA), and nuclei of cells were stained with DAPI (1 µg/mL).  
 
Antibodies used for Immunofluorescence      
Primary antibodies    Secondary antibodies    
Antigen Host species Supplier  Dilution   Supplier Dilution 
CD31 Rat BD Pharmingen 1:1000  Goat α Mouse IgG1 Alexa Flour®488 Invitrogen 1:500 
Desmin Mouse Dako 1:100  Goat α Rat Alexa Flour®594 Invitrogen 1:500 
Table 24: Antibodies used for immunohistochemistry on wound cryosections. 
 
6.11.2.1 Quantification of wound angiogenesis on CD31 and desmin 
stained sections 
For the quantification of the CD31 and desmin positive areas as well as of classical wound 
parameters (distance between epidermal tips, amount of granulation tissue, distance between the 
ends of panniculus carnosus), serial images of the entire wound area were taken using a Nikon 
eclipse E800 fluorescence microscope, and assembled in Adobe Photoshop CS5 (Adobe, Dublin, 
Ireland). Using the image analysis program ImageJ (Wayne Rasband, National Institute of 
Mental Health, Bethesda, USA), the channels were split, regions exhibiting a positive signal 
were selected manually via the thresholding tool, and the area was determined. The desmin and 
CD31-positive areas were analyzed in relation to the overall area of granulation tissue. 
Measurements were performed several times. Pictures shown were optimized in Adobe 
Photoshop CS5 (Dublin, Ireland) by background reduction 
 
6.11.2.2 Statistical analysis of CD31 and desmin stained section 
Data were obtained from a total of 11 mice, sacrificed at day 10 (n=7) and 14 (n=4) post injury. 
Data analysis was carried out using the GraphPadPrism 5 software package (La Jolla USA). 
Statistical significance was tested by paired t-tests and accepted for p<0.05. 
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Abbreviations 
 
% Percentage 
°C Degree Celsius 
Ang Angiopoietin 
APS Ammonium persulfate 
BAD Bcl-2-associated death promoter 
BCA Bicinochoninic acid 
Bcl-2 B-cell lymphoma-2 
bFGF Basic fibroblast growth factor 
BSA Bovine serum albumin 
C-terminus Carboxyl-terminus 
CAM Chorioallantoic membrane 
CD31 Cluster of differentiation 31 
Cdc42 Cell division control protein 42 
Cdk Cyclin-dependent kinase 
d Dermis  
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleoside triphosphate 
e Epidermis 
E. coli Escherichia coli 
ECL Enhanced chemiluminescence  
EDC/NHS 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide Hydrochloride/ N-Hydroxysuccinimide 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immuno sorbent assay 
Erk Extracellular signal regulated kinase 
F Fibrin 
FAK Focal adhesion kinase 
FCS Fetal calf serum 
FGF Fibroblast growth factor 
FLV Fibronectin type III domain 10 linker vascular endothelial growth factor-A mutant  
Lys 110/Pro111 
FNIII10 Fibronectin type III domain 10 
FPLC Fast protein liquid chromatography 
g Granulation tissue 
g Gram 
GST Glutathione-S-transferase 
GTP Guanosine triphosphat 
H&E Heamatoxylin & eosin 
HB-EGF Heparin-binding epidermal growth factor 
HEK Human embryonic kidney 
HGF Hepatocyte growth factor 
HIF Hypoxia-inducible factor-1 
HRP Horse radish peroxidase 
HSP Heat shock protein 
HSPG Heparan sulfate proteoglycans  
HUVEC Human Umbilical Vein Endothelial Cells 
Ig Immunoglobulin 
IgG Immunoglobulin G 
IPTG Isopropyl beta-D-1 thiogalactopyranosidase 
ka Association rate constant 
kb Kilo base pair 
kd Dissociation rate constant 
KD Equilibrum dissociation constant 
kDa Kilo Dalton 
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KGF Keratinocyte growth factor 
L Liter 
LB Lysogeny broth 
LC-MS/MS Liquid chromatography tandem mass spectronomy 
LPS Lipopolysaccharides 
M Molar 
m milli- 
m Meter 
MAPK Mitogen activated protein kinase 
MAPKAP K2 Mitogen-activated protein kinase activated protein kinase 2 
MEK Mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 
MKK3/6 Mitogen-activated protein kinase kinase 3 
MMP Matrix-metalloproteases 
mRNA Messenger Ribonucleic acid 
n nano- 
N-terminal Amino-terminal 
N-WASP Neuronal Wiskott-Aldrich symptome protein 
Nrp Neuropilin 
PAE Porcine aortic endothelial 
PAK p21 activated kinase 
PBS Phosphate buffered saline 
pc Panniculus carnosus 
PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
PDGF Platelet-derived growth factor 
PDMS Polydimethylsiloxane 
PDMS Polydimethylsiloxane 
PE Polyethylene 
PFA Paraformaldehyde 
PH Pleckstrin homology 
pH Potential of hydrogen 
PHD Prolyl-4-hydroxylase 
PI3K Phosphoinositide 3-kinase 
PKB Protein kinase B 
PKC Protein kinase C 
PKD Protein kinase D 
PL Plasmin sensitive site, LIKMKP  
PLC Phospholipase C 
PMF Peptide mass finger printing 
PMSF Phenylmethylsulfonyl fluoride 
PVDF Polyvinylidene fluoride 
RGD Arginine-Glycine-Aspartic aci 
ROCK Rho-associated coiled-coil-forming protein kinase 
ROCK Rho-associated coiled-coil-forming protein kinase 
rpm Revolutions per minute 
RU Resonance unit 
SAPK2/p38 Stress activated protein kinase 2 /p38 
sc Subcutaneous fat tissue 
SDS-PAGE Sodium dodecylsulfate polyacrylamide gel electrophoresis 
SH2 Src homology 2 
Shb Src homology 2 domain containing adaptor protein B 
SOC Super optimal broth with catabolite repression 
SPR Surface plasmon resonance 
TAE Tris-acetate-EDTA 
TBS Tris-buffered saline 
TBST TBS containing 0.1 % Tween-20  
TEMED N, N, N, N,-tetramethylethylendediamine 
TG Factor XIIIa substrate sequence of α2 plasmin inhibitor, NQEQVSPL 
TGF Transforming growth factor 
Tie Tyrosine kinase with immunoglobulin-like and EGF-like domains 
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TIMP Tissue inhibitor of metalloproteinase 
Tris Tris(hydroxymethyl)aminomethane 
U Units 
UV Ultra violet 
VE Vascular endothelial 
VEGF Vascular endothelial growth factor 
VEGFmut Vascular endothelial growth factor-A mutant Lys110/Pro111  
VEGFR Vascular endothelial growth factor receptor 
VPF Vascular permeability factor 
w/v Weigth per volume 
YT Yeast extract and tryptone 
µ mico- 
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